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How does the new diagnostic criteria for protein-energy
wasting in chronic kidney disease compare
with the ICD-10 AM definitions?
Sharyn Denmeade
1, Lynda Moynahan
2, Judy D. Bauer
3
1Nutrition Services Department, The Wesley Hospital,
Brisbane, Queensland, Australia;
2Haemodialysis Unit,
The Wesley Hospital, Brisbane, Queensland, Australia;
3School of Human Movement Studies, University of
Queensland, Brisbane, Queensland, Australia
Background and aims: Malnutrition is associated with
higher levels of morbidity and mortality in patients with
CKD. The aim of this study was to determine the
prevalence of protein-energy wasting (PEW) using new
diagnostic criteria compared with ICD-10 AM definitions
in patients with CKD.
Methods: Forty-two patients (22 male, 20 female; mean
age, 65.7 (SD 17.6)years) from a private haemodialysis unit
participated. To determine PEW, four categories are
assessed: biochemistry serum albumin (<38 mg/l) or serum
cholesterol (<100 mg/100 ml); body mass index (BMI) <23
or total body fat <10%; muscle mass, reduced mid-arm
muscle mass area; and reduced dietary intake, protein
<0.8 g/kg/day or energy <100 kJ/kg/day. At least three of
the four categories must be present to diagnose PEW. The
ICD-10 AM definitions of malnutrition include BMI <18.5
or evidence of weight loss, decreased intake and presence
of fat loss and muscle wasting. This was assessed using
subjective global assessment. Dietary intake was analysed
using Foodworks (version 5). Fat mass was determined
using bioelectrical impedance spectroscopy.
Results: Ten patients (24%) met the criteria for PEW
compared to eight patients (19%) using the ICD-10 AM
criteria; however, only three patients met the criteria for
both definitions. Thirteen patients had low biochemistry; 14
had low BMI; 19 had low muscle mass; 21 had low intake;
two had BMI <18.5; and six had evidence of weight loss,
decreased dietary intake, presence of subcutaneous fat loss
and muscle wasting. Time taken for the PEW diagnosis was
considerably longer than ICD-10 AM.
Conclusions: The new diagnostic criteria for PEW require
further validation studies in patients with CKD.
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Practice-guiding classification of cancer cachexia
in palliative cancer care (PCC): clinical pilot evaluation
of the SIPP assessment tool
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Background: The understanding of mechanism and impact
of cancer cachexia is evolving; a new generic definition of
wasting/cachexia includes weight loss (WL) and five addi-
tional criteria. Current nutritional assessment tools identify
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DOI 10.1007/s13539-010-0001-7patients at risk for malnutrition, but guide less practice. A
common clinical classification, with simple, robust assess-
ments specific for cancer and the PCC context, is required to
improve care decisions, outcomes, and clinical trial design.
The aim of this study is to develop a cancer-specific,
practice-guiding cachexia classification and assessment
system, based on the generic cachexia definition.
Methods: Three systematic literature reviews, two focus
group rounds, and a formal Delphi process among
clinical academic cancer cachexia experts were con-
ducted to reach an agreement, based on current evidence
and consensus on definition, diagnosis, classification,
and practical assessment of cancer cachexia. A resulting
classification/assessment (SIPP system) is pilot tested in
PCC clinics.
Results: Consensus on assessments is reached for domains,
but not (yet) for selection of measures. The SIPP contains
storage (gap of usual to current weight, WL duration,
control for fluid retention or obesity, and specific nutrients’
deficit), intake (anorexia, early satiety, percentage of
normal intake, 1–2 days dietary record, and secondary
nutrition impact symptoms), potential (tumor (catabolic)
activity and C-reactive protein), and performance (perfor-
mance status, cachexia-related suffering, and prognosis).
Three phases (pre-cachexia (risk for cachexia), cachexia
syndrome, and late unlikely-to-be-reversible cachexia) are
proposed. Feasibility, content validity, and independent
clinicians agreement on multidimensional interventions are
promising (n=10; age, 46–72 years).
Conclusion: The SIPP system seems promising to guide
practice in PCC, final agreement on assessments is
required, and prospective testing to refine cancer cachexia
phases and phenotypes is needed.
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Cachexia-related suffering: development
of an assessment system guiding clinical interventions
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Introduction: Interventions for cancer cachexia (CC)
patients typically focus on pharmacological and nutritional
approaches, rarely on the under-diagnosed CRS: psychoso-
cial suffering related to eating and weight loss (WL). The
aim of the study is to develop an assessment instrument for
CRS.
Methods: Based on patients’ and proxies’ focus groups
(Strasser, Palliat Med 21:129–137, 2007) and a systematic
literature review, a CRS item pool was developed. A
multidisciplinary team (nurses, nutritionists, and palliative
care physicians; n=9) reviewed and rated items (agreed, not
agreed, and discuss) in two rounds, resulting in 121 items.
We test their face validity, completeness, and practicability
(negative emotions) in a cross-sectional design, providing
each patient two-item sets (n=25). Demographics include
living situation, age, nationality, education, religion, BMI,
cachexia staging, cognition, Edmonton Symptom Assess-
ment Scale, Hospital Anxiety Depression Scale, subjective
(0=none, 10=maximal) importance of eating, eating with a
partner, amount of eating, and eating-related suffering
(ERS).
Results: Thirteen patients (age, 48–74 years; five female;
weight loss, 3–12.5%; HADS-A, 6; HADS-D, 9.5; ERS
patient,7.7;ERSfamily,7.5)judgedat15interviews36items
(eight items, ≥2 patients) as insufficient comprehensible
beforeexplanation.Theseitemscontainedsubordinateclauses
or complicated words and were reworded. Twenty-two items
(four items, ≥2 patients) released desire to talk or mild
emotions. Findings lacked an association to demographic
data. No items about ERS/CRS are missing.
Discussion: This is the first study investigating systemat-
ically items for a subjective assessment of cachexia-related
suffering. The item pool will be further refined by
multicenter calibration and analysis; the resulting CRS
questionnaire is likely to guide decision and practical
interventions.
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Background and aims: Hemodialysis patients suffer from
generalized fatigue and lack of energy. It has been
suspected that the observed excessive fatigue do not depend
only on muscle atrophy and weakness but also depend on
other factors. The aim of the current study was to
investigate whether factors related to quality of life and
general health contribute to the level of general fatigue in
patients receiving hemodialysis therapy.
44 J Cachexia Sarcopenia Muscle (2010) 1:43–128Methods: Fifty-two hemodialysis patients (15 female/37
male; age, 55±17; BMI, 25.4±4.4; years in dialysis, 2.4±
1.2) consented to participate in this study. Hemodialysis
patients were assessed for their functional capacity; body
composition (DEXA); levels of central adiposity, muscle
quality, and liver fat by CT; insulin resistance (OGTT);
perceived quality of life parameters; and fatigue by various
questionnaires.
Results: The overall quality of life score was below 70%
(67±18), implying a low level of perceived life quality.
Fatigue significantly correlated with gait speed (−0.397, P=
0.01), exercise performance (−0.338, P=0.01), abdominal
girth (−0.357, P=0.02), visceral adiposity (−0.421, P=
0.01), liver fat levels (0.528, P=0.01), indices of insulin
sensitivity (0.432, P=0.01), sleep diary (−0.435, P=0.01),
daily sleepiness (−0.354, P=0.01), and depression (−0.526,
P=0.01). Lean body mass and percentage of body fat did
not correlate significantly with fatigue score, while the
thigh muscle cross-sectional area correlated weakly (0.277,
P=0.08).
Conclusions: Hemodialysis patients present with increased
levels of generalized fatigue, leading to a considerable
reduction of physical activity, impaired insulin action, and
glucose disposal, implicating various metabolic alterations
with a common denominator: the increased cardiovascular
risk and a high mortality rate.
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Metabolic gene expression in skeletal muscle of chronic
heart failure patients: the effect of exercise training
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Background: Chronic heart failure (CHF) patients are
characterized by insulin resistance and impaired energy
metabolism. Adiponectin is an insulin-sensitizing adipo-
cytokine. In CHF, high adiponectin confers poor
prognosis. We investigated the expression of adiponec-
tin, the adiponectin receptor, and genes involved in
downstream lipid and glucose metabolism in the skeletal
muscle of CHF patients before and after exercise
training (ET).
Methods: Nine CHF patients and ten healthy subjects
underwent clinical assessment, echocardiography, and
CPET. Muscle biopsies (m. vastus lateralis) were taken
to assess mRNA expression of adiponectin, AdipoR1,
and downstream metabolic genes. The effect of com-
bined endurance-resistance ET (ambulatory training,
three sessions/week, and 60 min duration) in CHF was
assessed after 4 months.
Results: Adiponectin expression in CHF patients was
higher compared to healthy subjects (P<0.01), whereas
AdipoR1 was downregulated (P=0.04). In addition, the
expression of genes involved in lipid (PPAR-alpha,
ACADM) and glucose metabolism (AMPK-alpha1, HK2)
was reduced in CHF.
ET increased maximal workload and muscle strength and
lowered mRNA expression of adiponectin (P=0.02),
whereas AdipoR1 (P=0.01) expressed was increased to
levels comparable to healthy subjects. Furthermore, both
AMPK-alpha1 (P=0.02) and PPAR-alpha mRNA expres-
sion (P=0.05) were upregulated.
Conclusion: CHF patients are characterized by increased
adiponectin expression and decreased expression of
AdipoR1 and downstream metabolic genes. ET normal-
izes the expression of adiponectin and AdipoR1 and
reverses the disorders in lipid and glucose metabolism.
These alterations in metabolic gene expression following
exercise might help to understand the beneficial effects
of ET in CHF.
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Increased proteasome activity in skeletal muscle
of patients with chronic heart failure—a fluent
transition to cachectic disease state?
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Background: In chronic heart failure (CHF), weight loss
and the development of cardiac cachexia represent frequent
late state complications. The associated muscle wasting
accelerates the downward spiral of symptomatic status and
particularly poor prognosis. We investigated proteasome
activity in skeletal muscle as an indicator of protein
catabolism in cachectic and non-cachectic CHF patients
and healthy controls.
Methods: We studied 26 stable CHF patients (age, 65±
2.2 years (mean±SEM); BMI, 26.3±1.4; NYHA I/II/III, n=
J Cachexia Sarcopenia Muscle (2010) 1:43–128 452/21/11) and 30 healthy controls of similar age and BMI.
Muscle biopsies were obtained from the vastus lateralis of
the quadriceps using the Bergstrom needle technique. The
obtained samples were homogenized in lysis buffer. Of
protein, 20 μg was used for the fluorogenic assay
(substrate:benzyloxycarbonyl-Leu-Leu-Glu-7-amido-4-
methylcoumarin-Z-LLE-AMC, Biomol), in which substrate
turnover was determined. The activity was calculated by using
free amidomethylcoumarin (AMC) as working standard.
Results: Proteasome activity was significantly increased in
CHF patients compared to controls (0.35±0.16 vs 0.04±
0.01 units/mg; p=0.038). Among CHF patients, seven
subjects have been diagnosed as cachectic following the
current consensus-based definition. The highest proteasome
activity was observed in the cachectic subgroup (0.61±
0.46 units/mg) as compared to non-cachectic CHF (0.24±
0.13 units/mg) and to controls (Con: 0.04±0.01 units/mg;
ANOVA, p=0.04).
Conclusion: Our study shows that proteasome activity is
elevated in patients with CHF as compared to healthy
subjects of similar age. This finding is in accord with the
observed overall increased catabolic drive in CHF.
Proteasome activity is highest in the cachectic subgroup.
Increased proteasome activity may therefore be an
underlying mechanism of muscle wasting in CHF.
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Skeletal muscle measured at the time of ICU admission
may be determinant of clinical outcomes
Marina Mourtzakis
1, Charlene Fan
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2
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Introduction: Patients admitted to the intensive care unit
(ICU) often lose weight during hospital stay; however,
specific changes in body composition features of ICU
patients have not been quantified. We investigated the
relationship between muscularity and length of hospital stay
in ICU patients.
Methods: The charts of 54 ICU patients participating in a
nutrition study were searched retrospectively for CT images
that had been taken at the third lumbar vertebrae (L3) for
diagnostic purposes. Of the 54 patients, 24 (14 males, ten
females) had CT images taken at L3 close to the time of
entry into ICU (within 14 days). CT images were analyzed
for muscle cross-sectional area using Tomovision’s Sliceo-
matic software. Previously published cutoff points (males,
<55.4 cm
2/m
2; females, <38.9 cm
2/m
2)w e r eu s e dt o
identify sarcopenic patients.
Preliminary results: Sixteen of 24 patients (67%; nine
males, seven females) were classified as sarcopenic near the
time of admittance to ICU. Sarcopenic patients were in
hospital twice as long as non-sarcopenic patients (44±48 vs
17±9 days; p=0.043) and also tended to be in ICU longer
(19±20 vs 9±5 days; p=0.085).
Conclusions: Patients who are sarcopenic at the time of
ICU admission are in hospital for a longer duration than
non-sarcopenic ICU patients. Further research into nutri-
tional and rehabilitation interventions in this high-risk
group is warranted. Ultimately, CT scans may be used to
identify patients who require nutritional intervention and
may be used to evaluate such interventions.
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Novel changes in anabolic and catabolic pathways
considered to regulate mass in muscle of critically ill
patients
Despina Constantin
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Background and aims: A significant clinical feature of
critically ill patients (CIP) is the loss of skeletal muscle
mass. We aimed to compare the expression levels of genes
and proteins, purported from mainly animal work to control
muscle protein synthesis and breakdown, in muscle biopsy
samples from CIP and control volunteers.
Methods: T e nC I P( m e a nA P A C H EI Is c o r e ,1 7 . 6±4 . 8( S D ) )
and six control volunteers participated in a study approved by
the Local Ethics Committee. Gene (real-time PCR) and
protein (Western blotting) expression was determined in
biopsies obtained from vastus lateralis muscle. Significance
(one-way analysis of variance) was set at P<0.05.
Results: An increase in IL6 (P<0.01) and TNF-alpha (P<
0.01) mRNA was seen in CIP compared to controls. There
was a decline in phosphorylation of Akt1 (P<0.01), GSK3-
beta (P<0.05), mTOR (P<0.01), p70s6k (P<0.01), and
4EBP1 (P<0.01) protein in CIP, which was paralleled by an
increase in Akt1 (P<0.05), GSK3-beta (P<0.001), mTOR
(P<0.001), p70s6k (P<0.01), and 4EBP1 (P<0.001)
mRNA expression. Concurrently, MAFbx (P<0.001),
MuRF1 (P<0.001), 20S proteasome (P<0.001),
46 J Cachexia Sarcopenia Muscle (2010) 1:43–128cathepsin-L (P<0.01), and myostatin (P<0.05) mRNA
increased in CIP and was matched by an increase in
MAFbx (P<0.05), MuRF1 (P<0.05), 20S proteasome (P<
0.05), and myostatin (P<0.001) protein expression.
Conclusions: This study shows that a decrease in anabolic
signaling protein phosphorylation occurs in CIP, which was
accompanied by increased mRNA expression of the genes
encoding these proteins. Additionally, CIP presented with
increased MAFbx, MuRF1, 20S proteasome, and myostatin
mRNA expression, which was paralleled by increased
expression at the protein level.
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Muscle wasting in patients with chronic obstructive
pulmonary disease (COPD)
Hegoi Segurola, Cleofé Pérez-Portabella, Jaume Ferrer,
Eduardo Hermosilla, Mercé Planas, Rosa Burgos
Nutritional Support Unit,University HospitalVall d’Hebron,
Barcelona, Spain
Background and aims: Malnutrition is frequent in COPD
patients. However, little is know about the implications of
the depletion in different body compartments and dietary
intakes on pulmonary function.
Patients and methods: Consecutive outpatients with
stable COPD were included. Variables include age,
tobacco consumption, body mass index (BMI), muscle
mass estimated by mid-arm circumference and bioelectri-
cal impedance (fat-free mass index (FMMI)), fat stores
measured by triceps skin-fold thickness (TSF), muscle
function by handgrip strength (HG), pulmonary function,
dyspnoea degree, number of exacerbations last year, food
intake assessed by 24-h recall and food questionnaire and
energy and protein requirements.
Results: Ninety-six patients were included (95% men),
with a mean age of 62±21 years and smoking habits of
59.9±31.6 packets/year. Of patients, 4.2% had low
BMI, although muscle wasting was present in 5% by
MAMC and 37% by FFMI. Fat depletion was present in
23% by TSF. Muscle wasting was present in 79.3% of
normal weight patients and in 19% of overweight. Loss
of muscle mass correlated with pulmonary function
(FFMI with FEV1/FVC, r=0.238, p=0.021; MAMC
with FEV1, r=0.211, p=0.041). HG and TSF correlated
with morbidity (dyspnoea degree, r=−0.61, p<0.001;
number of exacerbations, r=−0.282, p=0.012). Protein
intake was reduced in 77.1% of patients with FEV1<50%
compared with 58.0% in those with FEV1 >50%,
p=0.0026.
Conclusion: Muscle wasting and low fat stores were
more prevalent and linked with functional capacity and
outcome in COPD patients than low body weight.
Protein requirements are compromised and need dietetic
counseling.
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Acute phase response (APR) cachexia and systemic zinc
redistribution
Pontus M. A. Siren
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2
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Background and aims: Several diverse factors such as
Ang-II, PIF, LPS, TNF-α, IL-6, and conditions such as
chronic inflammation, sepsis, and cancer induce cachexia.
We have hypothesized that systemic redistribution of Zn
and its accumulation in muscle tissue plays a key role in
muscle wasting. To help assess the validity of this
hypothesis, we suggest a link between cachexia inducing
conditions/factors and zinc redistribution.
Methods: The hypothesis is based on data on the
fluctuation and regulation of Zn homeostasis in animal
and man and the extensive literature on acute phase
response (APR).
Results: APR is the host’s normal acute response to
trauma, inflammation, and infection. APR is character-
ized by protein catabolism and appears to play a central
role in cachexia, but APR’s mechanism of action in
cachexia is unresolved
1.A P R ’s salient characteristics
include the steep decline of serum zinc levels and the
redistribution of internal zinc stores
2,3. Several factors
mediate APR, and at least TNF-α,I L - 6 ,a n dL P S
significantly reduce serum zinc levels and drive the
redistribution of internal zinc stores.
Conclusion: Chronic APR is a well-known host defense
mechanism commonly observed in cachexic patients.
APR is characterized by significant Zn redistribution
and hypozincemia. We have hypothesized earlier that in
cachexia, systemic Zn redistribution and hypozincemia
cause anorexia, growth failure in children, inflammation,
insulin resistance, and hypogonadism. We suggest that
chronic APR may explain the mechanism behind these
symptoms. APR also suggests a mechanism for how Zn
is mobilized for PKR-mediated muscle wasting (see
Figure).
1Curr Opin Support Palliat Care 2:267–274, 2008
2PNAS 102(19):6843–6848, 2005
3Am J Physiol 272 (Endocrinol Metab 35):E952, 1997
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Flexible modeling improves assessment of prognostic
value of C-reactive protein in advanced non-small cell
lung cancer
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1, Michal Abrahamowicz
2, Yongling
Xiao
2, Marie-Eve Beauchamp
2,N e i lM a c D o n a l d
3,
Goulnar Kasymjanova
4
1Department of Medicine and Oncology, McGill University,
Montreal, QC, Canada;
2Department of Epidemiology and
Biostatistics, McGill University, Montreal, QC, Canada;
3Department of Oncology, Cancer Nutrition and Rehabili-
tation Program, McGill University, Montreal, QC, Canada;
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C-reactive protein (CRP) is gaining credibility as a
prognostic factor in different cancers. A conventional Cox’s
model is usually used to assess prognostic factors.
However, this model imposes a priori assumptions that (1)
the hazard ratio associated with each prognostic factor
remains constant across the entire follow-up interval (PH
assumption), and (2) the relationship between the continu-
ous predictor and the logarithm of the mortality hazard is
linear (linearity assumption), which are rarely tested. We
tested these assumptions for CRP, using a flexible statistical
model, while adjusting for other known prognostic factors,
in a cohort of 269 patients newly diagnosed with non-small
cell lung cancer (NSCLC). In the conventional Cox’s
model, high CRP increased the risk of death (HR=1.11
per each doubling of CRP value; 95% CI, 1.03–1.20, p=
0.008). However, both the PH assumption (p=0.033) and
the linearity assumption (p=0.015) were rejected for CRP
measured at the initiation of chemotherapy, which kept its
prognostic value for only about 18 months. Our analysis
demonstrates that flexible modeling provides new insights
about the value of CRP as a prognostic factor in NSCLC,
and that a conventional Cox’s model underestimates early
risks associated with high CRP.
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Studies on intestinal blood flow in patients with chronic
heart failure compared to healthy control subjects
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Introduction: Chronicheartfailure(CHF)ischaracterizedby
reduced circulatory blood flow due to low cardiac output,
sympathetic activation, and impaired vasodilator capacity.
Impaired tissue perfusion may likely occur as well in the
intestinal vascular bed. This hypoperfusion may contribute to
impaired intestinal barrier function, increased bacterial trans-
location, chronic inflammation, malnutrition, and cachexia as
observed in CHF. Intestinal arterial blood flow in comparison
to limb blood flow has not yet been studied in CHF.
Methods: We prospectively investigated 16 patients with
CHF (age, 64.8±2.3 years; LVEF, 29.3±1.5%; peak VO2,
15.7±1.2 mL/kg/min; NYHA class, 2.3±0.1; BMI, 27.2±
Cachexia inducing conditions
Chronic heart failure, Chronic obstructive pulmonary disease,
Chronic kidney disease, Chronic infection, Sepsis, AIDS,
severe trauma, Cancer
WHAT IS THE LINK BETWEEN CACHEXIA INDUCING CONDITIONS /
FACTORS AND SYSTEMIC ZINC STATUS ?
Cachexia inducing factors
Factor (PIF), Lipopolysachharide (LPS), Interleukin-6
Normal Acute Phase Responses:
-Redistribution of systemic zinc
-Hypozincemia
-Protein catabolism
Acute Phase Response fails:
Host defence cascade & response 
continues chronic  Zn
redistribution and hypozincemia
Inflammation, infection,
trauma. etc resolved
Homeostasis / health
Cachexia
Tumour Necrosis Factor- , Angiotensin II, Proteolysis Inducing
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2) and 17 control subjects of similar age and
gender (peak VO2, 27.1±1.6 mL/kg/min; LVEF, 66.4±
2.1%; BMI, 26.4±1.2 kg/m
2). Forearm blood flow at rest
and post-ischemic peak blood flow were assessed by
venous occlusion plethysmography. Intestinal peak systolic
blood flow was calculated from peak systolic velocity and
vessel diameter of the mesenteric arteries, as well as of the
coeliac trunk using high-resolution ultrasound and Doppler
sonography. We assessed small intestinal permeability by
lactulose–mannitol test, bowel wall thickness by transcuta-
neous sonography, and mucosal bacterial biofilm by FISH
in biopsies taken during sigmoidoscopy.
Results: In CHF, we found a lower intestinal peak systolic
blood flow in the inferior mesenteric artery in CHF patients
compared to controls (6.03±0.72 vs. 8.40±0.74 mL/s, p<
0.04). Systolic blood flow in the coeliac trunk in CHF
patients was 39.38±6.45 vs. 56.20±6.20 mL/s in controls
(p=0.09). Intestinal systolic blood flow of the superior
mesenteric artery was similar in CHF and control subjects
(42.46±4.28 vs. 47.47±4.06 mL/s, p=0.4). CHF patients
had lower forearm resting blood flow (2.83±0.41 vs. 4.74±
0.86 mL/100 mL/min, p<0.05) compared to controls and
lower peak post-ischemic blood flow (13.84±1.53 vs.
19.57±2.01 mL/100 mL/min, p=0.03), indicating impaired
vasodilator capacity. Furthermore, CHF patients showed a
lower blood mid-regional proadrenomedullin concentration
as a biomarker of impaired endothelial function (0.82±0.09
vs 0.51±0.02 nmol/L, p=0.003). Impaired intestinal blood
flow in the inferior mesenteric artery was in accord with
previously observed greater bowel wall thickness (all p<
0.02 for all bowel segments), increased paracellular
intestinal permeability, and higher concentrations of adher-
ent bacteria within mucus on biopsies taken during sigmoid-
oscopy in patients compared to controls (permeability index
0.022±0.002 vs 0.016±0.002, p<0.05, and 230×106/mL
(1×106/mL and 80,320×106/mL) vs. 0.1×106/mL (0.1×
106/mL and 290×106/mL), p=0.02), respectively.
Conclusion: Impaired organ and tissue perfusion in CHF
occur in the limb (forearm) and in the intestinal vascular
bed. Mesenteric malperfusion may contribute to intestinal
hypoxia and may hence underlie increased bacterial translo-
cation with chronic inflammation, malnutrition, and cachexia
in CHF.
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Background: Impaired insulin sensitivity (IS) is a common
finding in chronic heart failure (CHF) patients contributing
to symptomatic status and mortality. Impaired glucose
metabolic efficiency is associated with increased fatty acid
utilisation. We tested the hypothesis that adipose tissue
catabolism is increased in CHF patients which might
contribute to impaired IS.
Methods: After an overnight fast, adipose tissue metabo-
lism was studied by microdialysis on CHF patients and in
age and body weight-matched healthy controls (both n=8)
at rest and during an oral glucose tolerance test (oGTT).
Dialysates were analysed for glucose, lactate, glycerol and
ethanol in order to assess changes in tissue metabolism and
perfusion (ethanol dilution technique).
Results: Serum glucose and insulin profiles and also
baseline and postprandial tissue perfusion and glucose
supply did not differ significantly between CHF patients
and controls (all p>0.2). In contrast, baseline adipose
tissue dialysate (lactate) was 0.51±0.10 and 0.26±
0.06 mmol/l (p<0.01) and (glycerol) 116±18 and 50±
8 μmol/l (p<0.001) in CHF patients and controls, respec-
tively, indicating increased adipose tissue glycolysis and
lipolysis. During oGTT, adipose tissue dialysate (lactate)
increased by about 50% and 160%, and dialysate (glycerol)
decreased by about 60% and 50% in CHF patients and
controls, respectively, but values were always significantly
higher in CHF patients vs. controls (all p<0.05).
Conclusion: Our data indicate increased catabolic stimula-
tion in adipose tissue of CHF patients and increased
anaerobic drive at rest and after an oral glucose load.
Increased lipid mobilisation may contribute to impaired
glucose utilisation and insulin resistance observed in CHF
patients.
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Adipose tissue in case of CHF and especially cardiac
cachexia obtains new qualities and changes regulation
mechanisms.
J Cachexia Sarcopenia Muscle (2010) 1:43–128 49Aim: The aim of this study is to evaluate weight, BMI,
levels of leptin in blood, lean mass, and percentage of
adipose tissue in patients with CHF I-IV FC NYHA.
Methods: In 60 patients with CHF of ischemic genesis, 10
patients have I FC, 15 have II FC, 15 have III FC, and 20
have IV FC. Height, weight, BMI, lean mass, percentage of
adipose tissue (Durnin methodic) and leptin, and NT-pro-
BNP in plasma were evaluated. At baseline, level of NT-
pro-BNP was evaluated.
Results: Patients with CHF III–IV FC were admitted to
hospital due to decompensation of CHF and have a level
of NT-pro-BNP >3,000 ng/l; patients with CHF I–II FC
were admitted to hospital due to arterial hypertension.
At baseline, BMI includes I FC, 31.8±2.1 kg/m
2;I IF C ,
31.6±2.7 kg/m
2; III FC, 28.4±1.9 kg/m
2;a n dI VF C ,
25.8±2.3 kg/m
2. Lean mass includes I FC, 56.8±4.5 kg; II
FC, 55.7±3.8 kg; III FC, 58.4±4.3 kg; and IV FC, 56.7±
4.2 kg. Percentage of adipose tissue includes I FC, 32.3±
2.3%; II FC, 34.1±2.5%; III FC, 26.9±2.1%; and IV FC,
18.9±1.9%. Leptin level includes I FC, 12.3±3 ng/ml; II
FC, 24.1±2.1 ng/ml; III FC, 36.9±2.5 ng/ml; and IV FC,
58.9±1.1 ng/ml.
Conclusions: In patients with III-IV FC CHF, we found
mainly fat mass lost in association of leptin increase.
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Chronic heart failure (CHF) is one of the most frequent
causes of cardio-vascular death. Patients with end stage of
CHF usually develop cardiac cachexia, which associated
with very poor prognosis.
Aim: The aim of this study is to evaluate morphology and
histological changes in adipose tissue in CHF I–IV FC
(autopsy material).
Methods: Forty-five autopsies with CHF of ischemic
genesis were analyzed: 10 cases, I FC; 10, II FC; 10, III
FC; and 15, IV FC. Course of death in patients with CHF of
III–IV FC was progression of heart failure, in patients with
CHF of I–II FC, acute coronary syndrome. Thickness of
adipose tissue (2 cm below umbilical), weight of sealing
gland, and histological analysis (morphometria, collagen
percent, and level of lymphocyte infiltration) of adipose
tissue were performed.
Results: Thickness of adipose tissue (2 cm below
umbilical) includes I FC, 2.9±0.7 nm; II FC, 3.6±
0.6 nm; III FC, 3.05±0.5 nm; and IV FC, 1.35±0.4 nm.
Weight of sealing gland includes I FC, 378±89 g; II FC,
511±104 g; III FC, 319±76 g; and IV FC, 84.5±44 g. In
histological analysis, in autopsy cases of CHF III–IV FC
lymphoid infiltration, collagen accumulation in perivascular
spaces was found.
Conclusions: In patients with III–IV FC of CHF, not only
amount of adipose tissue changes but also morphology,
with development of fibrosis, inflammation, and possibly
apoptosis of adiposities.
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ZAG is a serum factor involved in adipose tissue
metabolism, and higher levels have been reported in
cancer cachectic patients. Altered mitochondrial function
and beta-3 adrenergic receptor pathway activation have
been proposed as potential mechanisms of ZAG effects.
Our study aimed at evaluating the role of ZAG in
cardiac cachexia (CXC) and at determining its relation-
ships with adipose metabolism in a cohort of chronic
heart failure patients. Sixty-four advanced heart failure
(AHF, NYHA functional class III–IV) patients have been
recruited in a tertiary university hospital over a period of
4 years, 18 of whom showed CXC with an unwilling
a n do e d e m a - f r e er e d u c t i o ni nb o d yw e i g h to fm o r et h a n
7.5% in the last 6 months. Abnormal thyroid function,
previous or current cancer disease, severe chronic
obstructive pulmonary and severe renal or hepatic failure
have been excluded. No significant differences in age,
gender proportion, ejection fraction and blood pressure
between the two groups have been observed. Higher
plasma free fatty acid (FFA) concentrations were
measured in CXC patients as compared to AHF; ZAG
serum concentration (ELISA, Biovendor, Germany) was
similar in CXC and AHF, both groups showing higher
plasma levels versus an age-matched healthy group of
subjects. ZAG and FFA levels showed a positive
correlation in CXC patients (R
2, 0.29; p=0.02), whereas
such a relationship was missing in AHF group. Since
there are no differences in ZAG values between CXC and
non-CXC AHF groups, these preliminary data seem to
50 J Cachexia Sarcopenia Muscle (2010) 1:43–128suggest an increased sensitivity to ZAG in stimulating
lipolysis in CXC.
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Background: Profound loss of adipose tissue (AT) is a
hallmark of cancer cachexia, but the underlying mecha-
nisms remain elusive. Zinc-alpha2-glycoprotein (ZAG), a
recently identified adipokine, has been suggested as a
candidate in the regulation of adiposity. We investigated the
potential role of ZAG in adipose atrophy in human cancer
cachexia.
Methods: Twenty-five gastrointestinal (n=12) and pancre-
atic (n=13) cancer patients with cachexia (mean weight
loss being 14.7%) or without were recruited. ZAG mRNA
levels (real-time PCR) and protein expression (Western
blotting) were assessed in subcutaneous AT. Tissue mor-
phology was examined using light microscopy. Serum ZAG
levels were quantified by ELISA. The effect of recombinant
ZAG on lipolysis was evaluated in human primary
adipocytes.
Results: AT remodelling in cancer cachexia patients
(weight loss ≥5%) was characterised by shrunken
adipocytes with increased fibrosis evident by strong
collagen-fibril staining in the tissue matrix. ZAG mRNA
levels in AT were increased in cancer cachexia (2.7-fold,
P=0.028). Concurrently, ZAG protein expression was
enhanced in cachectic cancer patients. ZAG mRNA
showed a negative correlation with BMI (r=−0.43, P=
0.016), but a positive correlation with weight loss (r=
0.48, P=0.033). Furthermore, ZAG mRNA was positively
correlated with serum glycerol levels (r=0.58, P=0.0026).
Serum ZAG levels did not differ between weight-losing
and weight-stable patients. In vitro, ZAG production by
differentiated adipocytes was abundant. Treatment with
recombinant ZAG stimulated glycerol release by human
adipocytes.
Conclusions: Our results suggest that adipokine ZAG is
involved in adipose atrophy in human cancer cachexia. This
could be, at least partly, attributable to its lipid-mobilising
effect in human adipocytes.
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Background and aims: Adipose-secreted retinol binding
protein 4 (RBP4) circulates in free and transthyretin (TTR)-
bound forms and may be associated with obesity-related
inflammation. Involvement of RBP4 and its adipose
expression in systemic inflammation independently of
obesity and diabetes is unknown. Inflammation occurs,
impairs nutritional state, and reduces survival in chronic
kidney disease (CKD; particularly in hemodialysis (MHD),
and plasma RBP4 may increase with renal dysfunction.
Methods: We determined whether plasma RBP4 changes
are associated with CKD-related systemic inflammation and
whether adipose RBP4 expression contributes to plasma
RBP4 elevation and inflammation independently of obesity
and diabetes. Plasma and adipose RBP4, systemic inflam-
mation (plasma CRP), and passive RBP4 accumulation
(creatinine and TTR) were measured in non-obese, non-
diabetic CKD undergoing conservative (CT, n=10) or MHD
treatment (n=25), controls (C, n=11), and renal transplant
recipients (n=5).
Results: Plasma RBP4, TTR, and CRP increased with renal
dysfunction and were highest in MHD (P<0.05). Adipose
RBP4 mRNA was however comparably low in CT and
MHD (P<0.05). All parameters were normalized in trans-
plant recipients (P<0.05 vs MHD). In all subjects (n=51),
creatinine and TTR (P<0.05) but not RBP4 mRNA were
related to high plasma RBP4. Plasma RBP4 was associated
positively (P<0.05) with CRP independently of creatinine-
TTR in all subjects (n=51) and with blood cell TNF-alpha
mRNA and TNF/IL10 ratio in MHD.
Conclusions: Clustering of RBP4 and inflammation occurs
in MHD independently of obesity, diabetes, and renal
dysfunction; could involve monocyte TNF-alpha expres-
sion; and is normalized by transplantation. Involvement of
adipose tissue RBP4 in CKD-associated inflammation is
not supported by these results.
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Background: Lossofadiposetissueandlowplasmaphospho-
lipids (PL) are features of cancer cachexia. It is not known
whethertheseprocessescoincideacrossthecancertrajectorynor
has their relationship with survival been defined. Changes in
adiposetissuemassandplasmaPLwerecharacterizedduringthe
500 days prior to death and prognostic significance assessed.
Methods: Adipose tissue (AT) rate of change (percent/
100 days) was determined using two lumbar computed
tomography scans taken in the last 500 days of life in a
retrospective cohort of patients who died of colorectal and
non-small cell lung cancers (n=108). Plasma PL fatty acids
were measured prospectively in a similar cohort of patients
with metastatic cancer (n=72). Cutpoint analysis was used to
classify patients into high vs low risk of death. Multivariate
Cox regression was conducted to determine survival.
Results: Accelerated loss of AT (subcutaneous, visceral, and
intramuscular) begins at 7 months from death reaching average
losses of 29%/100 days of total, which equates to a 1,100-kcal
(4,600kJ)perdayenergydeficit.PlasmaPLfattyacidswere35%
lower in patients closest to death vs those surviving >8 months
(p=0.003). Median survival was 140 days shorter in subjects
with n-3 fatty acids in plasma PL below the cutpoint (RR=
2.1, p=0.004). Loss of PL fatty acids and adipose tissue
occurs in tandem, and both are predictive of survival.
Conclusion: Depletion of plasma PL indicates a deficit of
essential fatty acids in the periphery, which may contribute
to loss of adipose tissue mass.
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Background: Existing guidelines to define clinically
important weight loss in cancer patients are heterogeneous,
do not consider current trends in body weight, tend to lack
a point of reference (habitual body weight or time frame),
and as a result are often confusing for clinicians. We aim to
characterize the relationship of body mass index (BMI) and
weight loss to overall survival and develop a population-
based scoring system.
Patients and methods: Newly diagnosed cancer patients
completed a standardized nutrition assessment. Prospec-
tively collected data included self-reported height, weight,
6-month weight loss history, and functional status. The
relationships of BMI and percent weight loss to overall
survival were defined and entered into a multivariate
analysis controlling for age, gender, diagnosis, cancer
stage, and functional status. Scores for BMI and percent
weight loss were assigned proportional to their prognostic
weights.
Results: Patients (n=2214) were overweight (mean BMI,
25.5) and weight losing (7.0% in past 6 months). Risk of
death increased with decreasing BMI and increasing weight
loss. Variables independently prognostic at the multivariate
level included age (p<0.001), gender (p=0.01), diagnosis
(p<0.001), cancer stage (p<0.001), functional status (p<
0.001), BMI (p=0.004), and percent weight loss (p<
0.001). Scores for BMI (≥22.0=0, <22.0=1) and percent
weight loss (<0.0–7.9%=0, 8.0–13.9%=2, 14.0–19.9%=
3, and ≥20.0%=4) were summed (range, 0–5), and four
risk groups with significantly different (p<0.001,log-rank
test) survivals were defined.
Conclusion: An updated, population-based scoring system
for BMI and percent weight loss effectively separates
patients with different survivals, and may be useful for
making decisions regarding treatment and initiation of
clinical trials.
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Objective: The objective of this study is to improve
prognostification of patients with advanced non-small cell
52 J Cachexia Sarcopenia Muscle (2010) 1:43–128lung cancer (NSCLC) by creating two prognostic indices
(PIs), one for stage 3 and one for stage 4.
Methods: We studied 266 patients with NSCLC. We did
two separate analyses for stage 3 and 4 with follow-up to
24 and 12 months, respectively. Cox proportional hazards
regression models were used to create the PIs and Kaplan–
Meier curves to estimate each PI.
Results: The patients’ mean age was 65±11.04 years, and
the numbers of patients in stage 3 and stage 4 were 26%
(69/266) and 74% (197/266), respectively. The multivariate
analysis for stage 3 revealed that a lactate dehydrogenase
(≥300) and C-reactive protein concentrations (>10 mgl
−1)
were associated with an increased risk of death, while for
stage 4, C-reactive protein (>10 mgl
−1) absolute neutrophil
count (≥11), ECOG (2 and 3), lactate dehydrogenase
(≥300), and albumin (≤35) were associated with an
increased risk of death. The PIs, for patients with stage 3
and 4, were constructed using the significant predictors
divided into three categories {0, 1, 2}. The median (95% CI)
[p value] survival in months for stage 3 with a PI=0, 1, and
2 were >24 (13.8, −), 8 (8.5, 18.23), and 6.8 (2.1, −)[ p<
0.001] and for stage 4 were >24 (9.7, −), 9.2 (7.1, 10.7),
and 3.7 (2.0, 4.9) [p<0.0001], respectively.
Conclusion: Two different prognostic indices, one for each
stage (3 and 4), may be a better way to estimate survival of
patients with advanced NSCLC.
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Background: Weight reduction is a recommended treatment
goal in type 2 diabetes mellitus (DM) to improve metabolic
balance and reduce cardiovascular risk. In contrast, the so-
called obesity paradox suggests reduced mortality in over-
weight patients with pre-existing chronic cardiac disease. The
impact of weight and weight change in a type 2 DM
population with pre-existing cardiovascular disease on total
mortality is analysed in the PROactive study population.
Methods: PROactive was a double-blind, placebo-
controlled cardiovascular outcome study including 5,238
patients with type 2 DM and evidence of pre-existing
cardiovascular disease. Patients were randomized to
Pioglitazone (n=2605) or placebo (n=2633) in addition
to their concomitant glucose-lowering and cardiovascular
medication. Mean follow-up was 34.5 months. Baseline
weight and percent weight change were analysed in
univariable and multivariable models to predict all-cause
mortality.
Results: Documented weight reduction during the study
period was associated with increased mortality in the total
study population (HR per 1% weight loss, 1.14 (95% CI,
1.11–1.16)), as well as in both treatment groups separately
in univariable Cox analysis (Pioglitazone, HR 1.13 (1.10–
1.16); placebo, HR 1.14 (1.11–1.17); all P<0.0001). In
contrast, weight gain was not associated with increased
mortality. In multivariable Cox proportional analysis
including further cardiovascular risk factors (HR 1.13
(1.11–1.15), P<0.0001), weight reduction but not weight
gain remained a significant predictor of increased mortality
risk. In Cox proportional analysis of body mass index
(BMI) at baseline, the lowest risk for all cause mortality
was observed for patients with BMI 30–35 kg/m
2.I n
comparison, patients with BMI <22 (HR 1.93 (0.90–4.14),
P=0.09) and BMI 22–25 (HR 1.53 (1.04–2.25), P=0.03)
had an increased risk of all-cause mortality.
Conclusion: Weight reduction but not weight gain is
associated with increased all-cause mortality in patients
with type 2 DM and pre-existing cardiovascular disease.
This suggests the presence of the obesity paradox in
patients with type 2 DM who have a high risk of
cardiovascular events.
023
Serum creatinine as a surrogate of muscle mass
and 5-year survival in over 130,000 long-term
hemodialysis patients: 2001 to 2006 national US cohort
Elani Streja
1, Stefan D. Anker
3, Rajnish Mehrotra
2,
Joel D. Kopple
2, Allen R. Nissenson
4, Csaba P. Kovesdy
5,
Kamyar Kalantar-Zadeh
1,3
1HaroldSimmonsCenter,and
2Harbor-UCLA, Torrance, CA,
USA;
3Applied Cachexia Research, Charité Universitätsme-
dizin, Berlin, Germany;
4Salem VA MC, Salem, VA, USA;
5DaVita, El Segundo, CA, USA
Background: In long-term hemodialysis (HD) patients with
minimal to no residual renal function, serum creatinine
measured prior to each HD treatment is a reflection of muscle
mass. We hypothesized that higher pre-HD serum creatinine
intake is an incremental predictor of greater survival.
J Cachexia Sarcopenia Muscle (2010) 1:43–128 53Methods: Using Cox survival models, we examined
survival predictability of monthly measured pre-HD serum
creatinine—averaged into calendar quarterly values—in
138,773 patients undergoing thrice-weekly MHD in all
DaVita clinics during the period July 2001 to June 2006,
after adjustment for case-mix and measures of malnutrition-
inflammation cachexia syndrome (MICS).
Results: HD patients were 61.9±15.5 years old and
included 45% women, 32% African Americans, 15%
Hispanics, and 50% diabetics. Higher serum creatinine
values were incrementally and linearly associated with
greater survival in all models, within any selected period of
time (1- to 5-year cohorts) and after virtually any level of
multivariate adjustment (see Figure):
Conclusions: Assuming higher serum creatinine is a surro-
gate of larger muscle mass in HD patients; larger muscle mass
is incrementally and linearly associated with greater survival
in this patient population. Nutritional trials to examine this
effect of changes in muscle mass on survival are warranted.
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Purpose: The purpose of this study is to determine
nutritional variables prognostic of survival in advanced
cancer patients and to assess their predictive ability in the
development and validation of a prognostic scoring index
(PSI).
Patients and methods: In this prospective nested cohort
study, advanced cancer patients were accrued from different
units of a Regional Palliative Care Program. Patients
completed a standard nutritional assessment upon admis-
sion. Variables collected included age, sex, cancer site,
functional status, and nutrition features (height, weight,
weight history, dietary intake, and 13 nutrition impact
symptoms). These variables were evaluated using uni-
variate and multivariate analyses, and those variables that
were independently prognostic at the multivariate level
were assigned PSI scores proportional to prognostic
weight.
Results: A training set of patients in a palliative home care
service (n=1164) was used to identify prognostic variables.
A U-shaped relationship was seen between survival and
percent weight change, with increased risk of death with
increasing weight loss, or with short-term weight gain,
compared with stable weight. Obesity was protective, and
risk of death increased for BMI.
Conclusion: More accurate prognostication is feasible and
can be achieved by combining clinical and demographic
features with relevant nutritional features related to food
intake and body weight.
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Background and aim: Pancreatic cancer and chronic
pancreatitis are the most common reasons for operative
treatments on the pancreas. Cachexia, defined as loss of
more than 10% of stable weight, in pancreatic cancer has a
significant influence on resection rate and survival. The aim
of the study was to compare the prevalence of cachexia in
chronic pancreatitis and cancer patients with a special
interest to show differences.
Methods: In 605 patients who underwent operation in the
Department of Surgery, University of Heidelberg—437 with
54 J Cachexia Sarcopenia Muscle (2010) 1:43–128pancreatic cancer and 168 with chronic pancreatitis—an
evaluation of the preoperative clinical course and perioper-
ative data was available.
Results: Cachexia was present in 42% of CP and 37% of
cancer patients. Although the amount of weight loss did
not differ significantly, there was a more pronounced
systemic effect of cachexia in PDAC patients, with
significantly reduced protein, albumin, and hemoglobin
levels and elevated CRP levels. Cachexia developed over
a significantly longer period in CP patients. Cachexia in
cancer was significantly associated with metastases lead-
ing to a significantly reduced resection rate. With or
without tumor resection, cachexia had an ongoing effect
on survival.
Conclusions: Although there are significant effects on
nutritional status, neither morbidity nor 30-day mortality is
increased in patients with cachexia. There is a similar
prevalence of cachexia in patients with CP and PDAC and
no difference in the amount of weight loss between the
groups, but many more significant systemic effects are
detected in cancer patients with cachexia.
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Background and aims: The aim of the study is to
compare the use of the ODC (Evans, 2008) with the
recording of weight loss (WL) for profiling nutrition and
performance characteristics of advanced cancer patients
(ACP).
Methods: Two-hundred fourteen newly diagnosed ACP
with non-small cell lung and gastrointestinal primaries
were categorized as cachectic according to the ODC
(cachexia=WL ≥5% over ≤12 months (or BMI <20) plus
≥3/5 criteria including decreased muscle strength (hand
grip), fatigue (≥3/10 on ESAS), anorexia (≥3/10 on
ESAS), sarcopenia by DXA, and abnormal biochemistry
(CRP >5.0 mg/l or IL-6 >4.0 pg/ml or Hgb <12 g/dl or
albumin <3.2 g/l)) or as weight losing if they had >5% WL
over ≤6m o n t h s .
Results:
Cachectic vs. non
cachectic patients
WL vs. non-WL
patients
β
a 95% CI β
a 95% CI
McGill QOL score
0–10 (0 worst)
−1.54 −2.18 to −0.89 −0.95 −1.64 to −0.26
ESAS QOL score
0–10 (10 worst)
1.53 0.80 to 2.26 1.07 0.32 to 1.81
ECOG PS 0–4
(4 worst)
0.75 0.46 to 1.03 0.60 0.31 to 0.89
Quadriceps ext
60°/s peak torque
(Nm)
−21.88 −42.08 to
−1.68
−20.32 −41.72 to 1.07
Total fat mass by
DXA (kg)
−8.05 −12.60 to
−3.51
−8.74 −13.04 to
−4.44
Percent body fat
by DXA
−6.95 −11.57 to
−2.32
−7.64 −12.03 to
−3.25
HR
a 95% CI HR
a 95% CI
Survival (weeks) 1.94 1.36 to 2.75 1.85 1.28 to 2.66
aControlling for gender, age, diagnosis, treatment (radio/
chemo), survival, and medications
Conclusions: The ODC does not appear to have diagnostic
and prognostic advantages over the simple recording of WL.
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patients
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According to a recent consensus, cachexia is defined as “a
complex metabolic syndrome associated with underlying
illness and characterized by loss of muscle with or without
loss of fat mass. The prominent clinical feature of cachexia
is weight loss in adults (corrected for fluid retention) or
growth failure in children (excluding endocrine disorders).
Anorexia, inflammation, insulin resistance, and increased
muscle protein breakdown are frequently associated with
cachexia. Cachexia is distinct from starvation, age-related
loss of muscle mass, primary depression, malabsorption,
and hyperthyroidism and is associated with increased
morbidity” [1]. Although this definition is accompanied
by diagnostic criteria, it does not consider the problem of
staging. Indeed, stratification of patients is important when
J Cachexia Sarcopenia Muscle (2010) 1:43–128 55considering therapy. In fact, in the very first stages of
wasting, body weight loss is not necessarily involved—a
state known as pre-cachexia. The aim of the present score is
to overcome the problem of patient staging. The score
considers five main different factors: body weight and lean
body mass loss, anorexia, inflammatory, immunological
and metabolic disturbances, physical performance, and
quality of life. The score’s scale goes from 0 to 100: mild
cachexia (less than 25), moderate (more than 25 and less
than 50), severe (more than 50 and less than 75), and
terminal phase (more than 75 and up to 100). The score also
takes into consideration pre-cachexia. In conclusion, the
present score will facilitate cachexia staging and therefore
will allow for a more convenient therapy.
[1] Evans WJ, Morley JE, Argilés J, Bales C, Baracos V,
Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H,
Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand
A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols
A, Schuster M, Thomas D, Wolfe R, Anker SD (2008)
Cachexia: a new definition. Clin Nutr 27(6):793–799
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Background: Cachexia and body wasting is encountered in
advanced stage of many malignant and non-malignant
chronic disease. Once present, it is associated with grim
prognosis. The therapeutic approachto cachexia to date must
be considered as undefined, with few exceptions. Public
health primarily seeks for population-based strategies to
tackle diseases with major impact on health care system.
Epidemiology and management challenges: Several
definitions with different criteria and cut-offs were used,
and only recently, a consensus for clinically relevant
cachexia was reached. Epidemiological data is therefore
speculative, based on chronic disease prevalence and
assumption that 10–80% of patients, depending on the
condition and standards of care, eventually develop cachex-
ia. Geographical variations in prevalence of chronic disease
are substantial and conform with socioeconomic status and
available medical care. Our management approach should
therefore consider all circumstances including those beyond
the chronic disease and adopt the interventions with greatest
impact potential for selected community. Fighting infectious
disease and poverty is important and would transiently
decrease cachexia patient pool. However, since chronic
disease continuum is more and more present in developing
countries, this will eventually be counter- or ever over-
balanced, and cachexia will presumably remain an important
public health issue. It is therefore even more important to
intensify our therapeutic efforts to stop or even to reverse the
deadly cascade of events leading to cachexia and improve
the quality of life and clinical outcomes for our patients.
Clinical implications: Cachexia meets several criteria that
need to be addressed by public health practitioners.
Preventive and educational strategies, particularly in com-
munities with high prevalence of HIV infection, malnutri-
tion, and rheumatic fever-related cachexia, may be
beneficial. Public health strategies in developed countries
where cachexia is mainly related to cancer, chronic
cardiopulmonary, and kidney disease need to target other
issues than in non-developed countries.
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Anti-tumor and antioxidant effects of antioxidant
nutrients in breast cancer-implanted rats
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Background and aims: In the present study, we examined
the anti-tumor and anti-oxidative stress effects of antioxidant
nutrients in breast cancer-implanted rats, in order to investi-
gate the validity of antioxidants-containing enteral formula.
Materials: Female F344 rats were divided into two groups:
control diet and antioxidant (AO) diet. After 7 days offeeding
each nutrient diet, breast cancer Mat B-III cells were
transplanted subcutaneously, and each diet was continued
untilsacrificeineachgroup.Thebodyweights,intakevolume
of each diet, and tumor size were measured daily, and the rats
were sacrificed on post-transplantation days 7 and 14. Blood
samples were collected to measure serum total protein,
albumin, tumor necrosis factor-alpha (TNF-alpha), 2,2′-
azinobis-(3-ethylbenzthiazoline sulphonate) (ABTS) radical-
scavenging activity, superoxide dismutase (SOD), and cata-
lase(CAT)activity.Theseparameterswerecomparedbetween
56 J Cachexia Sarcopenia Muscle (2010) 1:43–128the two groups by Student’s t test and Dunnett test, and the
statistical significance was defined as p<0.05.
Results: Nutrient intake decreased in the control diet
group significantly on days 1, 3, 4, and 11 after
transplantation. The size of implanted tumor increased
from post-implantation day 4 in both groups, however,
significantly lower in AO diet group. There was a
significant correlation between SOD and CAT activities
in the AO diet group (r=0.88, p=0.02), but not in the
control diet group (r=0.12, p=0.78).
Conclusion: Our results suggest that the effects of nutrition
with antioxidants in breast cancer-bearing rats contribute to
a suppression of cancer growth and cachexia by maintain-
ing the balance of reactive oxygen scavenging enzymes.
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Cancer cachexia impairs heart function and alters
cardiac muscle structure in mice
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Background and aims: Cachexia is a common syndrome
in advanced cancer patients and significantly impairs
quality of life. It remains elusive whether cancer cachexia
causes heart failure. In this study, we investigated the effect
of cancer cachexia on heart function and cardiac muscle
structure in a mouse model for cancer cachexia.
Methods: Male CD2F1 mice were inoculated with either
1×106 colon-26 adenocarcinoma cells (tumor group) or
vehicle (PBS; no tumor group). Another group of mice
received PBS and was pair-fed to tumor group. An
indicator of heart function, fractional shortening was
measured in vivo using transthoracic M-mode echocardi-
ography. At necropsy (day 17 after tumor/PBS inocula-
tion), hearts were collected for histology and qRT-PCR
analysis.
Results: Mice from tumor group displayed a significantly
reduced fractional shortening compared to mice in no
tumor and pair-fed groups. In hearts of tumor mice
compared to other groups, there were marked increased
fibrosis revealed by Masson’s trichrome staining. Gene
expression of troponin I, a regulator of cardiac muscle
contraction, was reduced. Moreover, the fetal gene
program was reactivated as demonstrated by decreased
gene expression of the structural protein myosin heavy
chain (MHC)α (adult isoform) and increased expression
of MHCβ (fetal isoform).
Conclusions: Heart function was diminished in colon-26
tumor-induced cachectic mice, and this impaired function
was associated with increased fibrosis and altered gene
expression of contractile and structural proteins of cardiac
muscle.
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Investigation of endogenous pro-oxidant
and antioxidant pathways contributing to cardiac
muscle wastage in a mouse model of cancer-induced
cachexia
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Background and aims: Studies have shown that
reactive oxygen species (ROS) in patients and animal
models of cancer cachexia are increased and are linked
to the activation of proteolytic pathways. This study
aims to investigate pro- and antioxidant pathways as
possible contributors to cardiac atrophy in cancer
cachexia.
Methods: Eight-week-old nude mice received either an
intraperitoneal injection of MAC16 (murine adenocarcino-
ma cells; n=16) producing cancer-induced cachexia,
MAC13 (n=12) cells used as no cachexia control or an
equal amount of cell media (n=8) as no tumour control.
The levels of DNA damage by oxidation were examined,
mRNA levels for xanthine dehydrogena se, NADPH
oxidase subunits p47, p67, NOX2, NOX4 and total
superoxide dismutase (SOD) enzyme activity were ana-
lysed. A Western blot protein analysis was carried out
examining both NOX2 and P47 expression.
Results: Food and water intake did not vary between
groups. Heart weight was significantly decreased in the
MAC16 group by 15%. A marker for DNA oxidative
damage 8-OH-2dG was significantly increased in the
MAC16 group. Gene transcripts for xanthine dehydroge-
nase were significantly increased in cachectic heart muscle.
Significant decreases were found with total SOD enzyme
activity.
Conclusions: The significant increase in 8-OH-2dG and
gene expression of an ROS producer in the myocardium,
xanthine dehydrogenase may imply an important role for
this system in the atrophy of the cachectic heart. Further-
more, decreases in total SOD activity may indicate an
inability for handling ROS. Overall, oxidative stress may
switch on proteolytic systems in the cachectic heart leading
to significant atrophy.
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Efficiency of oxidative phosphorylation in liver
mitochondria is decreased in cancer cachexia: a role
for cardiolipin and reactive oxygen species (ROS)?
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Background and aim: Cancer cachexia is a complex
syndrome, and the underlying mechanisms are not fully
understood. Whether mitochondria function is altered during
this disease and may participate to hypermetabolism is not
clear. The aim of our study was to analyze liver mitochon-
drial function, especially the efficiency of ATP synthesis and
its regulating mechanisms (proton leak, oxidative stress, and
cardiolipin) in a rat model of cancer cachexia.
Methods: Oxygen consumption (oxygraph), ATP synthesis
(spectrophotometer), membrane potential (TPMP+ electrode),
ROS production (fluorimeter), and cardiolipin content (fluo-
rimeter) were measured in isolated liver mitochondria from
cachectic (peritoneal carcinosis (PC)) and pair-fed control rats.
Results: Our results showed that efficiency of ATP synthesis
was lower (−24%) in liver mitochondria from PC than
control rats. Proton leak was higher in PC than control rats as
state 4 oxygen consumption was increased (+22%) and state
4 membrane potential was decreased (−5%). ROS production
was increased (12-fold), and cardiolipin content was higher
(+55%) in liver mitochondria from PC than control rats.
Conclusions: Our results demonstrate that PC induces
important energy wasting in liver mitochondria. In conse-
quence, more nutrients are necessary to synthetize a given
quantity of ATP. Because liver is accounting for 25% of total
body energy expenditure, this could participate to hyperme-
tabolism and the weight loss associated to cancer cachexia.
Our results suggest that cardiolipin and ROS could partly
explain the decrease in ATP synthesis efficiency in liver.
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Does energy wasting in skeletal muscle mitochondria
play a role in hypermetabolism observed in cancer
cachexia? Study in a model of peritoneal
carcinocis-induced cachexia
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Cancer cachexia is a composite syndrome with a combina-
tion of anorexia and hypermetabolism, which leads to a
drastic loss in body weight. Mechanisms of hypermetabo-
lism remain to be fully elucidated. We hypothesize that
energy wasting in mitochondria of skeletal muscle (30% of
resting metabolism rate) could contribute to hypermetabo-
lism. Peritoneal carcinosis (PC), a frequent complication of
digestive cancer, was generated by an intraperitoneal
injection of PROb cells in BDIX rats. A group of rats was
pair-fed for PC rats in order to discriminate between the
effect of anorexia or cachexia. PC rats were sacrificed at a
severe cachexia state (food intake reduced to −80%).
Mitochondrial oxygen consumption and ATP synthesis
were measured (by oxygraphy and spectrophotometry,
respectively), and the efficiency of ATP production (ATP/
O ratio) was assessed on mitochondria isolated from skeletal
muscle. PC rats displayed a lower body weight gain as well
as lower muscle (−17%) and fat (−40%) masses than pair-fed
rats, suggesting a hypermetabolism state. Besides, serum
TNF-alpha was significantly increased in PC rats (27-fold).
Muscle mitochondria did not exhibit modification in the
ATP/O ratio. However, data also showed a decrease in
oxygen consumption linked to ATP synthesis in PC rats
mitochondria (480±69 vs 600±65 natomsOmin
−1mg
−1 in
PC and pair-fed rats, respectively). Contrary to our hypoth-
esis, there was no energy wasting in skeletal muscle
mitochondria in PC rats. However, as cancer cachexia is a
progressive syndrome, we cannot rule out that ATP/O ratio
alterations are present in earlier cachectic state.
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Background and aims: Many host and tumor-secreted
products act as mediators of cancer cachexia. The dermcidin
(DCD) gene is overexpressed in various types of cancer, and
its products may have biological functions in cancer etiology
and host pathophysiology. This study evaluates the role of
DCD in causing cancer cachexia in murine xenograft
models.
Methods: Groups of C57BL/6 or Balb/c nude mice (16–
25 g) were subcutaneously injected with murine mela-
noma B-16, human melanoma G-361 cell lines, human
58 J Cachexia Sarcopenia Muscle (2010) 1:43–128breast carcinoma MCF-7, and MDA-MB-361 cell lines with
stably overexpression of the gene or their derived clones
constitutively expressing shRNA against DCD mRNA
(knockdown) as well as the daily i.p. injection of rhDCD.
The body weight changes, tumor volume, and performance
status were monitored daily from 10 to 120 days.
Results: The body weights remained steady or did not
gained weight in the B16-DCD-, MCF-7-DCD-, and MDA-
361-implanted mice despite of larger tumors as compared to
controls. On the contrary, mice bearing G-361 melanoma
cells underwent a progressive loss of body weight, which
could be partially suppressed by expressing constitutively
shRNA against DCD or twice-weekly injection of rabbit
polyclonal antibody against DCD. The twice-a-week
exogenous administration of rhDCD for 10 days did not
cause any symptom associated with cachexia.
Conclusion: It is proposed that cancer cachexia is not
directly associated with the expression or activities of DCD
11 kDa protein but by others host and tumor cells products
in which the expression is regulated by DCD.
Support by FAPESP.
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Background and aims: Muscle atrophy associated with
chronic diseases mainly results from protein hypercatabolism.
In particular, the degradation of myofibrillar proteins occur-
ring in cancer cachexia eventually depends on the ubiquitin-
proteasome system. Recently, the possible contribution of the
autophagic/lysosomal pathway has been proposed. The
present study has been aimed to evaluate whether autophagy
is involved in cancer-induced skeletal muscle atrophy.
Methods: Balb-c mice were divided into controls (C) and
tumor bearers (TB). The latter were inoculated s.c. with 5×
105 C-26 tumor cells. After 13 days, mice were sacrificed,
and the gastrocnemius (GSN) muscle was excised and
stored for further analysis. C2C12 myocytes were exposed
to TNF-alpha during 48 h. Levels of LC3B-II and p62, two
accepted markers of autophagy, were analyzed by Western
blotting (WB) and immunofluorescence (IF).
Results: GSNweightloss inTBwas associatedwithincreased
levels of both LC3B-II and p62. To investigate if proinflam-
matorycytokinesmaycontributetosuchincrease,LC3B-IIand
p62 levels were evaluated also in TNF-alpha-treated C2C12
myotubes. Both WB and IF analysis showed high levels of
LC3B-II, associated with an increased number of autophagic
vacuoles. Similarly to the GSN of TB mice, also TNF-alpha-
treated myotubes displayed an accumulation of p62.
Conclusions: The results shown in the present study
suggest that autophagy may be hyperactivated in the
skeletal muscle of TB mice, as well as in C2C12 myotubes
exposed to the proinflammatory cytokine TNF-alpha.
Further analysis will be useful to understand the role
played by autophagy in muscle wasting.
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Background and aims: We know that the gut microbiota
is implicated in energy metabolism, and its role has
been mostly studied upon obesity. Here, we set the
hypothesis that the gut microbiota could also be implicat-
ed in metabolic alterations associated with cancer,
cachexia.
Methods: This hypothesis was assessed in BALB/c mice
intravenously injected with mouse proB BAF3 cells trans-
fected with BCR-ABL gene in order to allow the
development of chronic myelogenous leukemia (CML).
Muscles (tibialis and gastrocnemius), liver, intestine, and
adipose tissues were withdrawn 2 weeks after injection for
further biochemical and histological analysis. Gut micro-
biota composition was assessed by RT-qPCR.
Results: BCR-ABL expressing CML constitutes a new
model of cancer cachexia, as proven by a decrease in
adipose and muscle tissue weights. In both male and
female, Lactobacillus spp. levels in cecal content drastically
decrease, independently of food intake (p<0.001). More-
over, this decrease is highly correlated to muscle markers of
atrophy, such as Atrogin-1 mRNA (r=−0.8885, p<0.0001).
Finally, increasing the level of Lactobacillus spp. by dietary
prebiotics allows to lessen Atrogin-1 mRNA induction in
the muscle.
J Cachexia Sarcopenia Muscle (2010) 1:43–128 59Conclusions: In this new model of cancer cachexia, we
highlight that selective gut microbiota modifications occur
and are associated with muscle atrophy. Therefore, we
suggest that the gut microbiota may constitute a new target
in the treatment of this crucial metabolic disorder associated
with cancer development.
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Exercise counteracts cachexia and extends life span
in tumor-bearing mice
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Cachexia, experienced by most cancer patients, is a
negative prognostic factor, interfering with therapy and
worsening quality of life. Recent studies showed that
physical activity after cancer diagnosis lowers the risk of
both cancer-specific and overall mortality, although no
specific assessment of cachexia was performed in these
studies. With the aim to assess whether exercise may be
beneficial against cancer cachexia, we analyzed the effects
of spontaneous physical activity (wheel running) in colon
carcinoma (C26)-bearing mice. Two exercise protocols
were used: 5-day running or 19-day running (starting after
tumor implant). We found that while cachectic muscle
showed fiber damage and necrosis, wheel running did not
exacerbate muscle damage. The beneficial effects of
exercise in tumor-bearing mice were induced only by the
19-day running protocol and included the rescue of body
weight loss, muscle mass loss, fiber atrophy, and enhanced
protein catabolism. Besides, exercise was an appetite
stimulant. We noted that cachexia resulted in loss of muscle
resistance to fatigue and not of specific force, and we found
that exercise rescued muscle resistance of tumor-bearing
mice to healthy control levels. The effects of exercise
resulted in an average 50% life span extension in tumor-
bearing mice. In conclusion, according to all the diagnostic
criteria derived from the current consensus definition of
cachexia, wheel running started at the onset on pathology
efficiently counteracts cancer cachexia in mice and extends
their life span.
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in cachexia: role of interleukin (IL) 10
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Cachexia is a multifaceted syndrome whose aetiology is
extremely complex and is directly related to the reduction
of survival and to poor prognosis. Changes in lipid
metabolism in cancer cachexia include marked reduction
of total fat mass, increased lipolysis, total oxidation of fatty
acids, hyperlipidaemia, hypertriglyceridaemia and hyper-
cholesterolaemia. These changes are believed to be induced
by inflammatory mediators, such as tumour necrosis factor-
alpha (TNF-alpha). As an endocrine and inflammatory
organ, white adipose tissue (WAT) is an important source of
pro-inflammatory cytokines, which may trigger several
changes in WAT and systemic homeostasis. In addition to
pharmacological approaches, lifestyle modifications have
been advocated for the treatment of chronic inflammation.
In order to counteract inflammation in chronic disease, our
group has currently adopted chronic endurance exercise in
experimental models of cancer cachexia (Walker 256
carcinosarcoma) and chronic heart failure. Since it is clear
that white adipose tissue is strongly implicated in the
secretion of both pro- and anti-inflammatory factors in
disease, we chose to address its contribution to cachexia-
related inflammation and the effect of endurance training on
the capacity of cytokine expression and secretion by this
tissue. Our results show a reduction of tumour mass and
infiltrating macrophage cell number in WAT. An enhance-
ment of IL-10 adipose tissue and skeletal muscle content,
with concomitant increased IL-10/TNF-alpha ratio, was
also demonstrated after endurance training. Taken togeth-
er, our results suggest that the increase in IL-10
concentration might be induced by PPAR-ƒ× activation
induced by exercise training leading to a shift towards
decreased inflammation.
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039
Exercise increases liver fatty acid oxidation
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The effect of endurance training on hepatic carnitine
palmitoyltransferase (CPT) system activity was studied in
tumour-bearing (Walker 256) rats. Animals were assigned
60 J Cachexia Sarcopenia Muscle (2010) 1:43–128to a sedentary control (SC), sedentary tumour-bearing (ST),
or exercise control (EC) or exercise tumour-bearing (ET)
group. Trained rats ran on a treadmill (60% VO2 max)
60 min/day, 5 days/week, for 8 weeks. Gene expression of
CPT I and II, L-FABP and COX-2, and the maximal
activity of CPT I and CPT II were assessed in the liver. PGE2
content was measured in the serum, liver and tumour. CPT I
and CPT II activity was decreased (p<0.01) in ST (2.66±0.0
and 0.16±0.10 nmolmin
−1mg
−1protein, respectively) when
compared with SC (3.66±0.38 and 1.68±0.16 nmolmin
−1
mg
−1protein, respectively). In contrast, liver COX-2 mRNA
of cachectic animals was increased, as well as PGE2, in
serum (2.526±0.132 ng/mL, p<0.05), as compared to SC
(1.901±0.259 ng/mL). Liver PGE2 was increased (2.030±
0.047 ngμgprotein
−1, p<0.05) when compared to SC
(0.997±0.036 ngμgprotein
−1). Exercise restored CPT I and
CPT II activity in tumour-bearing rats (10.61±1.62 and
9.25±1.12 nmolmin
−1mg
−1protein, respectively, p<0.0001),
when compared to ST. Training decreased hepatic PGE2
levels in ET (1.150±0.053 ngμgprotein
−1, p<0.05) and
decreased tumour PGE2 content (ET, 2.750±0.096 ngμg
protein
−1 vs ST 4.580±0.088 ngμgprotein
−1, p<0.01). COX-
2 mRNA expression was decreased in the liver of ET when
compared with the sedentary counterparts. In conclusion,
endurance training was capable to promote the reestablish-
ment of liver mitochondrial carnitine palmitoyltransferase
(CPT) system activity due to a decrease in PGE2 levels in
cachectic tumour-bearing animals, preventing steatosis.
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The white adipose tissue (WAT) has been recently recognised
as a source of many endocrine and pro-inflammatory factors,
being a potential contributor to cachexia-related inflamma-
tion. Moderate intensity exercise training is known to
counteract chronic inflammation and affects the expression
of inflammatory factors in WAT. We compared three different
adipose pads (retroperitoneal (RPAT), mesenteric (MAT) and
epidiymal (EAT)) in regard to the effects of training (TBEx,
6 weeks treadmill, 60–65% VO2 max) upon inflammation in
cachectic Yoshida AH-130 tumour-bearing rats (TB), with
special focus on the NF-kappaB pathway. The results show
that training prevented the infiltration of mononuclear cells
and fibrosis in WAT (qualitative light microscopy) but was
not able to counteract the increase in NF-kappaB to DNA
(ELISA) in MAT due to cachexia, although a tendency (p<
0.055) to decreased NF-kappaB mRNA expression (real-
time PCR) was observed. In EAT, solely, training induced an
augment in phosphor-NF-kappaB expression (Western blot),
together with enhanced depot weight, as compared with TB.
For TARP, no significant differences were found between
groups. The marked decrease of weight expected due to
cachexia was prevented (p<0.0001) in the three muscles
examined (soleus, gastrocnemius and tibilalis) by training.
We conclude that the short period training protocol was able
to affect the NF-kappaB pathway in WAT in a heterogeneous
manner, as well as preventing inflammatory cell infiltration.
The preservation of muscle mass herein reported strongly
suggests the potential of exercise as an adjuvant therapy in
the control of wasting in cachexia.
Funding by FAPESP 08/54091-9.
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Heterogeneous response of rat and human adipose
tissue in cancer cachexia
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White adipose tissue (WAT), whose morphology and
physiology vary according to depot anatomical local-
isation, is markedly affected by cachexia. We demon-
strated that in the Walker 256 model of cachexia, the
retroperitoneal (RPAT), mesenteric (MAT), and epididy-
mal (EAT) pads respond differently: while EAT shows
the greatest decrease in weight, the other depots present
pronounced changes regarding adipocyte shape and size.
F a t t ya c i dc o m p o s i t i o ni sm o d i f i e di nM A Ta n dE A T ,b u t
not in RPAT. Ultrastructural abnormalities were observed
in RPAT and EAT, solely. In a subsequent investigation,
we found that the pads were markedly infiltrated with
macrophages resembling “fo am cells” in cachectic rats.
The extent of infiltration was greater in MAT, which
showed higher TNF-alpha production, although the
depots responded similarly in regard to decreased leptin
secretion. The IL10/TNF-alpha ratio, a marker of
inflammation, was also found to vary heterogeneously.
These results encouraged us to examine whether human
WAT would also show heterogeneous response to
cachexia. The omental (OAT) and subcutaneous (SC)
J Cachexia Sarcopenia Muscle (2010) 1:43–128 61pads of 18 cachectic cancer (gastric and colon, CCAC)
patients from the university hospital were studied and
compared withthe tissue ofnon-cachectic cancer patients (n=
8, CC) and with eight “control” subjects (non-cachectic,
hernia, or cirrhosis patients, CT). Results show macrophage
infiltration, along with a marked increase in WAT collagen
type I in both pads, alterations which were only evident in
CCAC. In SC of CACC, increased collagen type III was
found. CCAC showed decreased OAT adipocyte perimeter
and area in relation to CC and CT (p<0.01).
Funding by FAPESP.
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Changes in interleukin (IL) 10 and tumour necrosis
factor (TNF) alpha of rat white adipose tissue in cachexia
Miguel Batista Jr., Felippe F. Donatto, Rodrigo Neves,
Alex Shimura Yamashita, Marilia Seelaender
Cancer Metabolism Research Group, Institute of Biomed-
ical Sciences, University of São Paulo, São Paulo, Brazil
Background and aims: The white adipose tissue (WAT) is
severely affected by cachexia, a paraneoplastic inflammatory
syndrome, in which cytokines, such as tumour necrosis factor-
alpha (TNF-alpha), are known to play an important role. In
response to the cachexia-related pro-inflammatory cytokines,
thereisconcomitantenhancedproductionofanti-inflammatory
factors, such as interleukin 10 (IL-10). Recently, the TNF-
alpha/IL-10 ratio has been recently postulated as a marker for
the assessment of the degree of inflammation, which correlates
with disease-associated morbidity and mortality.
Methods: We measured (ELISA) the local concentration of
these cytokines in three WAT depots: retroperitoneal
(RPAT), epididymal(EAT), andmesenteric (MES) ofWalker
256 tumour-bearing rats in a time interval of 7 (T7) and 14
(T14)days after tumour-cell inoculation (5×10
−5 cells/mL).
Results: Higher concentration of TNF-alpha was found on
T14 (30%) of MES of cachectic rats, compared with T7.
EAT and RPAT IL-10 levels were reduced on T14 (86% and
60%, respectively) compared to T7. Regarding the TNF-
alpha/IL-10 ratio, there was an increase in EAT (15.4-fold)
and RPAT (2.4-fold) after 14 days (T14), compared with T7.
Conclusion: The results suggest a heterogeneous local
response of both TNF-alpha and IL-10 expression, with an
accentuated reduction in IL-10 mRNA levels and little change
inTNF-alphamRNAexpression.Inaddition,changesinTNF-
alpha/IL-10 ratio were more evident in EAT and RPAT of the
cachectic rats. We conclude that the degree of inflammation of
WAT is dependent of anatomical localization of the pad.
Funding by: FAPESP 2007/52782-1 and 08/54091-9.
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Cachexia decreases adipokine expression in Walker 256
tumour-bearing rats
Renata Silvério, Fabio S. Lira, Marilia Seelaender
Cancer Metabolism Research Group, Institute of Biomedical
Sciences, University of São Paulo, São Paulo, Brazil
Cancer cachexia markedly affects the white adipose tissue
(WAT), an important endocrine organ, releasing a plethora
of factors, the adipokines. Among these, leptin and
adiponectin are fundamental for metabolic and body
composition regulation. Interleukin-15 (IL-15) is an anti-
inflammatory cytokine showing direct effects on mature
adipocytes, decreasing leptin and increasing adiponectin
secretion. IL-15 expression in WAT has never been
addressed in cancer cachexia, while the effect of this
paraneoplastic syndrome upon adipokine secretion remains
controversial. We examined the expression of these factors
by WAT, with special focus on the heterogeneous response
of fat pads. Animals were assigned to a tumour-bearing
group (Walker 256, TB, n=9) or control group (C, n=6).
Plasma leptin and adiponectin (RIA), as well as gene
expression (real-time PCR) of leptin, adiponectin, interleu-
kin 15 (IL-15), nuclear-factor kappaB (NFkappaB), and
inhibitory protein kappaB-alpha (IkappaB-alpha), were
determined in the retroperitonial (RPAT) and epididymal
(EAT) adipose tissue. Adiponectin and leptin mRNA levels
werereducedinbothdepotsstudied(around99%inRPATand
78% and 96%, respectively, in EAT), as well as IL-15
expression (96% in RPAT, p<0.05 and 75% in EAT, p<
0.005). Plasma adiponectin (p<0.001) and leptin (p<0.001)
also decreased in TB. The present results show that in
advanced experimental cachexia WAT, capacity to produce
the studied factors is compromised, and this effect is more
pronounced in the RPAT. As IL-15 has been associated with
NFêB activation in neutrophils, we investigated whether its
decrease would concomitantly diminish the expression of
t h i st r a n s c r i p t i o nf a c t o ri nW A T ,h a v i n gf a i l e dt od e t e c t
changes.
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Altered circadian regulation of metabolic pathways
in liver and fat of C26 cachectic mice
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62 J Cachexia Sarcopenia Muscle (2010) 1:43–128Background and aims: The pathogenesis of cancer
cachexia is complex involving perturbations in the homeo-
static control of energy balance in fat, skeletal muscle and
liver. We explored the links between altered regulation of
metabolic pathways in liver and fat and tumour-derived
cytokines such as IL-6. As diurnal rhythm influences
metabolic control, the circadian expression patterns of
metabolic genes were characterised.
Methods: Colon-26 cells were implanted s.c. into mice and
tissues harvested on day 14 for molecular analyses at six
circadian time points for comparison with ad lib-fed and
pair-fed controls. Expression of genes involved in meta-
bolic pathways, nuclear receptors and other metabolic
regulators was analysed by qPCR. Liver proteins were
profiled by multiplexed mass spectroscopy using iTRAQ
labels.
Results: Extensive changes in lipid utilisation were evident
in liver and fat with alterations in PPAR-alpha and delta,
PGC1-alpha and genes (lpl, CD-36, perilipin, L-FABP,
PBE, CPT1-alpha and HADHA/B) involved in fatty acid
mobilization and beta-oxidation. Genes involved in lipid
accumulation (PPAR-gamma, C/EBP-alpha, FAS, SCD-1
and CD36) were similarly affected. These changes occurred
at specific times in the diurnal cycle, with distinctive
amplitude and phase shifts. Proteomic profiling by iTRAQ
quantified >1,500 hepatic proteins, confirmed these defects
in lipid handling and also showed a general impact on
mitochondria function. Plasma IL-6 levels progressively
increased to ~120 pg/ml, and in all organs analysed, IL-6
signaling was activated. Pair-feeding experiments showed
that these changes could not be attributed to reduced feed
intake.
Conclusions: Cachexia in the C26 mouse model is
associated with aberrant circadian regulation of metabolic
pathways, especially lipid handling. In the liver ATP,
generation may be severely compromised, while many
acute phase proteins are elevated.
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Cancer cachexia induced molecular and morphological
changes in bone
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Background and aims: Bone lytic effects due to cancer
cachexia are largely unknown. Cancer cachexia syndrome
(CCS) is a hypermetabolic disorder, affecting multiple
tissues in cancer sufferers. CCS is prevalent in up to 50–
80% of advanced cancer patients and directly contributes to
20–30% of cancer patient mortality. The upregulation of
catabolic processes and concurrent reduction in anabolic
pathways both contribute to weakened muscle and bone.
However, the molecular progression of cachexia that drives
these changes in bone metabolism and endocrinology is
poorly understood. Studies focusing on molecular regu-
lators, which control bone resorption during CCS, are
presented. Furthermore, it was anticipated that such
changes were coupled to morphological changes in bone
during overt cachexia.
Methods: The colon-26 adenocarcinoma mouse model of
cachexia has been established to investigate such tumour-
mediated changes in bone. Particular focus has been given
to the impact of tumour-derived factors in a tumour setting
by measuring changed molecular expression patterns of IL-
6; signalling molecules, e.g. ERK 1/2 MAPK; as well as
osteogenic bone regulators, e.g. bone morphogenic protein-
1 (BMP-1). Changes in osteoclast numbers were assessed
using TRAP staining.
Results and conclusions: The findings suggest that during
cancer cachexia, tumour-derived factors impact on regu-
lators of bone formation by changing molecular expression
patterns leading to increased osteoclasts and dysregulated
bone remodelling.
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In early colorectal cancer only minor muscle wasting
occurs but is preceded by depression of muscle protein
synthesis (MPS) with no evidence of elevated muscle
protein breakdown (MPB)
Sitaramachandra M. Nyasavajjala, Chetan Srinath,
Sarah Liptrot, Anna Selby, Debbie Rankin, Philip
Atherton, Kenneth Smith, John P. Williams, Jonathan N.
Lund, Rajeev Singh, Michael J. Rennie
School of Graduate Entry Medicine and Health, Royal
Derby Hospital, Derby, UK
Background and aims: Baracos et al. have developed a
useful method with clinical CT images to investigate
muscle wasting. We applied this technique retrospectively
to colorectal cancer patients, in a subset of whom we had
sought disordered muscle metabolism.
Methods: We analysed CT images (psoas major, L-3;
gluteus maximus, coccyx) for 65 patients (73±11 years)
with colorectal cancers and 56 patients (71±11 years) who
proved normal on investigation. In a subset (n=18, 74±
10 years) of the cancer patients, we also characterized
muscle metabolism by state-of-the-art stable tracer and
molecular methods.
J Cachexia Sarcopenia Muscle (2010) 1:43–128 63Results: In the healthy patients, psoas thickness was 30
(28, 31)mm (median (95% CI)) and 31 (26, 30)mm in
patients with cancers. Normal gluteus thickness was 30 (31,
36) mm and 29 (32, 38)mm in patients; normal psoas cross-
sectional area (CSA) was 2,873 (2,708, 3,299)mm
2 and in
patients was 3,049 (2,561, 4,155)mm
2. In patients in whom
protein metabolism was studied, psoas thickness was 30
(28, 35)mm, gluteus thickness was 36 (32, 38)mm and
psoas CSA was 2,973 (2,442, 3,074)mm
2. Thus, in patients
with early colorectal cancer (diagnosed <6 weeks of
referral), significant wasting could not be detected by
comparison with age-matched controls. However, in those
whose muscle metabolism was investigated, despite only
minor losses of leg muscle (2–15 g/day by successive DXA
scans over 8 weeks), muscle protein metabolism was
conspicuously deranged, showing “anabolic resistance” of
MPS (fed state, 0.030±0.003%/h vs. 0.071±0.003%/h),
with no evidence of elevated MPB or of mRNA or protein
“markers” of MPB.
Conclusion: Establishment of muscle metabolic dysfunc-
tion precedes major sarcopenia in colorectal cancer.
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Sarcoplasmic reticulum-mitochondrial abnormalities
related with muscle atrophy in cancer cachexia
Cibely Cristine Fontes-Oliveira, Paula Ventura da Silva,
Sònia Sirisi, Marcel Orpí, Maria Ines Genovese, Míram
Toledo, Albert García, Angelica Sette, Mireia Olivan,
Francisco J. López-Soriano, Sílvia Busquets, Josep M.
Argilés
Cancer Research Group, Departament de Bioquímica i
Biologia Molecular, Facultat de Biologia, Universitat de
Barcelona, Barcelona, Spain
Background and aims: Cachexia is a wasting condition
that manifests itself in several life-threatening diseases, and
the most prominent phenotypic is the profound loss of
muscle mass. The goal of this work was to evaluate the
putative role of mitochondrial in the skeletal muscle and
sarcoplasmic reticulum in cachexia animal models.
Methods: Transmission electron microscopy (TEM) was
carried out in muscles from control and tumour-bearing rats
(Yoshida AH-130 ascites hepatoma). The pattern of gene
expression was performed by RT-PCR and protein expres-
sion by Western blot.
Results: The morphological analysis was performed
through TEM and revealed mitochondrial abnormalities
such as swelling and cristae disruption. Moreover, a dilated
sarcoplasmic reticulum, together with glucogen accumula-
tion, was observed, thus supporting clear dystrophic muscle
morphology. Expression of genes involved in mitochondrial
dysfunction and muscle atrophy was also assessed. The
results showed differences in the pattern of gene expression
related with apoptosis, mitochondrial biogenesis, muscular
proteolysis and calcium metabolism.
Conclusion: Altogether, the results presented indicate that
during cancer cachexia, there are changes in genes involved
in stress/apoptosis that seem to be related with mitochon-
drial and sarcoplasmic abnormalities that lead to muscle
atrophy.
048
A central serotonin 2C receptor pathway regulates
gastrointestinal motor activity via ghrelin-neuropeptide
Y signaling, but does not require downstream activation
of melanocortin 3/4 receptors in rats
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Background and aims: Serotonin (5-HT) plays a key role
in the regulation of appetite and emotion in the brain. 5-
HT2c receptor agonists exert most of their anorectic effects
through downstream melanocortin 4 receptors (MC4R) in
the hypothalamus. We hypothesized that a central 5-HT2cR
pathway regulates physiological gastrointestinal (GI) motor
activity.
Methods: The 5-HT2cR agonist, m-chlorophenylpiperazine
hydrochloride (m-CPP) or fenfluramine, was administered
intracerebroventricularly (i.c.v.) to rats. GI motility was
measured in rats by a strain gauge force transducer method.
The effects of SB242084 (5-HT2cR antagonist), HS014
(melanocortin 4 receptor (MC4R) antagonist), SHU9119
(MC3/4R antagonist), neuropeptide Y (NPY), ghrelin,
phentolamine hydrochloride (alpha-adrenergic receptor
blocker), and hesperidine (the active flavonoid ingredient
in Rikkunshito) on the GI motility induced by fenfluramine
were examined. Plasma acyl ghrelin levels were determined
by enzyme immunoassay.
Results: Intracerebroventricular administration of m-CPP
and fenfluramine to fasted rats altered the fasted motor
activities in the antrum and duodenum to fed-like motor
activities, and the phase III-like contractions were de-
creased. The 5-HT2cR antagonist, but not the 5-HT1bR and
5-HT2bR antagonists, restored the fasted motor patterns in
the antrum and duodenum of fenfluramine-treated rats.
SB242084 also inhibited the decrease in plasma acyl
ghrelin induced by fenfluramine. The MC4R and MC3/4R
64 J Cachexia Sarcopenia Muscle (2010) 1:43–128antagonists failed to modify the decreased motor activities
induced by fenfluramine. In contrast, ghrelin and NPY
restored the fasted motor patterns in the antrum and
duodenum of fenfluramine-treated rats. Phentolamine and
hesperidine, which stimulate the secretion of endogenous
acyl ghrelin, restored the fasted motor activities in
fenfluramine-treated rats.
Conclusions: These results demonstrate direct neuroendo-
crine control over GI function by central 5-HT2c receptors,
which inhibit ghrelin-NPY signalling.
049
Akt activation is not reduced in the diaphragm
of emphysematous hamsters
Hieronymus W. H. van Hees, Marianne Linkels, Cindy
J. C. Pigmans, P. N. Richard Dekhuijzen, Leo M.A.
Heunks
Pulmonary Diseases, Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands
Background: Diaphragm weakness in COPD patients is
associated with loss of contractile protein. Protein loss
results from an imbalance between protein breakdown and
protein synthesis. We recently showed that increased
protein breakdown is involved, since proteasome inhibition
restores contractile protein content and improves diaphragm
force generation in an animal model for COPD. However,
modulation of pathways concerning protein synthesis was
not studied. The aim of this study is to investigate the
activation of Akt, an important promotor of protein
synthesis, in the diaphragm of emphysematous hamsters
(EH). In addition, we studied the effect of proteasome
inhibition on Akt activation.
Methods: Emphysema was induced by intratracheal instil-
lation of elastase. Four groups were studied; normal
hamster control (NH-Co), NH treated with Bortezomib i.v.
(NH-Bt), EH-Co, and EH-Bt. Diaphragm was excised, and
Western blotting and optical densitometry were used to
determine cytoplasmic protein contents of total Akt and
phosphorylated Akt (p-Akt).
Results: Content of p-Akt was 190% higher in diaphragm
from EH-Co animals than in NH-Co (p<0.05). Also,
content of total Akt was higher in EH-Co diaphragm,
170% of NH-Co (p<0.05). Total Akt and p-Akt levels in
EH-Bt and NH-Bt were not significantly different from
respective controls. The p-Akt to total Akt ratio did not
significantly differ between groups.
Conclusion: Emphysema does not reduce Akt activation in
the hamster diaphragm. Instead, absolute levels of activated
Akt (p-Akt) are elevated in EH diaphragm. These findings
support the concept that contractile protein loss results from
increased proteolysis rather than from inhibited protein
synthesis. Furthermore, unaffected Akt activation by bortezo-
mib treatment suggests that the positive effects of bortezomib
on contractile protein content result from reduced protein
breakdown and not from enhanced protein synthesis.
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Inactivation of the MyD88 gene protects from cancer
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The anorexia–cachexia syndrome, characterized by a rise in
energy expenditure that paradoxically is associated with
loss of appetite and decreased food intake, contributes
significantly to the morbidity and mortality in cancer. While
the pathophysiology of cancer anorexia–cachexia is poorly
understood, evidence indicates that pro-inflammatory cyto-
kines are key mediators of this response. Although
inflammation is recognized as an important component of
cancer anorexia–cachexia, the molecular inflammatory
pathways involved are largely unknown. We addressed this
issue in mice carrying a deletion of the gene encoding
MyD88, the key intracellular adaptor molecule in Toll-like
and interleukin-1 family receptor signaling. Wild-type and
MyD88-deficient mice were transplanted subcutaneously
with a syngenic methylcholanthrene-induced MCG 101
tumor, and daily food intake and body weights were
recorded. While wild-type mice typically display reduced
food intake at about 5 days after tumor transplantation and
had lost 2% in body weight at the end of the experiment,
MyD88-deficient mice did not develop anorexia–cachexia
despite similar tumor growth as the wild-type mice. These
data show that MyD88-dependent mechanisms are involved
in the metabolic derangement during cancer anorexia–
cachexia and suggest that innate immune signaling is
important for the development of this syndrome.
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Age-related lean tissue loss is attenuated by treatment
with a form of soluble activin receptor type IIB
Laura Hagerty, Jennifer L. Lachey, Ravi Kumar, R.
Scott Pearsall, Matthew Sherman, Jas Seehra
Acceleron Pharma, Cambridge, MA, USA
J Cachexia Sarcopenia Muscle (2010) 1:43–128 65Background: Normal aging results in loss of muscle mass,
deterioration of muscle quality, and decline in muscle
strength. Frailty resulting from age-related lean tissue loss
is correlated to an increase in falls and fractures and an
increase in loss of independent living. Multiple TGF-beta
superfamily ligands that negatively regulate muscle mass
mediate their effects through the activin receptor type IIB
(ActRIIB). Previous studies in normal animals demonstrat-
ed that administration of a non-signaling decoy ActRIIB
promotes gain of muscle mass. To examine whether
treatment with a soluble ActRIIB could offset the aging-
induced changes in lean tissue mass and strength, we
examined the effects of RAP-435, a fusion protein
comprised of an optimized extracellular domain of ActRIIB
linked to a murine Fc, in aged mice.
Materials and methods: Seventy-six-week-old male
C57BL/6 mice were treated with either vehicle (VEH) or
10 mg/kg RAP-435 (RAP) for 8 weeks. NMR scans to
measure body composition and forelimb grip strength were
performed longitudinally across the study.
Results: Over the course of the study, the RAP group
gained muscle mass (+19.6%), while the VEH cohort lost
lean tissue mass (−2.74%) compared to baseline. Starting at
study week 2 and continuing though the last trial at week 7,
the RAP group had significantly greater forelimb grip
strength compared to the VEH mice (p<0.01), supporting
the idea that the increased muscle mass resulted in
increased muscle function.
Conclusions: These data support the hypothesis that a
soluble ActRIIB would be efficacious in attenuating
sarcopenia associated with normal aging.
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Background and aims: Muscle loss remains one of the
major factors influencing morbidity and mortality in cancer
patients. The aim of this study is to investigate the
effectiveness of D-myo-inositol 1,2,6-triphosphate (alpha
trinositol (AT)) in counteracting muscle atrophy in cancer
cachexia and the mechanisms involved.
Methods: In vivo studies were performed in mice bearing
the cachexia-inducing MAC16 tumour, while mechanistic
studies were conducted in murine myotubes.
Results: When administered at the optimal dose of
40 mgkg
−1 to cachectic mice, AT attenuated the loss of
body weight through an increase in non-fat carcass mass.
This was due to an increase in protein synthesis in skeletal
muscle associated with attenuation of the elevated auto-
phosphorylation of dsRNA-dependent protein kinase
(PKR), eukaryotic initiation factor-2-alpha (eIF-2-alpha)
and eukaryotic elongation factor 2 (eEF2). There was also
a decrease in protein degradation due to decreased activity
of the ubiquitin-proteasome pathway and casapses-3 and -
8. The effect of AT was attenuated by co-administration of
Zn
2+, and AT inhibited the increased zinc concentration in
skeletal muscle with increasing weight loss. AT also
attenuated the decrease in protein synthesis and increase
in protein degradation in myotubes in response to
proteolysis-inducing factor, angiotensin II, tumour necro-
sis factor-alpha and lipopolysaccharide, and this effect was
also reversed by Zn
2+.
Conclusions: These results suggest a common signalling
mechanism amongst a group of catabolic activators involving
Zn
2+, ATand other chelators of Zn
2+ after a potential therapy
for muscle wasting in a range of catabolic conditions.
053
Targeting the androgen receptor to treat muscle-wasting
disorders
Philipp S. Turnbull, Bajin Han, Tianshun Xu, Yu Shen,
Stephen A. Stimpson, Richard V. Clark
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GlaxoSmithKline, Research Triangle Park, NC, USA
Background and aims: Modulation of the androgen
receptor has the potential to be an effective treatment for
hypogonadism, andropause, and associated conditions
such as muscle wasting, osteoporosis, and sexual dys-
function. Side effects associated with classical anabolic
steroid treatments have driven the quest for drugs that
demonstrate improved therapeutic profiles. Novel, non-
steroidal compounds that show tissue selective activity
and improved pharmacokinetic properties have been
developed at GSK.
Methods: Structure-based drug design was used to identify
a small molecule androgen receptor modulator. This
compound was profiled in vitro assays to determine its
potency, selectivity, and molecular fingerprint. Full phar-
macokinetic analysis was implemented to determine the
molecule’s suitability to profile in in vivo studies. Extensive
in vivo studies were conducted comparing the small
molecule to dihydrotestosterone (DHT).
Results: GSK420A has an ED50 in an ORX rat model of
ca. 0.03 mg/kg. GSK420A and DHT almost completely
66 J Cachexia Sarcopenia Muscle (2010) 1:43–128restored the levator ani muscle to eugonadal levels in
28 days in the ORX model. DHT completely reversed
ORX-induced prostate atrophy, while stimulation by
GSK420A is less than 10% of that in the DHT-treated
animals. GSK420A reduces prostate weight in the intact rat.
HPG axis, LH and FSH, suppression is dose dependent. In
the 28-day ORX rat study, GSK420A showed a clear trend
of increases in other anabolic parameters, such as lean and
total body mass, lumbar spine BMD/BMC, and hematocrit.
Conclusions: GSK420A represents a drug molecule with
features that make it an attractive candidate for clinical
investigations targeting muscle-wasting disorders.
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Extracellular signal-regulated kinase (ERK) inhibition
prevents muscle atrophy in experimental cancer cachexia
Fabio Penna, Domiziana Costamagna, Andrea Bonetto,
Valerio G. Minero, Francesco M. Baccino, Paola Costelli
Department of Experimental Medicine and Oncology,
University of Torino, Torino, Italy
Background and aims: Cancer cachexia is a syndrome
characterized by loss of skeletal muscle protein, depletion
of lipid stores, and hormonal perturbations. The role of
MAP/ERK kinase in the regulation of muscle mass is still
debated. Data in the literature show that ERK inhibition
prevents IGF1-induced muscle hypertrophy, while others
demonstrate that inhibition of the ERK pathway results in a
hypertrophic phenotype similar to that elicited by IGF1
treatment. The aim of the present study has been to evaluate
the effects of ERK inhibition in two different experimental
models of cancer cachexia.
Methods: Tumor-bearing (TB) rats received 108 Yoshida
AH-130 cells i.p. and were sacrificed 7 days after
transplantation. TB mice received 5×105 colon-26 adeno-
carcinoma cells s.c. and were sacrificed 13 days later.
Results: A marked loss of body and muscle weight was
detected at the end of the experimental period, and ERK
phosphorylation increased in the gastrocnemius of TB rats
and mice. Administration of the ERK inhibitor PD98059
(3 mg/kg) to TB rats resulted in improved body and muscle
weight loss. Similarly, PD98059 treatment (1 mg/kg) in TB
mice partially prevented the loss of body weight, muscle
mass, and strength. Moreover, PD98059 administration to
TB mice resulted in decreased atrogin-1 muscle expression.
Conclusions: In the present study, ERK inhibition reduced
muscle wasting in experimental cancer cachexia, suggesting
that this kinase may be considered a new therapeutic target.
Further studies are needed to unravel the role of ERK in the
modulation of both anabolic and catabolic pathways (i.e.,
IGF-1/Akt and myostatin/follistatin) in the skeletal muscle.
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Gastric electrical stimulation increases ghrelin
production: a new approach to anorexia–cachexia
Syrine Gallas, Guillaume Gourcerol, Philippe Ducrotté,
Pierre Déchelotte, Anne-Marie Leroi,Serguei O. Fetissov
ADEN Laboratory, Institute of Medical Research and
Innovation, Rouen University, Rouen, France
Background and aim: Gastric electrical stimulation (GES)
has emerged recently as a therapeutic option for refractory
gastroparesis. Beside amelioration of nausea and vomiting,
GES results in improved appetite; however, the mecha-
nisms of this improvement remain unknown. The present
study was designed to determine these mechanisms.
Methods: During laparotomy, two electrodes were implanted in
the rat stomach, and typical for gastroparesis, GES with Enterra
parameters was applied for 1 h. Expression of digestive and
hypothalamic hunger and satiety peptides was assayed.
Presence of c-Fos protein in the stomach and in the brain with
relation to ghrelin-producing cells or to catecholaminergic
neurons, respectively, was studied by immunohistochemistry.
Results: GES increased c-Fos in the gastric myenteric
plexus and increased expression of ghrelin mRNA and
protein in the stomach as well as plasma ghrelin level. In the
arcuate nucleus of the hypothalamus, GES increased c-
Fos and agouti-related protein mRNA expression. GES
reduced the number of c-Fos-positive cells throughout the
nucleus of the solitary tract including catecholaminergic
neurons.
Conclusions: This study shows that GES may improve
appetite mainly via stimulation of ghrelin production and its
downstream pathways in the hypothalamus, as well as by
reducing activity of catecholaminergic brainstem neurons.
These results suggest that GES with parameters used for
treatment of gastroparesis could potentially improve appe-
tite in patients with other pathological conditions charac-
terized by chronic anorexia and cachexia.
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Effect of SUN11031 (a synthetic human ghrelin) on
pulmonary and systemic abnormalities in the cigarette
smoke-induced chronic obstructive pulmonary disease
(COPD) model
Yoshiyuki Kamiide, Masako Sugiyama, Chihiro Tamaki,
Tsuyoshi Matsuo, Hiromitsu Takagi, Mayumi Furuya
Biomedical Research Laboratories, Asubio Pharma Co.,
Ltd., Osaka, Japan
Cigarette smoking is well known as a major risk factor for
chronic obstructive pulmonary disease (COPD) and causes
J Cachexia Sarcopenia Muscle (2010) 1:43–128 67not only the pulmonary abnormalities but also the extrap-
ulmonary pathophysiological changes such as malnutrition,
loss of body weight (BW), systemic inflammation, and
skeletal muscle wasting. Previously, it has been reported that
ghrelin improves body composition and exercise tolerance in
patients with COPD cachexia. We investigated whether
ghrelin improves the respiratory function and catabolic
changes in the animal model of COPD induced by chronic
cigarette smoke (CS) exposure. Rats were exposed to CS or
air twice a day and received SUN11031 (human ghrelin,
manufactured by Asubio Pharma Co., Ltd., 1 mg/kg,
subcutaneous, b.i.d.) for 12 weeks. BWand food intake were
measured throughout the study. After 12 weeks exposure,
respiratory function, pulmonary emphysema, and muscle
strength were evaluated. Compared with the air-exposed rats,
BW gain, food consumption, epididymal fat weight, and peak
air flow were significantly lower, while lung capacity was
significantly higher in the CS-exposed rats. The grip strength
of the forelimb tended to be lowered by CS exposure. In
contrast,SUN11031significantlyincreasedbothBWgainand
food efficiency, but not fat weight. SUN11031 also signifi-
cantly improved peak air flow and lung capacity. Moreover, a
trendfortheimprovementofgripstrengthwasobservedinthe
SUN11031-treated rats. These results suggest that SUN11031
may improve not only the energy balance but also the
respiratory function and the systemic abnormality in COPD
model induced by chronic CS exposure.
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Acyl ghrelin improves selective serotonin reuptake
inhibitor-induced gastrointestinal motility in rats
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Background and aims: Nausea, vomiting, and anorexia
are the common side effects caused by selective serotonin
reuptake inhibitors (SSRIs) and lead to early discontinua-
tion of treatments in patients with depressive disorder. We
examined the effects of SSRIs on gastrointestinal (GI)
motility and whether acyl ghrelin improves SSRI-induced
GI symptoms in rats.
Methods: SSRIs (fluvoxamine, paroxetine, fluoxetine, and
fenfluramine) were intraperitoneally administered to 24 h food-
deprived rats, respectively. GI motility was measured in
conscious,freelymovingrats byastraingaugeforcetransducer
method. Plasma acyl ghrelin levels were determined by EIA.
Phenol red retention in the stomach at 15 min was calculated to
assess the gastric emptying. Effects of acyl ghrelin (and
Rikkunshito, a traditional Japanese medicine which releases
endogenous acyl ghrelin) on these functions were examined.
Results: The fasted motor patterns in both the antrum and
duodenum were disrupted by the treatments of SSRIs and
replaced by the fed-like pattern. The motor activity was
increasedintheantrum,whereasdecreasedintheduodenum,
and the duodenal phase III-like contractions of fasted
motility, was decreased. All of the SSRIs significantly
decreased plasma acyl ghrelin concentration. When acyl
ghrelin or Rikkunshito was administered to fluvoxamine or
fenfluramine-treated rats, the motor activity in the antrum
was not changed, while the motor activity and the phase III-
like contractions in the duodenum were significantly
increased. In addition, acyl ghrelin or Rikkunshito improved
the decrease in food intake and gastric emptying rate. The
pretreatment with GHS-R antagonist (D-Lys3) GHRP-6
blocked the effects of Rikkunshito on theses parameters.
Conclusions: These results indicate that SSRIs decrease
plasma acyl ghrelin and induce GI motility similar to
anorexigenic peptides. Acyl ghrelin may be effective in
relieving SSRI-induced GI symptoms.
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Efficacy of orally available selective melanocortin-4
receptor antagonists in animal models of cancer cachexia
Philipp Weyermann, Robert Dallmann, Achim Feurer,
Cesare Mondadori
Santhera Pharmaceuticals Ltd., Liestal, Switzerland
Background and aims: Cachexia is among the most
debilitating and life-threatening aspects of cancer and
includes anorexia, fat, and muscle tissue wasting. The
anorexigenic peptide alpha-MSH is believed to be crucially
involved in the regulation of food intake. It has been
proposed that blockade of its central physiological target,
the melanocortin-4 receptor (MC4-R), might provide a
promising treatment strategy. This concept is supported by
the fact that agouti-related protein (AgRP), the endogenous
antagonist at the MC4-R, was found to affect two hallmark
features of cachexia, namely to increase food intake and to
reduce energy expenditure. Based on this rationale, we
pursued the discovery and development of small-molecule
MC4-R antagonists for the treatment of cancer cachexia.
Methods: A recently discovered, selective and orally
bioavailable MC4-R antagonist, which penetrates the
blood–brain barrier, was studied. Specifically, stimulation
of food intake in healthy mice and efficacy in rodent
models of cancer cachexia were investigated.
Results: Our compound, which was very well tolerated in
mice and rats, was found to distinctly increase food intake
68 J Cachexia Sarcopenia Muscle (2010) 1:43–128in healthy animals. Moreover, in tumor-bearing animals,
repeated oral administration ameliorated tumor-induced
weight loss and diminished loss of lean body mass and fat
mass. Concommitantly, expression of atrogenes in gastroc-
nemius muscle was reduced compared to vehicle-treated
tumor-bearing animals.
Conclusions: In contrast to previously reported peptidic or
small-molecule MC4-R antagonists, the compound de-
scribed here was effective after oral administration and
was very well tolerated. In light of patient care, orally
applied drugs might offer a considerable advantage for the
treatment of cancer cachexia.
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Right on target: melanocortin (MC) 4 receptor mediated
increase in food intake and decrease in energy exependiture
with orally bioavailable small molecule antagonists
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Background and aims: The melanocortin system is
crucially involved in the regulation of food intake and
energy expenditure in the healthy, physiological state. In a
pathophysiological situation like cachexia, these two
parameters are dysregulated, i.e., food intake is decreased
and energy expenditure is increased, a vicious combination
leading to a catabolic state. Blockade of the melanocortin-4
receptor (MC-4R) might provide a promising treatment
strategy for cachexia because agouti-related protein (Ag
RP), the endogenous antagonist at the MC-4R, was found
to increase food intake and to reduce energy expenditure.
Based on this rationale, we designed small-molecule MC-
4R antagonists for the treatment of cancer cachexia.
Methods: We studied the efficacy of our recently discov-
ered, in vitro selective and potent MC-4R antagonists in an
in vivo situation. Specifically, stimulation of food intake
and regulation of energy expenditure measured as oxygen
consumption were investigated. Furthermore, using MC-
4R-deficient mice, we confirmed that the effects of our
compounds are indeed MC-4R mediated.
Results: Single and multiple oral administration of our
compounds significantly increased food intake and de-
creased energy expenditure in wild-type mice. In MC-4R-
deficient mice, however, these effects were absent.
Conclusions: We demonstrated that our small molecule
MC-4R antagonists were orally effective on both food
intake and energy expenditure, and that these effects were
MC-4R mediated. These findings open up the possibility of
treating two hallmarks of cachexia with one drug.
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A pharmacologically active monoclonal antibody
against the human melanocortin-4 receptor as a possible
treatment of cachexia
Jean-Christophe Peter, Anne-Catherine Lecourt, Marjorie
Weckering, Géraldine Zipfel, Karl G. Hofbauer
Applied Pharmacology, Biozentrum, University of Basel,
Basel, Switzerland
Background: Blockade of the melanocortin-4 receptor
(MC4R)bylowmolecularweightantagonistshasbeenshown
to be effective in preventing anorexia and cachexia in rodents.
Comparableresultshavebeenobtainedinourpreviousstudies
with active immunization against the MC4R. In the present
experiments, we validated the pharmacological profile of a
monoclonal antibody (mAb) against the MC4R.
Methods and results: We produced an mAb (1E8a)
directed against the N-terminal domain of the human (h)
MC4R. This mAb showed specific binding in HEK-293
cells expressing the hMC4R and blocked the activity of this
receptor in vitro. When mAb 1E8a (1 μg) was injected
intracerebroventriculary (i.c.v.) into the third ventricle of rats,
their 24-h food intake increased (26.6±0.7 vs 21.4±1.0 g, p<
0.05). After 7 days of continuous i.c.v. administration of
mAb 1E8a via osmotic minipumps in rats cumulative food
intake (160±5 vs 134±9 g), body weight change (+8.4±5.8
vs −8.6±9.5 g), and fat pad weights (3.9±0.2 vs 3.0±0.4 g)
were significantly (p<0.01) increased. Intravenous (i.v.)
injection of mAb 1E8a was ineffective, but a single chain
variable fragment (scFv) derived from this mAb increased
significantly (p<0.01) food intake (24.5±0.2 vs 19.7±1.0 g)
and body weight (+0.3±0.7 vs −6.0±1.2 g) within 24 h after
i.v. administration (300 μg/kg).
Conclusion: The positive results obtained with scFv 1E8a
after i.v. administration suggest that such derivatives of
mAbs against the MC4R may have therapeutic potential in
the treatment of anorexia or cachexia.
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Myostatin inhibition attenuates atrophy and loss
of muscle function in mice with cancer cachexia
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J Cachexia Sarcopenia Muscle (2010) 1:43–128 69Background and aims: Cancer cachexia describes the
progressive skeletal muscle wasting and weakness in many
cancer patients. Cancer cachexia impairs mobility, causes
severe fatigue, and accounts for >20% of cancer-related
deaths. We tested the hypothesis that antibody-directed
myostatin inhibition would attenuate the atrophy and loss of
function in skeletal muscles of tumor-bearing mice.
Methods: Twelve-week-old C57BL/6 mice received a
subcutaneous injection of saline (control) or 7.5×10
5 Lewis
lung carcinoma (LLC) tumor cells. One week later, mice
began once-weekly injections of saline (control, n=12;
LLC, n=9) or a mouse chimera of anti-human myostatin
antibody (PF-354, 10 mg/kg/week, Pfizer Global Research
and Development, Groton, USA; LLC+PF-354, n=11),
which continued for 5 weeks.
Results: Compared with controls, LLC mice had a lower
muscle mass (8–10%, P<0.05) which was prevented with
PF-354 (P>0.05). Peak tetanic in situ force production of the
tibialis anterior (TA) muscles of LLC mice was reduced by
8% (P<0.05), but this reduction was attenuated with PF-354
(P>0.05). In contrast, normalized peak tetanic force of
diaphragm muscle strips in vitro was not different between
groups (P<0.28). TA muscles and diaphragm muscle
strips from LLC mice exhibited reduced fatigability
compared with controls (P<0.001), which was prevented
with PF-354.
Conclusions: Antibody-directed myostatin inhibition atten-
uated the skeletal muscle atrophy and loss of muscle force-
producing capacity in a murine model of cancer cachexia.
The findings highlight the therapeutic potential of myo-
statin inhibition for cancer cachexia.
Supported by research grant funding from the National
Health and Medical Research Council (Australia) and
Pfizer Inc. (USA).
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Activin type II receptor fusion protein (ACVR2B-FC)
preserves skeletal muscle and adipose tissue in two
models of cancer cachexia
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Background and aims: Myostatin is a potent tonic
inhibitor of skeletal muscle growth that binds the activin
type II receptor ACVR2B. An ACVR2B-Fc fusion protein
has been shown to bind myostatin and induce muscle
hypertrophy in mice. We sought to determine how
inhibition of myostatin by ACVR2B-Fc might affect
muscle wasting in two models of cancer cachexia.
Methods: Athymic nude mice were injected with CHO
cells expressing ACVR2B-Fc or no recombinant protein as
a control. Mice were also injected with either Lewis lung
carcinoma (LLC) or colon-26 (C26) adenocarcinoma cells
to induce cachexia.
Results: ACVR2B-Fc administration improved skeletal
muscle and fat mass in LLC cachexia. Triceps mass was 25%
greater (p<0.05), and pectoralis mass was 28% greater (p<
0.05) in ACVR2B-Fc-treated mice versus controls. Adipose
tissue was also protected, with epididymal fat pad mass
2,127% larger (p<0.01) in the ACVR2B-Fc-treated group.
LLC and CHO tumor weights were not different between
groups. ACVR2B-Fc administration also inhibited C26
cachexia. ACVR2B-Fc-treated mice had 12% greater tumor
free body weight (p<0.01), and gastrocnemius and quadriceps
masses were 26% greater (p<0.001) than in control mice.
ACVR2B-Fc mice in this model also demonstrated 154%
increased adipose tissue versus controls (p<0.05). CHO and
C26 tumor weights were not different between groups.
Conclusions: The myostatin-family inhibitor, ACVR2B-
Fc, potently inhibited muscle wasting and protected adipose
stores in two models of cancer cachexia, without affecting
tumor growth. Thus, targeting myostatin-family proteins
may be a potential clinical therapy for patients with muscle
wasting in cancer cachexia.
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Novel effects of myostatin inhibition on skeletal muscles
of aging mice: implications for sarcopenia
Kate T. Murphy, René Koopman, Bertrand Leger,
Jennifer Trieu, Chikwendu Ibebunjo, Gordon S. Lynch
Basic and Clinical Myology Laboratory, Department of
Physiology, The University of Melbourne, Victoria, Australia
Background and aims: Sarcopenia is the progressive loss
of muscle mass with advancing age associated with a
significant age-related decline in muscle strength and
power. We tested the hypothesis that antibody-directed
myostatin inhibition would improve the mass and function
of skeletal muscles from aged mice.
Methods: Eighteen-month-old C57BL/6 mice were treated
for 14 weeks with saline (control, n=9) or a mouse chimera
of anti-human myostatin antibody (PF-354, 10 mg/kg/
week, Pfizer Global Research and Development, Groton,
CT, USA; n=12).
Results: PF-354 completely prevented the age-related
reduction in body mass (P<0.05). Treatment with PF-354
increased muscle mass by 8–18% and increased muscle
fiber size by 12% (P<0.05). Consequently, peak tetanic in
70 J Cachexia Sarcopenia Muscle (2010) 1:43–128situ force production of tibialis anterior (TA) muscle was
improved by 35% after treatment (P<0.03), without
affecting the muscle’s susceptibility to contraction-
mediated injury (P=0.48). PF-354 treatment resulted in a
shift to a greater proportion of type IIa fibers by 114% (P<
0.01) and enhanced muscle fiber oxidative capacity by 39%
(P<0.01). Treatment with PF-354 also reduced apoptosis
by 56% (P<0.03) and caspase-3 mRNA expression by 65%
(P<0.04), and tended to reduce protein abundance of the
cleaved form of caspase-3 (P<0.06).
Conclusions: Antibody-directed myostatin inhibition im-
proved the mass and function of skeletal muscles of aging
mice. Apoptosis was reduced with myostatin blockade,
identifying a novel role of myostatin for apoptotic
signaling. These findings support the therapeutic potential
of myostatin inhibition for sarcopenia.
Supported by research grant funding from the National
Health and Medical Research Council (Australia) and
Pfizer Inc. (USA).
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In vivo antagonism of activin receptor type IIB (ActIIB)
pathway reverses muscle wasting and prolongs survival
in experimental models of cancer cachexia
Xiaolan Zhou, Jay Wang, Yanping Song, Keith Kwak,
John Lu, Eric Jiao, HQ Han
Metabolic Disorders Department, Amgen Inc., Thousand
Oaks, CA, USA
Cancer cachexia affects up to 80% of patients with advanced
cancers and is the cause of more than 20% of cancer-related
mortality. A key feature of cachexia is the progressive
depletion of skeletal muscle, which occurs in concert with
the loss of adipose tissue. Muscle wasting has long been
postulated to be a key risk factor for cancer-related death, but
to date, there has been no direct experimental research
evidencetosubstantiatethishypothesis.Here,wedemonstrate
thatintwoindependentpreclinical modelsofcancercachexia,
the colon-26 tumor-bearing mice and inhibin-alpha-deficient
mice, pharmacological blockade of ActRIIB-mediated signal-
ing pathway not only prevents muscle wasting but also
reverses muscle loss, thereby significantly prolonging sur-
vival. We show that mechanistically, ActRIIB pathway
antagonism is able to prevent the induction of critical
components of the Ub-proteasome system in skeletal muscle
and also stimulates muscle stem cell growth. These findings
(1) establish a crucial link between the ActRIIB signaling
activities and the pathogenesis of muscle wasting and cancer
cachexiaand(2)showthatpharmacologicalantagonismofthe
ActRIIB pathway may hold therapeutic potential for the
treatment of cancer cachexia.
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A myostatin decoy receptor prevents loss of muscle mass
and function in cancer cachexia
Peter Bialek, Jascha Parkington, Paul Yaworsky, Carl
Morris
Tissue Repair, Wyeth, Cambridge, MA, USA
Background: Cachexia is a complex syndrome which is
characterized by decreased protein synthesis and increased
protein degradation. Cytokines and other secreted factors
are believed to mediate muscle wasting, although the exact
mechanisms are not completely understood. Myostatin, a
negative regulator of muscle mass and member of the TGF-
beta/BMP superfamily, has been implicated in cachexia. To
determine if myostatin activity is important for cachexia, we
tested a soluble myostatin decoy receptor (ActRIIB-Fc) in a
mouse ascites tumor model.
Methods: Ten-week-old SCID female mice were injected
withS180cellstoinitiateascitestumorformationorPBS.The
mice were then subdivided intotwo cohorts and given weekly
injections of vehicle or 10 mg/kg ActRIIB-Fc for 2 weeks.
Results: S180-induced cachexic mice lost 15% gastrocne-
mius and quadriceps muscle mass and showed a 27%
decline in grip strength compared to controls after 2 weeks.
However, cachexic mice treated with ActRIIB-Fc did not
lose muscle mass or show decline in grip strength. Analysis
of muscle extracts from cachexic mice revealed a ~25%
increase in proteasome activity and a decrease in FOXO1
phosphorylation which was not reversed by ActRIIB-Fc
treatment. However, the increased mRNA expression of
muscle-specific E3 ubiquitin ligases, Murf-1, and atrogin/
MAFbx in the untreated cachexic mice was significantly
reduced following ActRIIB-Fc treatment. Further, a maker
of protein translation, 4EBP1, was increased in ActRIIB-
Fc-treated mice compared to vehicle-treated cachexic mice.
Conclusions: The data suggests that ActRIIB-Fc maintains
muscle mass and function by balancing the catabolic
activity during cachexia by increasing protein translation.
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Theophylline is able to partially revert cachexia
in tumour-bearing rats
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J Cachexia Sarcopenia Muscle (2010) 1:43–128 71Background and aims: Cancer cachexia occurs in the
majority of cancer patients before death and seems to be
responsible for the death of 22% of cancer patients. The
abnormalities associated with cancer cachexia include
anorexia, weight loss, muscle loss, atrophy, anemia, and
alterations in carbohydrate, lipid, and protein metabolism.
Different nutraceuticals, i.e., w3 fatty acids of marine
origin, have been proposed to counteract muscle wasting
during cancer. The aim of the present investigation was to
examine the anti-wasting effects of theophylline (present in
tea leaves) on a rat model of cancer cachexia.
Methods: Individual muscle weights, muscle gene expres-
sion, body composition, and cardiac function were mea-
sured in rats bearing the Yoshida AH-130 ascites hepatoma,
following theophylline treatment.
Results: Theophylline treatment resulted in a clear anti-
proteolytic effect on muscle tissue (soleus and heart), which
was associated with a decrease in circulating TNF-alpha
levels. Treatment with the nutraceutical also resulted in an
improvement in body composition and cardiac function.
Conclusion: Theophylline—alone or in combination with
drugs—may be a candidate molecule for the treatment of
cancer cachexia.
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Bakground and aims: Duchenne muscular dystrophy
(DMD) is a severe progressive disease resulting from
mutations of the dystrophin gene and leading to progressive
muscle degeneration and weakness. Several evidences
suggest that enhanced activation of proteasomal degradative
pathways underliescritical stepsinthepathogenesisofDMD
dystrophic process. We previously demonstrated that treat-
ment with the proteasome inhibitor MG-132 rescued the
protein levels and cell membrane localization of dystrophin
and the dystrophin glycoprotein complex (DGC) in mdx
mice, an experimental model of DMD. This work was
aimed to define the therapeutic potential of Velcade, a drug
selectively blocking the ubiquitin-proteasome pathway, in
dystrophinopathies. Velcade is particularly intriguing since,
being FDA-approved for the treatment of multiple myelo-
ma, its side effects in humans are already known.
Methods: Dystrophic mdx mice were systemically admin-
istered Velcade (0.8 mg/kg) over a 2-week period.
Results: Velcade proved efficient in inhibiting proteasome
activation, as well as serum CK level increase. Moreover, it
reverted the membrane expression of dystrophin and DGC
members, prevented both NF-kB nuclear translocation and
the inflammatory reaction, enhanced muscle regeneration,
and improved the dystrophic phenotype by increasing
muscle CSA and reducing the number of both centralized
nuclei and necrotic fibers.
Conclusions: In the present work, we reported that
Velcade-induced proteasome inhibition partially prevents
muscle degeneration in dystrophic mice and promotes the
expression and membrane localization of dystrophin and
dystrophin-associated proteins. Future studies will investi-
gate the efficacy of Velcade in combination with other
agents, such as corticosteroids, as well as their effects on
muscle strength and functional motility.
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The fast skeletal troponin activator, CK-2017357,
increases skeletal muscle force and reduces muscle
fatigue in vitro and in situ
Alan J. Russell, Ken Lee, Jim J. Hartman, Alex Muci,
Bradley Morgan, Fady Malik
Cytokinetics Inc., South San Francisco, CA, USA
CK-2017357 is a member of a class of fast skeletal
troponin activators that were identified by high through-
put screening of skeletal sarcomere preparations. We
sought to understand how this compound altered isomet-
ric force development in skinned and live muscle fibers.
Treatment of skinned muscle fibers with 0.1–10 μMC K -
2017357 caused a left shift of the force–pCa relationship
without altering the maximum force, consistent with a
calcium-sensitizing effect on force production. In rat
flexor digitorum brevis (FDB) muscle in vitro, CK-
2017357 (10 μM) caused increases in sub-tetanic force
(150% at 10 Hz) without altering maximum force.
Similar experiments were performed using rat extensor
digitorum longus (EDL) muscle in situ, where nervous
and vascular connections were left intact and the muscle
was stimulated via the peroneal nerve. Infusions of CK-
2017357 up to 10 mg/kg increased sub-tetanic force
(200% at 30 Hz). One cause of muscle fatigue is reduced
Ca
2+ r e l e a s ef r o mt h es a r c o p l a s m i cr e t i c u l u m .W et e s t e d
whether CK-2017357 would alter the rate of fatigue in
FDB fibers. Muscle was pretreated with 5 μMC K -
72 J Cachexia Sarcopenia Muscle (2010) 1:43–1282017357 and stimulated at a frequency giving 50%
maximal force every 6 s for 15 min (30°C). Treatment
significantly reduced the rate of fatigue (terminal force,
33.7±5% vs 53.9±5%). In summary, we have identified a
skeletal troponin activator that sensitizes the sarcomere to
calcium, increases sub-maximal force development, and
reduces fatigue. We believe that this may translate to
improved physical power and efficiency in diseases where
muscle function is compromised due to injury, disease, or
age.
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Background and aims: Perhaps the most common
manifestation of advanced malignant disease is the devel-
opment of cancer cachexia. Indeed, cachexia occurs in the
majority of cancer patients before death and seems to be
responsible for the death of 22% of cancer patients. The
abnormalities associated with cancer cachexia include
anorexia, weight loss, muscle loss, atrophy, anemia and
alterations in carbohydrate, lipid and protein metabolism.
β2-adrenergic agonists are potent muscle growth promoters
in many animal species, resulting in skeletal muscle
hypertrophy, while they cause a reduction of the body fat
content. Formoterol is a highly potent, β2-adrenoceptor-
selective agonist combining the clinical advantages of rapid
onset of action with duration of action. The aim of the
present investigation was to examine the anti-wasting
effects of formoterol.
Methods: Individual muscle weights, total physical activity
and grip force were measured in rats bearing the Yoshida
AH-130 ascites hepatoma, following formoterol treatment.
Results: Administration of the β2-agonist formoterol to
tumour-bearing rats resulted in an important reversal of the
muscle-wasting process, as reflected by individual muscle
weights. The anti-wasting effects of the drug were also
observed in terms of total physical activity and grip force.
Conclusion: Formoterol treatment resulted in an improve-
ment in physical performance in cachectic tumour-bearing
rats.
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The effects of the catabolic/anabolic transforming agent
MT-102 on body weight, body composition, food intake,
physical activity and survival compared to imidapril
and bisoprolol in a rat model of cancer cachexia
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Background: The ACE inhibitor imidapril has been
investigated as an anti-cachexia drug in a phase III trial.
Depending on the cancer type, a small weight gain was
observed. Beta-blockers such as bisoprolol have been
shown to reduce the onset of cardiac cachexia and are
generally known to increase body weight (i.e. mainly
fat mass) in patients with cardiovascular illness. In this
study, both compounds were compared to MT-102, a
new catabolic/anabolic transforming agent (CATA). MT-
102 has a pharmacologic profile that includes muscle
anabolic effects, appetite stimulation, reduction in
energy expenditure, lipolysis inhibition and cardio-
protection.
Methods: Wistar rats (weight approximately 200 g) were
inoculated intra-peritoneally with AH-130 hepatoma cells
or saline (sham). Animals were treated with 0.4, 1 or
10 mg/kg/day imidapril; 0.5, 2, 5 or 50 mg/kg/day
bisoprolol; 0.3 or 3 mg/kg/day MT-102; or placebo. Food
intake and locomotor activity per day were assessed before
tumor inoculation and on day 11 of the 16-day protocol.
Weight and body composition (NMR scan) were assessed
on day 0 and after sacrifice (maximum day 16, without
tumor).
Results: Animals of all groups showed similar baseline
values for weight, body composition and heart function. All
imidapril and bisoprolol doses, as well as low-dose MT-
102, significantly reduced loss of lean tissue mass. Only
high-dose MT-102 induced lean tissue gain compared to
baseline. The same pattern was found for body weight
overall. Imidapril did not improve quality of life (food
intake and spontaneous activity). The higher doses of
bisoprolol and both doses of MT-102 did improve quality
of life. The two doses of MT-102 had the best results for
physical activity. Mortality was higher in imidapril-treated
groups compared to placebo. Five and 50 mg/kg/day
bisoprolol significantly improved survival, as did high-
dose MT-102. Low-dose MT-102 displayed a strong trend
(p=0.064) (see Table).
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*p>0.05; **p<0.01; ***p<0.001; ****p=0.064 vs placebo
Conclusion: The catabolic/anabolic transforming agent
MT-102 demonstrates a strong anti-cachexia treatment
profile. Only MT-102 maintained true weight gain in this
model of severe cancer cachexia. MT-102 improved
measures of quality of life and survival. In our model
system, imidapril was not a successful anti-cachexia
therapy. Bisoprolol reduced weight loss and, at higher doses,
resulted in improved physical activity, food intake and
survival.
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The xanthine oxidase inhibitors oxypurinol
and allopurinol reduce wasting and improve cardiac
function in experimental cancer cachexia
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Background: Cachexia is a common co-morbidity in cancer
patients. Uric acid is a danger signal and associated with
inflammation. In chronic heart failure, high serum uric acid
levels are associated with metabolic illness and poor survival.
We hypothesised that xanthine oxidase (XO) inhibition can
reducetissuewastingandimprove survival incancercachexia.
Methods: Rats (weight approximately 200 g) were inocu-
lated intra-peritoneally with AH-130 hepatoma cells and
treated with 4 mg/kg/day (n=11) and 40 mg/kg/day (n=12)
oxypurinol (Oxy), 40 mg/kg/day (n=11) allopurinol (Allo)
or placebo (n=49). Heart function (echocardiography), food
intake and locomotor activity were assessed before inocula-
tion and on day 11 of the 16-day protocol. Weight and body
composition (NMR scan) were assessed on day 0 and day 16
after sacrifice (without tumour). XO activity for generation
of reactive oxygen species (ROS) was assessed by EPR after
purification of XO. Activity was assessed without Oxy or
Allo. Proteasome activity was measured by turnover of
flurogenic substrates in gastrocnemius homogenates.
Results: Wasting of both fat and lean tissue was signifi-
cantly reduced (see Table) by 4 mg/kg/day oxypurinol and
to a somewhat lesser degree by allopurinol. The food intake
and spontaneous activity were significantly higher in the
low dose oxypurinol and allopurinol groups. Also, cardiac
function was improved. Sham animals (n=16) showed an
increase in body weight (59.8±2.1 g), lean mass (41.6±
2.0 g) and fat mass (9.1±0.9 g). The values for reactive
oxygen species (ROS) were 3.23±0.99 nmolROS/μg
protein/min. The proteasome activity (174.4±15.9 nmol/
mgprotein/min), IL-6 (50.5±9.6 pg/ml), TNF-α (14.5±
2.6 pg/ml) and NF-κB (100±24.9%) were lower in sham
animals. Uric acid level were significantly lower (1.58±
0.32 mg/dL) compared to tumor-bearing animals.
N ΔBW (g) Δlean (g) Δfat (g) Food (g/24 h) Activity (counts/24 h) Hazard ratio vs
placebo (95% CI)
Placebo 78 −53.7±1.8 −39.8±1.6 −12.4±0.4 4.3±0.5 29,509±1,775 –
0.4 mg Imidapril 10 −30.0±14.1*** −21.6±10.5** −8.9±2.7* 7.9±3.0 29,379±7,205 1.23 (0.49–3.09)
1 mg Imidapril 14 −24.8±6.9*** −13.4±4.8*** −5.8±1.8*** 5.8±3.4 21,170±7,148 4.03*** (1.55–10.52)
10 mg Imidapril 15 −21.9±6.8*** −14.9±4.8*** −5.31.3*** 6.3±4.0 22,732±9,073 6.35*** (2.37–17.01)
0.5 mg Bisoprolol 13 −37.8±7.5** −25.3±5.7** −9.3±1.2** 5.8±2.0 33,701±6,559 1.35 (0.58–3.14)
2 mg Bisoprolol 14 −25.6±13.2*** −20.4±9.4*** −6.4±3.0*** 16.7±6.9** 38,777±6,981 0.54 (0.26–1.13)
5 mg Bisoprolol 23 −21.8±10.6*** −16.7±7.7*** −5.9±1.9*** 10.9±2.0*** 43,755±3,741*** 0.32*** (0.18–0.59)
50 mg Bisoprolol 20 −30.6±9.8*** −24.4±6.9*** −8.4±1.6*** 10.1±2.0** 43,124±5,722** 0.44* (0.23–0.83)
0.3 mg MT-102 14 −20.3±14.6*** −9.7±11.3*** −9.5±2.4* 6.4±2.9** 46,872±6,684*** 0.52**** (0.25–1.04)
3 mg MT-102 15 +17.8±17.9*** +15.1±13.8*** −4.3±2.8*** 12.9±3.1*** 51,268±6,521*** 0.29*** (0.15–0.57)
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*p<0.05; **p≤0.01; ***p<0.001 vs placebo
Conclusion: Inhibition of XO can reduce tissue wasting and
improve survival in an animal model of cancer cachexia.
ROS generation and proteasome activity are reduced
compared to placebo. Low-dose oxypurinol had superior
properties compared to tenfold higher dose of allopurinol.
Interestingly, the dose–response relationship for oxypurinol
was inversed. Studies using even lower doses of oxypurinol
are necessary.
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Erythropoietin (EPO) and insulin-like growth factor
(IGF) 1 have limited effects on cancer cachexia
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Background: Loss of lean mass is an important aspect
of cachexia, and hence the anabolic IGF-1 and the
tissue-protective EPO were chosen in order to reduce
wasting.
Methods: Wistar rats (weight approximately 200 g) were
inoculated intra-peritoneally with AH-130 hepatoma cells or
saline (sham). Food intake and locomotor activity were
assessed before inoculation and on day 11 of the 16-day
protocol. Weight and body composition (NMR scan) were
assessed on day 0 and day 16 after sacrifice (without tumor).
Tumor-bearing animals received 100, 500, 2,500, or 5,000 U
EPO/kg/day; 0.3 or 3 mg/kg/g IGF-1; or placebo.
Results: Animals of all groups showed similar baseline
values for weight, body composition, and heart function.
Both anabolic compounds did not increase total tumor cell
number. Low-dose IGF-1 as well as 100, 500, and 2,500 U/
kg/day EPO reduced wasting. While EPO reduced both loss
of lean and fat mass, IGF-1 did not reduce loss of fat mass.
Low-dose EPO improved quality of life (activity and food
intake). Only 2,500 U/kg/day EPO significantly improved
survival compared to placebo (HR, 0.44; 95% CI, 0.22–
0.89; p=0.022).
BW body weight
*p<0.05; **p<0.01; ***p<0.001 vs placebo
Placebo (n=49) 4 mg/kg/day Oxy 40 mg/kg/day Oxy 4 mg/kg/day Allo 40 mg/kg/day Allo
Delta BW (g) −50.2±2.2 −15.4±14.2*** −45.3±11.8 −31.9±14.9* −26.4±17.1*
Delta fat (g) −11.2±0.4 −6.8±2.6** −14.4±1.9* −9.9±2.0 −8.1±2.9
Delta lean (g) −37.1±2.0 −10.6±10.4*** −33.0±11.8 −28.4±10.9 −19.9±12.6*
Uric acid (mg/dL) 2.57±0.23 0.40±0.08*** 0.26±0.02*** 0.62±0.17*** 0.21±0.02***
Urea (mg/dL) 182.4±17.4 122.6±32.2 140.5±38.8 117.5±51.1 108.7±28.6*
Albumin (g/L) 7.9±0.2 8.3±0.3 7.8±0.2 8.6±0.2 7.7±0.3
NmolROS/μgprotein/min 169.51±52.5 25.6±6.5** 17.3±8.3** 38.2±5.7* 31.2±12.6*
Proteasome activity (mU) 254.8±73.2 37.8±12.7* 112.2±69.3 84.3±33.4 97.1±42.3
IL-6 (pg/ml) 81.72±12.6 37.63±8.2* 37.41±8.0* 51.44±13.6 48.78±8.3
TNF (pg/ml) 23.98±2.9 13.86±1.2* 20.14±2.6 20.74±1.8 17.25±1.6
NF-κB GC (% of sham) 191.3±31.3 92.90±16.7* 153.9±25.7 125.8±22.7 130.7±27.7
Placebo 100 U EPO 500 U EPO 2,500 U EPO 5,000 U EPO 0.3 mg IGF-1 3 mg IGF-1
N 78 20 16 14 16 14 15
Cell No. (×10
9) 2.98±0.27 3.03±0.29 2.91±0.26 2.76±0.32 2.25±0.25 2.84±0.42 2.5±0.28
Delta BW (g) −53.7±1.8 −30.6±9.6*** −39.6±8.9* −29.1±10.1*** −47.4±5.9 −39.6±11.1* −42.7±8.8*
Delta lean mass (g) −39.8±1.6 −23.7±7.4** −30.3±6.81* −21.6±7.7*** −35.4±4.6 −28.8±8.4* −30.6±7.4
Delta fat mass (g) −12.4±0.4 −8.0±1.7*** −10.5±1.5 −8.4±1.5*** −11.2±0.9 −12.4±1.9 −11.0±1.3
Food (g/24 h) 4.3±0.48 7.85±1.66** 6.56±1.73 6.57±1.89 5.38±1.19 2.5±1.66 11.8±9.82
Activity (counts/24 h) 29,509±1,775 38,550±4,412* 36,915±3,854 38,893±6,012 40,342±4,630* 35,685±4,637 29,962±5,139
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compounds EPO and IGF-1 have limited beneficial effects
on survival and body wasting.
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Background: The Macmillan Weight and Eating Studies
(2000–2008) have developed the first complex psycho-
social intervention for weight- and eating-related
distress in people with cancer cachexia and their
carers: The Macmillan Approach to Weight and Eating
(MAWE).
Aim: This paper is about a phase II trial of MAWE. It
presents (1) challenges of conducting the exploratory
trial in the context of palliative care, and how these
were successfully addressed, and (2) evidence that
MAWE can help patients and their carers live with
advanced cancer.
Methods: The phase II trial, conducted in the UK in 2006–
2007, was of cluster randomised design. It used mixed
methods to compare an intervention group (n=25), who
were supported by MAWE trained Clinical Nurse Special-
ists (CNSs), with a group who received standard care (n=
25), the control group. The trial was a feasibility study. Its
purpose was to test (1) recruitment and data collection
process, (2) the deliverability and acceptability of MAWE
and (3) the effect of MAWE on weight- and eating-related
distress.
Results: The study achieved its recruitment target, data
collection tools were acceptable to participants and CNSs
were able to deliver MAWE in the context of their everyday
practice. Contamination of the MAWE group prior to
baseline data collection was problematic. However, both
quantitative and qualitative data analysis support the
proposition that MAWE can help patients and their carers
live with cancer cachexia.
Conclusion: The evidence collated supports the argument
that an RCT of MAWE is warranted, but it should be of a
revised design.
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What is an appropriate diet for peopleliving with cancer
andinvoluntaryweightloss:asytematicliteraturereview
Jane B. Hopkinson, Ikumi Okamoto, Julia M.
Addington-Hall
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Background: Up to 80% of people with cancer experience
involuntary weight loss, a symptom of cancer cachexia
syndrome (CCS). Feeding these people has little effect on
their weight or survival.
Purpose: The purpose of this study is to report a systematic
review of the evidence base that can inform dietary advice
for patients with CCS.
Methods: Searches were conducted ofMEDLINE,EMBASE,
PsycINFO, and CINAHL databases for publications about diet
and cancer patients off treatment with symptoms of CCS.
Limits were English language, 1998 to September 2008, and
adults. Seven hundred eighteen abstracts were assessed against
inclusion/exclusion criteria, and 90 were selected for full-text
independent examination by two researchers. Information,
from 60 papers, was extracted, quality assessed, thematically
analyzed, and presented as a narrative description.
Results: Two dominant perspectives emerged. The majority
of authors advocated a nutrition dense diet, achieved
through (1) education on the fortification of foods and (2)
advice to feed frequently. The alternative approach was to
advise the patient to “eat what they want.” There is little
robust evidence to justify either approach as able to deliver
on the objectives they aim to achieve. Research is needed to
establish which subgroups of weight-losing cancer patients
can benefit from a nutrition dense diet.
Conclusion: A new model for nutritional care with non-
traditional objectives, such as mitigation of eating-related
distress, may help identify patients with CCS for whom
feeding is not futile. It could also facilitate optimal nutritional
intake within the confines of the patient’s (1) disease process
andtreatment,(2)copingapproach,and(3)beliefsaboutfood.
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76 J Cachexia Sarcopenia Muscle (2010) 1:43–128Cachexia is a chronic inflammatory syndrome, characterised by
weight loss and abnormalities in intermediary metabolism.
Disruption of liver lipid metabolism, comprising higher uptake
of long-chain fatty acids (LCFA), along with diminished
oxidation and incorporation into very low-density lipoproteins
(VLDL), aggravate cachexia. L-Carnitine is required for the
transport of LCFA into the mitochondria, and cachectic patients
present decreased plasma carnitine concentration. L-Carnitine
supplementation is adopted in the treatment of many diseases,
and we sought to examine whether cachectic rats would benefit
from this strategy. Rats were inoculated with the Walker 256
carcinosarcoma and divided into two groups: supplemented with
L-carnitine (1 g/Kg, for 28 days; TBC) and control (receiving
saline; TB). Twenty-four non-tumour-bearing rats were divided
into a L-carnitine-supplemented group, NC, and the respective
control, N. Liver and plasma triacylglycerol (TAG), liver mRNA
expression (semi-quantitative RT-PCR) of carnitine palmitoyl-
transferase I and II (CPT I and II), microsomal triglyceride
transfer protein (MTP), fatty acid-binding protein (L-FABP),
fatty acid translocase (FAT/CD36) and peroxisome proliferator-
activated receptor-alpha (PPARα), and the maximal activity
(radioassay) of CPT I and II, were evaluated. Gene expression
of MTP and CPT I activity was reduced in TB (6%, p<0.05,
and 42%, p<0.01, respectively). TB also showed increased (p<
0.01) liver and plasma TAG content in relation to N. Chronic
treatment with L-carnitine restored mitochondrial LCFA oxida-
tion (p<0.01) and VLDL assembly capacity, suppressing
cachexia-related hypertriglyceridemia (p<0.001) and steatosis.
Attenuation of cachexia was accompanied by reduced tumour
weight (62%) after supplementation. The results indicate that L-
carnitine improves liver lipid metabolism in cachexia.
Supported by FAPESP.
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Creatine plays an essential role in muscular functioning. It has
been show that creatine supplementation in a healthy condition
leads to increased muscular energy content and lean body mass.
We have investigated whether creatine supplementation in a
cancer-induced cachectic condition affects muscular perfor-
mance and body composition. Male CD2F1 mice, 5–6w e e k so f
age,weredividedintobodyweight-matchedgroups:(1)control,
(2) tumour-bearing and (3) tumour-bearing receiving creatine
(10 gkg
−1 food). Tumourswere induced by s.c.inoculationwith
murine colon adenocarcinoma (C26) cells. Food intake, body
mass and tumour size were monitored. At day 20 after tumour/
vehicle inoculation, animals were sacrificed, and muscle
function was tested ex vivo. Creatine supplementation did not
result in differences in organ and skeletal muscle weights, nor in
changes in maximal isometric force. In contrast, creatine
supplementation resulted in an increase in endurance capacity
of the muscle. There was a decrease in loss of maximal force
during an intermittent exercise series of high intensity. No
differences in glycogen and high-energy phosphates were
found. The muscular hydration level was decreased in cachectic
mice and partially attenuated by creatine supplementation.
Therefore, the observed increase in relative performance
capacity might be linked to an improved muscular hydration
level. In conclusion, no effects on absolute force output were
observed after creatine supplementation, but we clearly demon-
strated that the loss of relative muscular functionality during an
intermittent exercise series in a murine cachexia model could be
partially counteracted by creatine supplementation.
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Appetite enhancement and weight gain by peripheral
tyrosine kinase receptor (TrkB) agonists in non-human
primates
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Loss of function mutations in the brain-derived neurotrophic
factor (BDNF) or tyrosine kinase receptor TrkB results in
hyperphagia and obesity in human and rodents. Conversely,
peripheral or central stimulation of TrkB by its natural ligands
BDNF or NT4 reduced body weight and food intake in mice
(Tsaoetal.,Endocrinology149:1038,2008),supportingtheidea
that TrkB is a key anorexigenic signal. Here, we will describe
the surprising discovery that in non-human primates, TrkB
agonists were anorexigenic when applied centrally, but unex-
pectedly orexigenic, leading to gain in appetite, body weight, fat
deposits, and serum leptin levels, when given peripherally (Lin
et al., PLoS ONE 3(4):e1900, 2008). The orexigenic and
anabolic effects of peripherally administered TrkB agonists
appear to be dose dependent, not associated with fluid retention
nor with evidence of receptor downregulation. Furthermore,
changes in several serum biomarkers in response to TrkB
agonist treatment suggest the possible mechanisms of
appetite and weight regulation via peripheral TrkB activa-
tion. Our findings indicate that TrkB signaling exerts dual
control on energy homeostasis in the primates that could be
targeted for the treatment of either cachexia or obesity.
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Background and aims: Cancer cachexia occurs in the
majority of cancer patients before death and seems to be
responsible for the deathof22% ofcancerpatients.The use of
megestrol acetate (MEGACE) for the treatment of cachexia is
widely spread despite its adverse effects and the fact that, at
least in humans, it seems to only increase fat and water body
content and not lean body mass. The aim of the present
investigation was to re-examine the anti-wasting effects of
MEGACE using an experimental cancer cachexia model.
Methods: Individual muscle weights, muscle gene expres-
sion, total physical activity and grip force were measured in
rats bearing the Yoshida AH-130 ascites hepatoma, follow-
ing MEGACE treatment.
Results: Administration of the MEGACE to tumour-bearing
rats resulted in an important reversal of the muscle-wasting
process, as reflected by individual muscle weights. The anti-
wastingeffectsofthedrugwerealsoobservedintermsoftotal
physical activity and grip force. MEGACE also decreased the
rate of protein degradation in incubated skeletal muscle. Real-
time PCR analysis revealed that MEGACE treatment resulted
in a decrease in ubiquitin, E2 and atrogin mRNA content in
gastrocnemius muscles, therefore suggesting that the main
anti-proteolytic action of the drug may be based on an
inhibition of the ATP-ubiquitin-dependent proteolytic system.
Conclusion: MEGACE treatment was effective in treating
muscle wasting in tumour-bearing rats as reflected by the
obtained results that clearly show an improvement in
muscle mass and physical performance in cachectic
tumour-bearing rats.
079
Different nutraceuticals are able to inhibit muscle
proteolysis in vitro
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Background and aims: Cancer cachexia occurs in the
majority of cancer patients before death and seems to be
responsible for the death of 22% of cancer patients. The
abnormalities associated with cancer cachexia include anorex-
ia, weight loss, muscle loss, atrophy, anemia, and alterations
in carbohydrate, lipid, and protein metabolism. Different
nutraceuticals, i.e., w3 fatty acids of marine origin, have been
proposed to counteract muscle wasting during cancer. The aim
of the present investigation was to examine the anti-wasting
effects of other nutraceuticals such as geninstein (soybean),
resveratrol (grapes), theophylline (tea), epigallocatechin gal-
late (tea), and diallyl sulfide (garlic). Bearing this in mind, the
in vitro effects of these nutraceuticals on proteolysis were
examined on muscle cultures.
Methods: C2C12 muscle cell cultures were submitted to
hyperthermia to increase the proteolytic rate. The different
nutraceuticals were added to the cultures to examine their
potential in inhibiting the increased proteolytic rate.
Results: All the nutraceutical used showed an anti-
proteolytic effect on muscle cell cultures submitted to
hyperthermia. The largest effect was observed with resver-
atrol (15% inhibition).
Conclusion: The nutraceuticals studied are candidate
molecules for future in vivo studies using cancer cachexia
models.
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muscle recovery following hind limb suspension in aged
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Bed rest or muscle immobilization causes a rapid loss of
muscle force and atrophy. This is particularly exacerbated
in aged muscles along with a slow rate of muscle recovery.
This is an undesirable consequence of hospitalization in the
elderly. In this study, we evaluated the effects of HMB
(beta-hydroxyl-beta-methylbutyrate), a leucine metabolite,
on muscle recovery following hind limb suspension (HLS)
in aged (>32 months) Fisher Brown Norway (FBN) rats.
Male rats were fed either control 2018S chow (CON) or
Ca-HMB (340 mg/kg bw)-supplemented chow (HMB) over
a 14-day HLS (unloading) period, followed by recovery
(reloading) for 7 or 14 days. Unloading caused significant
reduction in muscle force in all groups. Neither groups
recovered their baseline force even after 14 days of
78 J Cachexia Sarcopenia Muscle (2010) 1:43–128reloading, and both groups lost similar amounts of muscle
mass. However, histological staining revealed that during
recovery, the HMB groups had significantly larger muscle
fiber cross-section area (1,034.1±150.3 μm
2) than the CON
(951.1±298 μm
2) , indicating muscle hypertrophy. Along
this line, the HMB groups also displayed improved satellite
cell activation (BrdU positive nuclei) upon reloading (HMB,
8.1±2%; CON, 4.2±2%). TUNEL assays revealed the
HMB groups to have significantly fewer apoptotic nuclei
than the CON (HMB, 10±5%; CON, 18±7%). Thus,
administration of HMB appears to induce muscle fiber
hypertrophy as well as protection against muscle atrophy,
possibly by protecting myonuclei from apoptosis. This
study demonstrates the potential for using HMB to facilitate
muscle recovery following extended limb immobilization.
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Fish oil and leucine decrease plasma calcium levels
in tumour-bearing mice concommitant with changes
in plasma levels of interleukin (IL) 6, prostaglandin E2
(PGE2) and interleukin (IL) 4
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Cancer-induced hypercalcaemia induces neuromuscular
complications like fatigue. Development of hypercalcae-
mia involves inflammatory cytokines, like IL-6 and
cyclooxygenase-2, while IL-4 has been shown to inhibit
osteoclast formation in mice, thus reducing plasma
calcium (pCa
2+). A specific nutritional combination
(SNC) of high protein, leucine (Leu), fish oil (FO) and
oligosaccharides increased muscle performance and re-
duced proinflammatory cytokine levels in a tumour-
bearing mouse model. We speculated that this might have
a direct ameliorating effect on pCa
2+ and thus positively
affect the cancer-induced fatigue. Male CD2F1 mice were
subcutaneously inoculated with tumor cells (0.5×
106 cells) or were sham treated and divided in controls,
tumour-bearing (TB) controls and TB receiving experi-
mental diets. At termination of the experiment (day 20),
bone mineral density (BMD) was measured (DEXA scan),
muscle function was tested ex vivo and blood was taken
for analysis of total pCa
2+ (free+albumin-bound), cyto-
kines and PGE2. BMD decreased and pCa
2+ increased in
TB compared to control mice. Supplementation with
either Leu or FO had no effect. However, supplementation
with the combination of Leu and FO or supplementation
with the SNC did reduce pCa
2+ (32%; p<0.05) and
increased BMD (42%; p<0.05). Moreover, pCa
2+ corre-
lated positively with serum TNF-alpha, IL-6 and PGE2
and negatively with serum IL-4 (R>0.05; p<0.005).
Muscle function parameters and daily activity correlated
negatively with pCa
2+ (R<−0.7, p<0.05andR=−0.85, p<
0.001, respectively). The SNC increased BMD and
reduced plasma pCa
2+, which was related to increased ex
vivo muscle function and daily activity, possibly due to
the SNC-induced changes in serum cytokine levels.
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Eicosapentaenoic acid administration attenuates
arthritis-induced decrease in liver and serum
insulin-like growth factor (IGF) 1 in rats
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Background and aim: Adjuvant-induced arthritis is an
experimental model of rheumatoid arthritis that decreases
body weight and anabolic hormones such as IGF-I.
Eicosapentaenoic acid (EPA) is an omega-3 fatty acid that
has anti-cachectic actions in several chronic illnesses. The
aim of this study was to elucidate whether EPA adminis-
tration is able to prevent the inhibitory effect of arthritis on
IGF-I.
Methods: Arthritis was induced by a Freund’s adjuvant
injection; rats were gavaged with 1 g/kg EPA or coconut oil
daily. On day 15 after adjuvant injection, rats were killed,
and liver, gastrocnemius and serum were harvested.
Results: In arthritic rats, EPA administration decreased
TNF in liver and gastrocnemius, the external signs of
arthritis, and attenuates the decrease in gastrocnemius
weight. Arthritis decreased serum concentration of IGF-I
and its gene expression in the liver in rats treated with
coconut oil (P<0.01), but not in rats treated with EPA. In
contrast, arthritis did not modify IGF-I mRNA in the
gastrocnemius muscle, but it increased IGFBP-3 and
IGFBP-5 mRNA in the rats treated with either EPA or
coconut oil. In control rats, EPA administration did not
modify IGF-I or IGFBPs in serum, liver or gastrocnemius
muscle.
Conclusion: Our data suggest that the beneficial effect of
EPA administration to arthritic rats on gastrocnemius mass
can be due to the increase in serum concentration of IGF-I
J Cachexia Sarcopenia Muscle (2010) 1:43–128 79as well as its synthesis in the liver, rather to modifications
in the muscular IGF-IGFBPs system.
Supported by grants BFU2006-11899/BFI, BFI06.31 to E.
C. and BES-2007-16001 to M.LM.
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Loss of skeletal muscle during chemotherapy treatment
is attenuated by n-3 fatty acid supplementation
in non-small cell lung cancer patients
Rachel A. Murphy
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Background: We recently reported low n-3 fatty acids
relate to sarcopenia in patients receiving chemotherapy. The
effect of chemotherapy on muscle loss is unknown but may
be an important determinant in chemotherapy response and
patient outcomes. We aimed to determine how chemother-
apy affects muscle mass and evaluate the ability of n-3 fatty
acids to attenuate muscle loss during chemotherapy.
Methods: Non-small cell lung cancer patients received
four capsules of fish oil per day (2.2 g EPA+240 mg
DHA; n=14) or no intervention (n=27) for ~3 months.
Skeletal muscle cross-sectional area was evaluated using
lumbar computed tomography (CT) images. Previously
established cut-points (males below 55.4 cm
2/m
2 and
females below 38.9 cm
2/m
2)w e r eu s e dt oc l a s s i f yp a t i e n t s
as sarcopenic (control n=15, supplementation n=8) or
non-sarcopenic (control n=12, supplementation n=6).
Muscle change was determined using two CT images
from a given time interval (200 days) and expressed as a
standard unit (percent change/100 days) to facilitate
comparison between individuals. Amounts and types of
plasma phospholipid fatty acids were determined using
gas liquid chromatography.
Results: Patients receiving n-3 supplementation maintained
muscle (−0.02%/100 days) compared to control patients
who averaged muscle loss at a rate of −5.4%/100 days (p=
0.05). Muscle rate of change was similar between sarco-
penic and non-sarcopenic patients in response to n-3
supplementation. Plasma EPA and DHA was positively
correlated to muscle rate of change (r=0.57, p=0.04) in the
supplementation group. Maximal muscle gain was observed
in patients with highest plasma EPA and DHA.
Conclusions: Muscle mass decreases during chemotherapy
treatment, but attenuation can potentially be achieved
through fish oil supplementation.
084
Effects of omega-3 fatty acids on blood cytokines
in the patients with sepsis and cachexia
Igor E. Khoroshilov
Department of Clinical Nutrition, Saint Petersburg I. I.
Mechnikov State Medical Academy, Saint Petersburg,
Russia
Aims: We aim to study changes of blood cytokines in
patients with sepsis and cachexia before and after intrave-
nous injection of omega-3 fatty acids.
Methods: Twenty patients with severe sepsis and cachexia
(eight men and 12 women), aged from 33 up to 86 years old,
located on treatment in ICU, were randomized to two even
groups. The patients from the first group on the background
of parenteral nutrition were prescribed with lipid emulsion,
enriched by omega-3 fatty acids (“Lipoplus” (B. Braun,
Germany)). The patients of the second group were pre-
scribed parenteral nutrition without application of lipid. At
the beginning of research and on the sixth day, the content in
serum blood following cytokines emulsions was identified in
all patients. At the beginning of research and on the sixth
day, the content in serum blood following cytokines was
identified in all patients: IL-2, IL-4, IL-6, IL-8, IL-10, IFN-
gamma, and TNF-alpha (Bio-Plex, Bio-Rad, USA).
Results: The content of cytokines in the blood serum of the
first group of patients, receiving the parenteral nutrition
with inclusion of omega-3 fatty acids, was significantly
lower than in the second (control) group of patients. So, IL-
6 level in serum blood in the first group was reduced to
65% and, in the second group, increased to 25%. The level
of IL-8 at the first group was reduced to 87% and, in the
second group, to 28%; the level of tumor necrosis factor
(TNF-alpha) was reduced to 15% and 1% suitably.
Conclusions: Omega-3 fatty acids substantially hold down
the level of cytokines and the inflammatory reactions of the
patients with sepsis and cachexia.
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Increased amino acid provision does not lead to insulin
resistance in lung cancer cachexia
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Background and aims: Studies in healthy persons have
suggested that hyperaminoacidemia compromises peripheral
80 J Cachexia Sarcopenia Muscle (2010) 1:43–128glucose uptake leading to insulin resistance through altered
insulin signalling and glucose transport. Insulin resistance is
commonly reported in cancer cachexia, and increased protein
intakes are recommended to favour protein anabolism and
preventmuscleloss.Wetestedwhetherasustained,physiolog-
ical elevation of circulating amino acids would interfere with
glucosemetabolism.
Methods: Insulin resistance was assessed in six men with
non-small cell lung cancer (NSCLC) and seven age-
matched controls with healthy BMI using the hyperinsuli-
nemic (1.25 mU/kgLBMmin), euglycemic (5.5 mM), iso-
aminoacidemic clamp (IsoAA) for 2.5 h, followed by 2.5 h
of hyperaminoacidemia (HyperAA) at postprandial levels.
Glucose kinetics was quantified by tracer (3H3-glucose)
methodology.
Results: NSCLC patients had 7.3±1.2% weight loss, lower
muscle mass, higher CRP and GH levels and lower serum
prealbumin and urea than controls. Fasting plasma glucose,
insulin and branched-chain amino acids (BCAA) and
glucose rate of appearance (Ra, production) and disappear-
ance (Rd, uptake) did not differ. During IsoAA, insulin
reached 436±33 in NSCLC vs. 551±36 pM in controls (p=
0.04). Glucose production was equally suppressed in both,
but glucose uptake was less stimulated in NSCLC (6.2±0.7
vs. 8.6±0.8 mg/LBMmin, p=0.038, adjusted for insulin)
indicating peripheral insulin resistance. During HyperAA
(732±70 μM of total BCAA), serum insulin and glucose
production did not change significantly. However, glucose
uptake increased similarly in both groups, Rd remaining
lower in NSCLC (7.3±0.8 vs. 10.0±0.7 mg/LBMmin, p=
0.027). Glucose uptake negatively correlated with fasting
TNF-alpha (Spearman’s r=−0.71, p=0.033).
Conclusions: Inflammation was associated with insulin
resistance in lung cancer patients. However, in both these
and in insulin-sensitive controls, providing a high avail-
ability of amino acids, equivalent to a physiological
postprandial state (~25 g protein), did not interfere with
insulin action on glucose metabolism, rather it may enhance
glucose uptake. Presence of insulin resistance should not be
viewed as a deterrent to recommending higher protein
intakes in patients with cancer cachexia.
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Effects of the insulin sensitizer rosiglitazone on cachexia
outcomes in mice with colon-26 tumors
Michelle L. Asp, Min Tian, Michael B. Stout, Martha A.
Belury
Department of Human Nutrition, The Ohio State University,
Columbus, OH, USA
Background and aims: Insulin resistance is a metabolic
derangement associated with cancer cachexia. We previously
demonstrated that rosiglitazone (RGZ) improved insulin
sensitivityandbodyweightandsuppressedquadricepsmRNA
of E3 ligases Atrogin-1 and MuRF-1 before the onset of overt
cachexia in tumor-bearing mice. Additionally, adipose IL-6
mRNAwas decreased,and adiponectinmRNAwas increased.
ThepositiveeffectsofRGZearlyincachexiapathogenesisled
ustotestthehypothesisthatRGZwouldalsoimprovecachexia
outcomesinlatestagecancer.
Methods: Male CD2F1 mice were inoculated with 1×106
colon-26 adenocarcinoma cells and treated with 10 mg/kg/
day RGZ or vehicle (PBS). RGZ-treated mice were fed ad
libitum or pair-fed to PBS-treated mice.
Results: RGZ delayed the onset of weight loss by 2 days,
decreased total weight loss, and increased white and brown
adipose mass compared to PBS-treated mice. Pair-feeding
negated the effects of RGZ on body weight and white
adipose mass, and decreased quadriceps muscle mass.
However, the RGZ-induced increase in brown adipose mass
was maintained in the pair-fed group. Insulin-stimulated
glucose disappearance, muscle fiber diameter, muscle
strength, plasma IL-6, and quadriceps E3 ligase mRNAwere
not different between groups at the end of the study.
Conclusions: Although RGZ delayed weight loss and
attenuated adipose atrophy, it did not improve muscle mass,
strength, or proteolytic gene expression in severely cachec-
tic mice. Some effects of RGZ appear to be dependent on
the increased food intake associated with RGZ, emphasiz-
ing the importance of targeting both dysregulated metabo-
lism and anorexia for optimal cachexia treatment.
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Peroxisome proliferator-activated receptor-α (PPAR-α)
agonist fenofibrate ameliorates arthritis-induced
upregulation of proteolysis and regenerative response
in the gastrocnemius muscle of rats
Estibaliz Castillero, Ana Isabel Martín, Maria López-
Menduiña, Asuncion López-Calderón, Maria Angeles
Villanúa
Departamento de Fisiología, Facultad de Medicina,
Universidad Complutense de Madrid, Madrid, Spain
Background and aims: Adjuvant induced arthritis is an
animal model of chronic inflammation that leads to marked
skeletal muscle atrophy, activation of the ubiquitin protea-
some pathway, and regenerative response. PPAR-α is an
important target in the inflammatory processes. Our aim was
toinvestigatetheeffectoffenofibrateinexperimentalarthritis.
Methods: Arthritis was induced in male Wistar rats by an
intradermal injection of Freund’s adjuvant. Control and
arthritis rats were divided into two groups and were daily
gavaged with 300 mg/kg bw of fenofibrate or vehicle
J Cachexia Sarcopenia Muscle (2010) 1:43–128 81during 12 days. Gene expression of TNF-α in the liver, and
atrogin-1, MuRF-1, myogenin, MyoD, and PCNA in
gastrocnemius muscle were measured by real-time PCR.
Protein levels of myogenin, MyoD, and PCNA were
measured by Western blot.
Results: Arthritic rats treated with fenofibrate had lower
arthritis score, hind paw swelling, and splenomegaly (P<
0.01). Arthritis-induced increase in liver TNF-α mRNA
was blocked by fenofibrate (P<0.01). Fenofibrate admin-
istration to arthritic rats increased gastrocnemius weight and
prevented arthritis-induced increase in atrogin-1 and
MuRF-1 mRNA in this muscle (P<0.01). There was an
increase in myogenin, MyoD, and PCNA gene expression
and protein in the gastrocnemius of the arthritic rats (P<
0.01), whereas fenofibrate normalized this effect (P<0.01).
Conclusion: In addition to its anti-inflammatory effect in
arthritic rats, activation of the PPAR-α by fenofibrate
prevents the upregulation of the ubiquitine proteasome
pathway and normalizes the regeneration and differentiation
processes in the skeletal muscle.
Work supported by grants IV M. Madrileña, G. Vasco
BFI06.31 to E.C. and BES-2007-16001 to M.LM.
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Acetylation of heat shock protein (HSP) 70
and regulation of Foxo transactivation
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The Foxo transcription factors are upregulated in response to
multiple conditions of skeletal muscle wasting and are both
sufficient and required for the normal atrophy program.
Although Foxo is largely regulated in skeletal muscle
through its phosphorylation and inactivation by Akt, we
recently demonstrated that Foxo-dependent transcription can
be inhibited by heat shock protein 70 (Hsp70). However, the
precise mechanism responsible for this inhibition remains
unknown. Because acetylation of Hsp70 has been shown to
regulate its function in other cell types, the current study
sought to determine whether Hsp70 is acetylated in skeletal
muscle,andwhether thiscontributestoitsrepressionofFoxo
transactivation. Immunoprecipitation of total acetylated
proteins from whole muscle revealed Hsp70 to be acetylated
during weight bearing conditions, which was significantly
reduced following 3 days of immobilization. Subsequent co-
immunoprecipitation experiments revealedbindingof Hsp70
to the histone acetyltransferase p300. To determine if acetyla-
tion of Hsp70 is mediated via p300, and whether this affects
Hsp70-mediated repression of Foxo activity, we subsequently
transfected whole muscle with a WT p300 expression plasmid
or a p300 mutant lacking its acetyltransferase activity
(p300DY) plus Hsp70 and a Foxo-responsive reporter prior to
weight bearing or immobilization conditions. Expression of
WT p300, but not p300 DY, prevented the decrease in Hsp70
acetylation in response to immobilization. Importantly, expres-
sion of the p300DY reversed the inhibitory effect of Hsp70 on
Foxo transactivation. These findings suggest that modulating
the acetylation status of Hsp70 could be an important
mechanism of Foxo regulation in skeletal muscle.
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Toll-like receptor 4 mediates muscle wasting
Alexander Doyle, Yi-Ping Li
Department of Integrative Biology and Pharmacology,
University of Texas Health Science Center at Houston,
Houston, TX, USA
Background and aims: Cachectic muscle wasting is a
complication of inflammatory diseases. Lipopolysaccharide
(LPS) is known to stimulate muscle catabolism by
upregulating specific ubiquitin ligases via inducing inflam-
matory cytokines. Here, we investigated the direct stimu-
lation of muscle protein degradation by LPS via the
activation of muscle Toll-like receptor 4 (TLR4).
Methods and results: Incubation of C2C12 myotubes with
the TLR4 ligand LPS (100 ng/ml) for 48 h resulted in
myosin heavy chain loss and thinner myotubes. Expression
o fa t r o g i n - 1 / M A F b xw a su p r e g u l a t e db yL P Sw i t h i n1ha n d
peaked at 2 h. On the other hand, expression of MuRF1 was
initially downregulated at 1 and 2 h, and then upregulated at
3 h. To understand the signaling mechanism of the LPS
actions, we observed that LPS activated p38 MAPK and
AKT within 30 min. The latter resulted in hyperphosphor-
ylation and inactivation of Foxo1/3, which could explain the
downregulation of MuRF1. Pretreatment of C2C12 myo-
tubes with p38 inhibitor SB202190 blocked LPS upregula-
tion of atrogin-1/MAFbx, but not MuRF1. Conversely,
overexpression of active MKK6 (MKK6bE) upregulated
atrogin-1/MAFbx expression. TLR4 knockdown with
siRNA abolished LPS activation of p38 and AKT. In mice,
pre-administration of SB202190 or TLR4 gene knockout
blocked LPS upregulation of atrogin-1/MAFbx expression
and stimulation of tyrosine release by muscle.
Conclusions: LPS direct activation of muscle TLR4
accelerates muscle protein degradation by upregulating
muscle E3 ligases. TLR4/p38 signaling upregulates
atrogin-1/MAFbx expression and contributes significantly
to LPS-induced muscle loss. These results depict a new
paradigm for the mechanism of cachexia.
Supported by NIH grant R01 AR049022.
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Low-dose dexamethasone prevents protein loss
and the impairment of carbohydrate oxidation
in rat skeletal muscle during endotoxaemia
Hannah Crossland, Dumitru Constantin-Teodosiu, Sheila
M. Gardiner, Paul L. Greenhaff
School of Biomedical Sciences, Queen’s Medical Centre,
University of Nottingham, Nottingham, UK
Background and aims: We previously suggested a role for
cytokine-mediated impairment of Akt/Forkhead box O
(FOXO) signalling in the induction of muscle atrophy and
impairment of muscle carbohydrate oxidation during
lipopolysaccharide (LPS)-induced endotoxaemia. We aimed
to determine whether low-dose dexamethasone (Dex; anti-
inflammatory agent) infusion during endotoxaemia would
dampen LPS-induced impairment of Akt/FOXO signalling,
thereby blunting muscle atrophy and the impairment of
carbohydrate oxidation.
Methods: Chronically-instrumented rats received a continu-
ous intravenous infusion of either LPS (15 μgkg
−1h
−1), Dex
(12.5 μgkg
−1h
−1), Dex+LPS or saline for 24 h at 0.4 mlh
−1.
Results: Dex co-administration during endotoxaemia (1)
blunted the LPS-induced increase in muscle cytokines, the
reduction in Akt and FOXO1 phosphorylation and the
decline in the muscle protein:DNA ratio; (2) suppressed
LPS-induced cathepsin-L upregulation, but not the increase
in MAFbx or MuRF1 mRNA expression; and (3) blunted
LPS-induced muscle PDK4 mRNA upregulation and
glycogen breakdown and lactate accumulation (see Table).
Measurement Effect of LPS
from control
a
Effect of Dex in
LPS-treated rats
b
Protein:DNA ratio ↓1.7-fold** ↑63%*
mRNA expression
Tumour necrosis factor-α
(TNF-α)
↑10-fold*** ↓51%**
Interleukin-6 (IL-6) ↑14-fold*** ↓85%***
Muscle atrophy F-box
(MAFbx)
↑4.6-fold*** No change
Muscle RING finger 1
(MuRF1)
↑13-fold*** No change
Cathepsin-L ↑9.7-fold*** ↓43%*
Pyruvate dehydrogenase
kinase 4 (PDK4)
↑16-fold*** ↓47%**
Protein expression
Phosphorylated-Akt ↓2-fold* ↑128%*
Phosphorylated/total-FOXO1 ↓1.9-fold* ↑43% (NS)
Metabolites
Glycogen ↓1.3-fold* ↑30%*
Lactate ↑1.53-fold** ↓27%**
*P<0.05; **P<0.01; ***P<0.001
aSignificantly different from control
bSignificantly different from LPS-treated group
Conclusions: Low-dose Dex infusion blunted muscle
protein loss and the impairment of muscle carbohydrate
oxidation, possibly through suppression of cytokine-
mediated Akt/FOXO inhibition.
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C2 skeletal myoblast survival, death, proliferation
and differentiation: regulation by Adra1d
Amarjit Saini, Nasser Al-Shanti, Claire E. Stewart
I.R.M, MMu, Manchester M1 5GD, Manchester, UK
Background: Apoptosis represents one potential pathway
underlying skeletal muscle wasting associated with chronic
diseases. Cytokines (e.g. TNF-α) act to trigger catabolism
while the insulin-like growth factor (IGF) system influences
anabolism and is essential for skeletal muscle regeneration
and maintenance. Up-regulation of inhibitors of apoptosis
(e.g. IGF) could be beneficial in the treatments of cachexia
and sarcopenia. Using C2 skeletal myoblasts, we have
reported that while 10 ngml
−1 TNF-α-induced apoptosis is
rescued by IGF-I, 1.25 ngml
−1 TNF-α (which alone is not
myotoxic) elicits MAPK-mediated apoptosis when co-
incubated with IGF-I (1.5 ngml
−1).
Aims, methods, and results: Array technology followed by
qRT-PCR identified Adra1d as a potential gene regulating pro-
and anti-apoptotic roles of IGF-I. Expression was up- or down-
regulated in conditions of survival or apoptosis, respectively.
Administration of TNF-α ( 1 . 2 5o r1 0n g m l
−1) induced a
significant (p<0.05) decrease (~50%) in Adra1d expression
relative to controls. Addition of IGF-I to 10 ngml
−1 TNF-α
induced significant myoblast survival and a return in Arda1d
expression to basal levels. However, IGF-I addition to 1.25 ng
ml
−1 TNF-α induced elevated death and a 55% decline (p<
0.05) in Adra1d expression. Twenty micromole PD98059
(MEK inhibitor) administration rescued death induced by
1.25 ngml
−1 TNF-α and IGF-I and returned Adra1d levels to
baseline. Since Adra1d was elevated following survival, we
investigated the impact of Adra1d gene silencing. Adra1d
knockdown resulted in elevated cell death under all incubation
conditions (p<0.05).
Conclusion: These novel findings suggest that Adra1d
expression is essential for skeletal muscle cell survival and
may have implications for cachexia and sarcopenia.
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C2 skeletal myoblast survival, death, proliferation
and differentiation: regulation by SIRT1
Amarjit Saini, Nasser Al-Shanti, Claire E. Stewart
I.R.M. John Dalton Building, MMU, Oxford Road,
Manchester, UK
J Cachexia Sarcopenia Muscle (2010) 1:43–128 83Introduction and aim: Sirt1 is a key regulator of cell
defences and survival in response to stress. Deletion of
Sirt1 abolishes the increase in lifespan induced by calorie
restriction or sublethal cytokine stress, indicating that Sirt1
promotes longevity and survival. We have demonstrated
that sublethal TNF-α (1.25 ngml
−1) administration inhibits
myotube formation, and co-incubation with IGF-I (1.5 ng
ml
−1) facilitates C2 myoblast death rather than rescuing
differentiation. Higher dose TNF-α (10 ngml
−1) resulted in
significant apoptosis, which was rescued by IGF-I (1.5 ng
ml
−1; 50% rescue; p<0.05). We aimed to investigate the
role of Sirt1 in the conflicting roles of IGF-I.
Methods and results: qRT-PCR revealed that Sirt1
expression was elevated in myoblasts following incubation
of 10 ngml
−1 TNF-α or 1.25 ngml
−1 TNF-α plus IGF-I (5–
7.2-fold increases vs. control; p<0.05). Of TNF-α,1 0n g
ml
−1 induced ~21±0.7% apoptosis, which was reduced
(~50%, p<0.05) when administered with IGF-I. Similarly,
Sirt1 expression was elevated following 10 ngml
−1 TNF-α
administration, but was reduced (~30%, p<0.05) in the
presence of IGF-I. Incubations that induced the greatest
myoblast stress/damage resulted in elevated Sirt1 expres-
sion; we therefore investigated the effects of Sirt1 gene
silencing. Of TNF-α,1 0n g m l
−1 or co-incubation of
1.25 ngml
−1 TNF-α/IGF-I resulted in apoptosis (20.33±
2.08% and 19±2.65%), which was increased when myo-
blasts were pre-administered with Sirt1 siRNA (31±2.65%
and 27.33±2.52%; p<0.05). Under basal condtions, Sirt1
inhibition had no impact on death.
Conclusion: These findings suggest that Sirt1 expression
increases under conditons of stress, functioning to reduce or
dampen myoblast death.
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on the interleukin (IL) 6 secretion from the precursors
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Background: Critical illness myopathy is a frequent
condition in the emergency units. Its pathophysiology and
final outcome is complex and depends not only on the
extent of muscle damage but also on the efficiency of
muscle regeneration, which is triggered by muscle injury.
Muscle regeneration starts from the mytotically and
metabolically quiescent satellite cells. After injury, they
are released from their location and enter the cell cycle as
mononuclear myoblasts. Muscle mass formed in the
regeneration process critically depends on the myoblast
proliferation, and since critical illness is accompanied by
extensive cytokine signaling, it is important to know how
this signaling affects the mechanisms participating in the
myoblast proliferation.
Aim and methods: A great body of evidence supports the
concept that with regard to the cytokine signaling, major
response of the skeletal muscle is IL-6 secretion. IL-6
promotes myoblast proliferation and is an essential regula-
tor of satellite cell-mediated muscle hypertrophy. Therefore,
it is very likely that it plays an important role in muscle
regeneration. In this study, we followed the effects of pro-
inflammatory (TNF-alpha and LPS) and anti-inflammatory
factors (dexamethasone and IL-10) on the IL-6 secretion
from the cultured human myoblasts. The effects on
proliferating myoblasts were compared with the effects on
non-proliferating myotubes.
Results and conclusion: Pro-inflammatory factors TNF-
alpha- and LPS stimulated IL-6 release in both myoblasts and
myotubes. Anti-inflammatory factor dexamethasone sup-
pressed constitutive secretion of IL-6, while IL-10 decreased
secretion of IL-6 but only in myoblasts. Our results suggest
complex and differentiation stage-specific control of IL-6
from precursors of human muscle regeneration.
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Systemic inflammation and nuclear factor-kappa B
(NF-kB) dependent muscle atrophy in a mouse model
of acute pulmonary inflammation
Ramon C. J. Langen, Astrid Haegens, Emiel F. M.
Wouters, Annemie M. W. J. Schols
Department of Respiratory Medicine, Maastricht University
Medical Centre, Maastricht, Netherlands
Background and aims: Skeletal muscle atrophy is a
prominentanddisablingfeatureofinflammatorylungdisease.
Theaimofthisstudywas toaddresswhetheracute pulmonary
inflammation is sufficient to induce systemic inflammation
and loss of muscle mass, and whether local NF-kB activity is
required for muscle atrophy.
Methods: C57/bl6 mice received a single bolus of
Escherichia coli LPS by intra-tracheal (IT) instillation to
induce acute pulmonary inflammation or 0.9% NaCl as a
control.
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72 h and almost completely resolved at 120 h post-LPS.
Loss of bodyweight (bw) and muscle weight (mw) was
maximal 48–72 h post-LPS (10–15% decrease), and
recovery was almost complete 120 h post-LPS. Assessment
of MuRF1 and atrogin-1 in muscle revealed a transient
increase in mRNA abundance (24–72 h post-LPS),
preceding maximal loss of mw. Pair-fed experiments
revealed that reduced food intake was responsible for
only a minor part of the changes observed in bw, mw, and
Atrogin-1/MuRF1 expression. Systemic inflammation was
evidenced by increased circulating levels of a number of
cytokines and chemokines, as well as NF-kB activation in
circulating neutrophils and peripheral tissues including
skeletal muscle measured in NF-kB-luciferase reporter
mice, which was verified by increased KC (IL-8) and IkBa
expression. Importantly, muscle specific abrogation of
NF-kB signaling strongly attenuated MuRF1 expression
and loss of muscle mass following IT-LPS instillation in
transgenic mice.
Conclusions: These data demonstrate that acute pulmonary
inflammation induces systemic inflammation, and that
subsequent muscular NF-kB activation contributes to
muscle atrophy, potentially via the induction of MuRF1.
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Skeletal muscle is a prominent tissue involved in the
regulation of metabolic homeostasis by its capacity to
oxidize fatty acids and glucose. To test the adaptations of
skeletal muscle cells following food deprivation, we
developed an in vitro experimental model of C2C12
myotubes submitted to a metabolic challenge consisting in
4 h of food deprivation followed by 20 h of refeeding.
During the time course of this metabolic challenge, we
determined the morphological and metabolic responses of
C2C12 myotubes. Myotube area decreased progressively
(~20% at 4 h) during food deprivation and increased
progressively to reach control values 18 h after refeeding.
Accordingly, the phosphorylation of ribosomal protein S6,
which is involved in the regulation of protein synthesis,
decreased and increased in a time-dependant manner during
food deprivation (~75% at 4 h) and refeeding (~500% at
4 h), respectively. Refeeding was accompanied by a strong
increase in glucose consumption (~400% at 15 min), which
progressively decreased to control level 20 h after refeed-
ing. During this period, glucose metabolism, which was
initially oxidative, progressively switched to a glycolytic
metabolism (~35%). Furthermore, food deprivation was
accompanied by a transient decrease (~20% at 15 min) in
hexokinase and citrate synthase activities, which recovered
progressively during food deprivation and refeeding. The
expression of sirtuin 1, a NAD
+-dependent histone deace-
tylase, potentially involved in the regulation of hexokinase
expression, decreased during food deprivation (~40% at
4 h). We are currently assessing the contribution of sirtuin 1
in these morphological and metabolic adaptations.
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Redox balance and carbonylated proteins in limb
muscles and heart of cachectic rats
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In fast- and slow-twitch limb muscles and heart of cachectic
rats, redox balance and muscle structure were explored.
Furthermore, the nature of the oxidatively modified
proteins was also identified in these muscles. Reactive
carbonyls, hydroxynonenal (HNE)-, and malondialdehyde
(MDA)-protein adducts and antioxidant enzyme levels were
determined in limb muscles and heart of cachectic (7 days
J Cachexia Sarcopenia Muscle (2010) 1:43–128 85after inoculation of Yoshida A H-130 ascites hepatoma) and
control rats. Moreover, carbonylated proteins were identified
(proteomics), and fiber-type composition was evaluated
(morphometry) in these muscles. In cachectic rats, compared
to the controls, (1) HNE- and MDA-protein adducts levels
were greater in gastrocnemius, tibialis anterior, soleus, and
heart; (2) in the gastrocnemius, type II fiber size was reduced,
and the intensity of carbonylated protein immunostaining was
significantly greater in these fibers; and (3) proteins involved
inglycolysis,ATPproductionanddistribution,carbondioxide
hydration, muscle contraction, and mitochondrial metabolism
were significantly more carbonylated in limb muscles and
heart. Cancer cachexia alters redox balance in fast- and slow-
twitch limb muscles and heart of rats, inducing increased
oxidative modifications of key proteins involved in muscle
structure and function. Additionally, it induces a reduction in
type II fiber size in the gastrocnemius, which is associated
with increased protein oxidation.
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Impact of exercise training on myostatin expression
in the myocardium and skeletal muscle in a chronic
heart failure model and patients with chronic heart
failure (CHF)
Karsten Lenk, Volker Adams, Axel Linke, Robert
Schur, Sandra Erbs, Gerhard Schuler
Department of Cardiology, Heart Center, Leipzig,
Germany
Background: In terminal chronic heart failure (CHF),
elevated cytokines and cachexia are often observed. Several
studies documented that exercise training exerts beneficial
effects on skeletal muscle in this setting. Furthermore, it has
been shown that the expression of myostatin, a key
regulator of skeletal muscle mass, is increased in a variety
of cachectic states.
Aims: The aim of the present study was to investigate
the expression of myostatin in CHF, the influence of
exercise training, and its regulation by tumor necrosis
factor-alpha (TNF-a). Furthermore the effects of exercise
training on myostatin in patients with CHF were
examined.
Methods and results: In an animal model of CHF (LAD
ligation model), protein expression of myostatin was
elevated 2.4-fold in the skeletal muscle and more than four
times in the myocardium as compared to control. Exercise
training on a treadmill over 4 weeks lead to a significant
reduction of myostatin protein expression in the skeletal
muscle and the myocardium of CHF-animals back to
baseline levels. In differentiated C2C12 cells, TNF-α
induced the expression of myostatin through a
p38MAPK-dependent pathway under participation of NF-
kB. In patients with CHF, exercise training lead to a
significant reduction of myostatin in the skeletal muscle
compared to controls.
Conclusion: These alterations of myostatin expression
seen under exercise training in the skeletal and heart
muscle could be one possible mechanism explaining the
beneficial anti-catabolic effects of exercise training in
CHF.
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Skeletal muscle transcriptional responses to short-term
resistance exercise greatly differ among individuals
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While resistance exercise training increases muscle mass
and can be exploited to aid rehabilitation following
wasting, our understanding of the molecular events that
underpin these processes remains at a rudimentary level.
Here, we explored the transcriptional events that occur in
healthy skeletal muscle following resistance exercise.
Sixteen, young, healthy males, divided into exercise or
control groups, had basal muscle biopsies taken (vastus
lateralis, day 0). Subjects in the exercise group then
performed 5×30 maximal isokinetic knee extensions
(180º/s), which was repeated on days 2 and 4. Control
subjects abstained from exercise. Additional biopsies
obtained on days 1, 3, and 7 at rest allowed global gene
expression changes to be examined using gene microarrays.
The data was filtered using Ingenuity’s IPA software,
constricting analysis to genes considered relevant to muscle
processes.
Principal component analysis revealed two disparate
transcriptional responses to resistance exercise between
individuals on days 1 and 3 (but not day 7). Subjects
grouped according to these responses resulted in one
cohort (n=5) with 0, 8, and 0 genes significantly (FDR≤
0.05) altered from basal on days 1, 3, and 7, respectively.
In the three remaining subjects, 630, 1,042, and 419
genes were altered over the same period with 20% of
identified genes altered at multiple time-points. These
observations could not be rationalized by volume of
isokinetic work performed or initial muscle mass of
volunteers. No significant changes were observed in
control subjects.
86 J Cachexia Sarcopenia Muscle (2010) 1:43–128Resistance exercise elicits a markedly different transcrip-
tional response among individuals, with some showing an
exaggerated and prolonged response.
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Curcumin treatment blocks increased proteasome
and apoptosome activities in immobilized rat skeletal
muscle without inhibiting muscle atrophy
Emilie Vazeille, Hugues Magne, Dominique Dardevet,
Didier Didier Attaix, Lydie Combaret
UMR 1019 Nutrition Humaine, INRA, Saint Genes
Champanelle, France
Background and aim: Sustained muscle wasting ultimately
leadstobedrestandimmobilization.Designingnewstrategies
that prevent muscle wasting following immobilization is of
major importance to maintain autonomy and to reduce public
health care costs. Immobilization is characterized by a
concomitant activation of the ubiquitin (Ub)-proteasome-
dependent proteolytic system and of the mitochondria-
associated apoptotic pathway. Increased oxidative stress and
inflammatory response also occur in immobilized skeletal
muscle. We evaluated the role of curcumin on muscle atrophy
in immobilized animals. This compound exhibits anti-oxidant
and anti-inflammatory properties and has been reported to
block proteasome activation in intact animals.
Methods: Wistar rats were subjected to unilateral hindlimb
immobilization for 8 days, and the contralateral muscle of
the non-casted leg was used as a control. Half of the
animals received a daily administration of curcumin (1 mg/
kg, i.p.). Proteolytic and apoptotic pathways were studied in
gastrocnemius muscles.
Results: Curcumin did not reduce immobilization-induced
muscle atrophy. Similarly, the increase amount of ubiquiti-
nated conjugates and the increased caspase-3 activity that
both prevail in immobilized muscles were unchanged in
curcumin-treated rats. By contrast, curcumin suppressed the
increased chymotrypsin-like activity of the proteasome and
apoptosome activities in the immobilized muscles.
Conclusions: T h el a c ko fe f f e c to fc u r c u m i no nm u s c l e
wasting in immobilized muscles suggests that curcumin does
not inhibit rate-limiting steps for muscle atrophy. Alternative-
ly, the datamay suggest thatthe i.p.modeofadministrationof
curcumin does not provide enough biologically active
metabolites on the signaling pathways of muscle proteolysis.
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Loss of USP19 increases transcription of myofibrillar
proteins in L6 muscle cells and decreases muscle
wasting in response to denervation in mice
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Background and aims: Although many enzymes involved
in ubiquitination are activated in atrophying muscle, little is
known about the role of deubiquitinating enzymes (DUBs).
We previously showed that the USP19 DUB is induced in
various conditions of muscle atrophy including cancer. We
tested the effects of loss of USP19 in muscles cells and
transgenic mice.
Methods: Methods include RNAi of USP19 in muscle cells
and gene inactivation in mouse.
Results: Depletion of USP19 by siRNA in L6 myotubes
resulted in 1.5–2.5-fold increases in protein levels of myosin
heavy chain (MHC), actin, troponin T, and tropomyosin.
USP19 depletion also increased MHC and tropomyosin
mRNA levels, suggesting that this effect is due to increased
transcription. Consistent with this, USP19 depletion in-
creased myogenin protein and mRNA levels by ~2-fold.
Lowering myogenin using siRNA prevented the increase in
MHC and tropomyosin upon USP19 depletion, indicating
that myogenin mediated the increase in myofibrillar
proteins. Dexamethasone or TNF-α treatment lowered
MHC and increased USP19. USP19 siRNA reversed the
suppression of MHC by these agents. Mice lacking USP19
were grossly normal, but lost 25–53% less mass in
gastrocnemius/tibialis anterior muscles than WT mice upon
denervation.
Conclusions: These studies demonstrate for the first time a
role for a DUB in muscle wasting. Interestingly, the
induction of USP19 in wasting appears to suppress
synthesis of myofibrillar proteins, indicating that the
ubiquitin system not only mediates the increased protein
breakdown but also is involved in the decreased protein
synthesis seen in atrophying skeletal muscle.
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Structural remodeling of human skeletal muscle
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J Cachexia Sarcopenia Muscle (2010) 1:43–128 87Background and aims: Long-term inactivity leads to
muscle atrophy and weakness. The aim of the present
study was to investigate the mechanisms of human skeletal
muscle remodeling in chronic disuse.
Methods: Two paradigms of disuse were used for this study:
unilateral lower limb suspension (ULLS) and bed rest (BR).
Nine males (aged 22.3±3.8 years) participated to a 23-day
ULLSstudy,whiletenmales(aged22.3±2.2years)tookpart
to a 35-day BR study. Evidence of skeletal muscle remodel-
ing was obtained by measuring vastus lateralis (VL) muscle
fibre fascicle length (Lf) using ultrasound. To investigate the
mechanism underlying this structural alteration, focal adhe-
sion kinase activity and content (FAK, an integrin-associated
phosphoprotein involved in mechanotransduction) were
measured on VL muscle biopsy samples obtained in the
same individuals. Since FAK is an upstream modulator of
protein synthesis, concomitant fractional rate of protein
synthesis was measured after infusion of stable isotopes.
Results: VL Lf decreased by 5.5% after just 10 days of
unilateral lower limb suspension (ULLS) and by 9% after
35 days of bedrest. This decrease in Lf, indicating a rapid
loss of sarcomere in series, was associated with a
concomitant decrease in concentration (−20%) and activity
(−30%) of FAK. Myofibrillar fractional rate of protein
synthesis, measured on the same biopsy samples, dropped
by 50% within 10 days of unloading.
Conclusions: Sarcomere remodeling, in response to
unloading in humans, is a very fast process associated with
marked changes in cytoskeletal proteins involved in
mechanotransduction, leading to a dramatic decrease in
protein synthesis. The results also suggest that counter-
measures aimed at preventing muscle atrophy should start
from the very early phases of the disuse period.
102
The transcription factor activating transcription factor 4
(ATF4) promotes skeletal myofiber atrophy during fasting
Manish Suneja, Scott M. Ebert, Alex Mas Monteys,
Beverly L. Davidson, Christopher M. Adams
Department of Internal Medicine, University of Iowa, Iowa
City, IA, USA
Background and aims: Prolonged fasting alters skeletal
muscle protein metabolism and promotes skeletal myofiber
atrophy,buttheunderlyingmolecularmechanismsarenotfully
understood. Here, we examined the potential role of ATF4, a
transcription factor that plays an evolutionarily ancient role in
protein metabolism and the cellular response to starvation.
Methods: We studied adult male C57BL/6 mice and used
electroporation to transfect their tibialis anterior muscles
with plasmid DNA.
Results: Reduction of ATF4 expression with an artificial
microRNA designed to target ATF4 (miR-ATF4) did not alter
myofiber size under nonfasting conditions, but it prevented
myofiber atrophyunder fasting conditions. Likewise, when we
reduced the fasting level of ATF4 mRNA with a
phosphorylation-resistant form of eukaryotic intitiation factor
2-alpha, myofiber atrophy was reduced. To determine if
increased ATF4 expression was sufficient to reduce myofiber
size, we overexpressed ATF4 and found that it reduced
myofiber size in the absence of fasting. In contrast, a
transcriptionally inactive ATF4 construct did not alter myo-
fiber size, suggesting a requirement for ATF4-mediated
transcriptional regulation. To begin to determine the effect of
ATF4 on skeletal muscle gene expression, we examined
mRNAsencodingatrogin-1,MuRF1,andtheproteinsynthesis
inhibitor 4E-BP1, all of which were increased by fasting.
Underfastingconditions,miR-ATF4reducedlevelsofatrogin-
1, MuRF1, and 4E-BP1 mRNAs. However, in the absence of
fasting, ATF4 overexpression increased only 4E-BP1 mRNA.
Conclusions: Taken together, these data suggest that ATF4
plays an essential role in modifying skeletal muscle gene
expression to promote myofiber atrophy during starvation.
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Intramyocellular lipid content in human cancer
cachexia—an ultrastructural analysis
Nathan A. Stephens, Richard J. E. Skipworth, Carolyn
A. Greig, James A. Ross, Kenneth C. H. Fearon
Department of Clinical and Surgical Sciences (Surgery),
University of Edinburgh, Edinburgh, UK
Background and aims: Fat infiltration in skeletal muscle is
thought to be a pathological feature and associated with
muscle frailty in several conditions. However, few data
exists on its relevance in human cancer cachexia. We
hypothesised that intramyocellular lipid content is increased
in the muscle of patients with cancer cachexia and could
represent a marker of muscle frailty.
Methods: Nineteen patients with upper gastrointestinal
cancer (pancreatic, gastric or oesophageal) and six weight-
stable non-cancer controls were recruited. Rectus abdomi-
nis biopsy was taken at the time of open surgery. Samples
were processed, embedded in resin and 60-nm sections
were cut and stained with uranyl acetate/lead citrate. Images
were taken using a Phillips CM120 transmission electron
microscope at ×2,650 magnification. Lipid vacuoles were
counted manually in at least two fields per patient, and the
average count was recorded. Three groups were analysed
(using SPSS ver. 15 software): A, controls; B, weight-stable
cancer patients (weight loss <5%) and C, weight-losing
cancer patients (weight loss ≥5%).
88 J Cachexia Sarcopenia Muscle (2010) 1:43–128Results: Mean weight loss was −0.25% in group A, −0.19%
in B and 11.6% in C. Control patients were younger than the
cancer groups (52 (A) vs 69 (B) vs 63 years (C); p=0.016).
Mean lipid vacuole count was significantly higher in group
C patients compared with group A and B (10.2 vs 1.8 vs
2.2, respectively; p=0.004) and correlated positively with
weight loss (R=0.50, p=0.014).
Conclusions: Intramyocellular fat deposition appears to
increase in cancer patients with weight loss. This may have
implications on muscle function and furthermore could be
used as a marker of muscle frailty.
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Reduced muscle quality is observed with progressive
weight loss in patients with cancer
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Background and aim: Previous studies have suggested
that cancer cachexia is not associated with a reduction in
leg muscle mechanical quality when defined as muscle
strength per unit cross-sectional area (CSA). We tested this
hypothesis in a group of patients with mixed upper
gastrointestinal (UGI) cancer.
Methods: PatientswithUGI cancer(gastric,oesophagealand
pancreatic) were recruited. Maximal voluntary isometric knee
extensor strength was measured using dynamometry. Sequen-
tialT1-weightedaxialimagesofthethighwereobtainedusing
magnetic resonance (MR) imaging. MR images were ana-
lysed offline to obtain quadriceps CSA. A k-means clustering
technique was used to allow subtraction of intermuscular
fatty infiltration. Muscle quality was defined as muscle
strength/CSA of the quadriceps (Newtons (N)cm
−2). Data
was analysed using SPSS statistical software.
Results: Eighteen patients participated, mean (SD) age of
the cohort was 62 (10)years and male to female ratio was
7:11 with a mean weight loss of 12.8%. There was a
significant negative correlation between percentage weight
loss and quadriceps muscle quality (r=−0.54, p=0.020).
Patients with a weight loss of >15% had significantly lower
muscle quality compared with patients with weight loss.
Conclusions: Contrary to previous evidence, this study
suggests that muscle quality is impaired in cancer patients
with significant weight loss. Efforts should thus focus on
identifying patients at risk of cancer cachexia early in the
disease process in order to allow treatment prior to
deterioration in muscle quality.
105
Near-infrared measured lean body mass is correlated
with serum creatinine in long-term hemodialysis
patients
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Background: In long-term hemodialysis (HD) patients
who receive an adequate dose of dialysis treatment, serum
creatinine that is measured immediately prior to an HD
treatment session maybe a measure of nutritional status
including total body muscle mass and probably striated
meat intake in food, but this notion has not been well
studied.
Methods: We measured body composition including total
body fat percentage and lean body mass (LBM) using a
portable near-infrared interactance (NIR) technology in 747
HD patients from eight DaVita dialysis clinic and compared
them to 3-month averaged pre-HD serum creatinine.
Results: Patients were 53.6±14.8 years old and included
48% women, 32% Blacks, and 51% diabetics. Three-month
averaged serum creatinine was 10.2±3.1 mg/dL. The
correlation coefficient between serum creatinine and LBM
was 0.26 and 0.19 without any adjustment and adjustment
for case-mix (age, gender, race, diabetes, vintage, Charlson
comorbidity index, and Kt/V). After dividing the LBM into
five a priori selected groups, pre-HD serum creatinine was
incrementally higher across higher LBM quintiles. Spline
models showed an almost linear association between LBM
and serum creatinine even after multivariate adjustment (see
Figure).
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J Cachexia Sarcopenia Muscle (2010) 1:43–128 89Conclusions: In HD, serum creatinine is a correlate of
LBM, among others. Hence, studies that indicate a positive
association between higher serum creatinine and greater
survival may indicate the salutary impact of higher LBM.
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Diagnostic markers of cancer-associated skeletal muscle
wasting obtained using 1H-NMR profiling of urinary
metabolites analyzed by a machine learning approach
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Background and aim: Sensitive detection of the loss of
muscle in cachexia requires image-based methods such as
computed tomography (CT) which are costly and inconve-
nient. We assessed a non-invasive metabolomic approach to
detect early or slowly evolving muscle wasting.
Methods: We identified and quantified 63 metabolites in
1H-NMR spectra from urine of 91 cancer patients. Rate
of dynamic change of total skeletal muscle area (cm
2)a t
the third lumbar vertebra was assessed from serial CT
images. A common statistical technique (partial least
squares discriminant analysis (PLS-DA)) and a novel
machine-learning technique were used to identify metab-
olite patterns that discriminated patients with muscle loss
rate >0.75%/100 days versus patients maintaining or
gaining muscle.
Results: By viewing known biochemical pathways as a
Gaussian Markov random field, we built a classifier
“pathway-informed analysis” that achieved a prediction
accuracy of 76.5% for muscle loss, which outperformed
PLS-DA (prediction accuracy, 68.1%). Urine metabo-
lites related to muscle loss included creatin(in)e, 3-
hydroxyisovalerate, branched chain and other amino
acids, TCA cycle intermediates, and glucose.
Conclusions: We present a robust classifier based on
metabolite profiles of single spot urine samples. The
accuracy of this already promising diagnostic test may
potentially be strengthened by assessing additional metab-
olites by using other metabolomic methods (such as MS-
based methods) and by accounting for some of the
presently unexplained sources of variation. In this test,
some metabolites correlated with muscle loss appear to
originate in skeletal muscle, including creatinine and
branched chain amino acids.
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Potential role of defective insulin signaling in skeletal
muscle wasting of cancer cachexia
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Cancer cachexia syndrome (CCS) is a highly debilitating
paraneoplastic disease observed in more than 50% patients
with advanced cancers and directly contributes to 20–30% of
cancer deaths. Atrophy of skeletal muscle is a defining and
often fatal characteristic of cancer cachexia. Pathological
mechanisms of CCS are complex and multi-factorial, which
limits the development of an effective means of predicting,
preventing, or treating cachexia. To date, research into the
disorder was done primarily on various catabolic pathways in
skeletal muscle. In the present study, we focus on the
dysregulation of glucose utilization in muscle mediated by
the impact of aberrant cytokine signaling on components of
the insulin responsive pathway together with nuclear recep-
tors. The colon-26 (C26) adenocarcinoma model of cachexia
has been established to characterize the morphological and
molecular changes which occur during muscle wasting.
Molecular analysis revealed altered protein levels of key
molecules in the insulin-signaling pathways. Immunohisto-
chemical staining for mouse myosin heavy chain variants also
suggests more prominent atrophy in glycolytic type II
myofibers in the soleus of cachectic mice. These results
suggest that the susceptibility to atrophy in type 2 myofibers
maypotentiallybeanadaptiveresponseforalternativecellular
energy source due to dysregulated glucose utilization.
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Muscle insulin-like growth factor (IGF) 1 signaling
during the progression of cancer cachexia
in the ApcMin/+ mouse
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In healthy individuals, muscle mass is maintained by the
regulation of protein synthesis and degradation. Wasting
can induce an imbalance between these two important
processes and lead to the loss of muscle mass. The
induction of muscle protein degradation and mechanisms
90 J Cachexia Sarcopenia Muscle (2010) 1:43–128related to this process are critical mediators of muscle loss
in many wasting conditions. The evidence for a regulatory
role of muscle protein synthesis and associated signaling
that can contribute to muscle wasting is equivocal. The
purpose of this study was to determine if IGF-1/mTOR
signaling was repressed during the progression of cachexia
in ApcMin/+ mice. Male ApcMin/+ mice, an established
cachexia model related to intestinal tumors, were sacrificed
at peak body weight (12 weeks) and after the onset of
cachexia (20 weeks). The gastrocnemius muscles were
examined for gene expression and signaling related to
protein synthesis. Mice were given an injection of D5Phe
30 min prior to sacrifice to quantify myofibrillar protein
synthesis. Cachectic muscle had a 57% reduction in muscle
IGF-1 mRNA. mTOR and P70S6 kinase phosphorylation
was reduced 53% and 29%, respectively, with the progres-
sion of cachexia. The phosphorylation of the eukaryotic
initiation factor 4-BP1 was decreased by 88% by cachexia.
During the progression of cachexia, the myofibrillar protein
synthesis rate was reduced 46%. In summary, muscle from
cachectic ApcMin/+ mice has a reduction in IGF-1 gene
expression and associated signaling. This corresponds to a
reduction in myofibrillar protein synthesis. Future work
needs to examine if the induction of protein synthesis
during cachexia can reduce muscle mass loss.
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Macrophages protect against muscle atrophy
and promote muscle recovery in vivo and in vitro:
a mechanism partly dependent on insulin-like growth
factor (IGF) 1 signaling
Nicolas Dumont, Jérôme Frenette
Réadaptation, Université Laval, Centre de Recherche du
CHUQ (CHUL) Quebec, QC, Canada
Macrophages can play pro- and anti-inflammatory functions
during muscle injury and recovery. In the present study, in
vivo and in vitro models were used to determine the role of
macrophages in muscle atrophy and regrowth. In the in vivo
model,contractilepropertiesofsoleusmusclesweremeasured
in mice depleted in macrophages (etoposide, 15 mg/Kg) and
submitted to a hindlimb unloading and reloading protocol.
Ambulatory mice were used as control. In the in vitro model,
large C2C12 myotubes were incubated for 2 days in low
serum medium (DMEM 2% horse serum) and co-cultured
with macrophages that contained apoptotic neutrophils (anti-
inflammatory macrophage) and/or insulin growth factor-1
antibody (anti-IGF-1, 5 μL/mL). Myotube diameter was
measured in light microscopy, and protein content was
quantified with BCA assay. In vivo experiments showed that
mice depleted in macrophages had roughly a 30% decrease in
maximalmuscleforcecomparedtomatchedplacebomiceat7
and 14 days post-reloading. Alternatively, in vitro experi-
ments showed that the presence of anti-inflammatory macro-
phages completely prevented the loss of protein content as
well as the myotube atrophy after 2 days in low serum
medium. Interestingly, the addition of anti-IGF-1 to the co-
culture significantly decreased the ability of anti-
inflammatory macrophages to protect against the myotube
atrophy. Theseresults clearlyindicatedthatmacrophages with
anti-inflammatory phenotype prevent muscle atrophy while
promoting muscle recovery. The protective effect of this
macrophage phenotype is partly mediated by the release of
IGF-1.
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Background and aims: Loss of muscle mass occurs in a
variety of diseases, including cancer, chronic heart failure,
acquired immunodeficiency syndrome, diabetes, and renal
failure, often aggravating pathological progression. Pre-
venting muscle wasting by promoting muscle growth has
been proposed as a possible therapeutic approach. Myo-
statin is an important negative modulator of muscle growth
during myogenesis, and myostatin inhibitors are attractive
drug targets. However, the role of the myostatin pathway in
adulthood and the transcription factors involved in the
signaling are unclear. Moreover, recent results confirm that
other transforming growth factor- β (TGF-β) members
control muscle mass.
Methods: Using genetic tools, we perturbed this pathway
in adult myofibers, in vivo, to characterize the downstream
targets and their ability to control muscle mass.
Results: Smad2 and Smad3 are the transcription factors
downstream of myostatin/TGF-β and induce an atrophy
program that is muscle RING-finger protein 1 (MuRF1)
independent. Furthermore, Smad2/3 inhibition promotes
muscle hypertrophy independent of satellite cells but
partially dependent of mammalian target of rapamycin
(mTOR) signaling. Thus, myostatin and Akt pathways
cross-talk at different levels.
Conclusions: These findings point to myostatin inhibitors as
good drugs to promote muscle growth during rehabilitation,
especiallywhentheyarecombinedwithIGF-1-Aktactivators.
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Role of insulin-like growth factor (IGF) 1 in follistatin-
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Follistatin (FS) exerts its muscle anabolic action by inhibiting
several members of the TGF-β superfamily, including myo-
statin. We have previously shown that FS-induced muscle
hypertrophy is associated with increased levels of insulin-like
growth factor (IGF)-II mRNA, a potent inducer of myogenesis.
The aim of this study was to investigate the role of IGF-II in
FS-induced muscle hypertrophy. To test this hypothesis, FS
was overexpressed in muscle of IGF-II KO mice. The tibialis
anterior (TA) muscles of KO IGF-II as well as wild-type (WT)
mice were electroporated with the plasmid pM1-FS288 (left
leg) and the control plasmid pM1 (right leg). Seventeen days
afterelectroporation,TAmuscleswereremoved,weighted,and
frozen for biochemical analysis or embedded in paraffin for
morphological analysis. Our results show that FS overexpres-
sion in TA muscle of WT mice caused muscle hypertrophy
characterized by increased muscle mass (+36%, 50.2±2.9 vs
37.1±1.3 mg, P<0.01; n=5), fiber cross sectional area (CSA;
2.3-fold, 4,081±225 vs 1,812±114 μm
2, P<0.001; n=5),and
IGF-II mRNA (2.3-fold, P<0.05; n=5). In IGF-II KO mice,
FS induced the same degree of muscle hypertrophy. Indeed,
muscle mass was increased by 33% (23.1±1.6 vs 17.4±1.0,
P<0.05; n=6) and CSA by twofold (3,973±387 vs 1,970±
113, P<0.01;n=6). In conclusion, our data suggest that IGF-
II is not mandatory for muscle hypertrophy induced by FS.
So, IGF-II must be considered as a marker more than a
crucial player in FS-induced muscle hypertrophy.
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Background and aims: Myostatin (MSTN) is a negative
regulator of muscle mass. We recently demonstrated that
MSTN expression is upregulated in an experimental model
of cancer cachexia, suggesting that modulations of this
signaling might have a pathogenic role in cancer-related
muscle wasting. The present study was aimed at investi-
gating whether MSTN signaling is modulated in the muscle
of lung (LC) and gastric cancer patients (GC).
Methods: Rectus abdominis and dentatus anterior biopsies
were obtained intraoperatively in 16 GC and in 17 LC
patients, respectively. Control biopsies (C) were obtained
among patients undergoing thoracic or abdominal surgery
for non-neoplastic diseases. MSTN, phosphorilated-Smad
(p-Smad), and phosphorylated-GSK-3β (p-GSK-3β) pro-
tein levels were assayed in muscle biopsies by Western
blot. Nutritional assessment was performed for each patient.
Results: Percentage of body weight loss was 3.71±4.58 in
LC and 5.59±5.87 in GC. MSTN protein levels were
significantly increased in the muscle GC (p<0.001), while
no differences were observed in the muscle of LC even
when stratified for disease stage. P-smad did not change
with respect to C in GC. By contrast, in LC, p-smad
progressively increased, and p-GSK-3β is significantly
increased in GC vs C (p<0.05). In LC, only a tendency to
increase could be observed in stage I/II of the diseases. By
contrast, a decrease was observed in stage III/IV subjects.
Conclusions: The present results support the role of MSTN
signaling in the pathogenesis of cancer-related muscle
wasting and suggest that this pathway may be considered
a target for future strategies aimed at preventing or reducing
cancer cachexia.
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Although it is well known that catecholamines inhibit skeletal
muscle protein degradation, the molecular underlying mecha-
nismremainsunclear.Thisstudywasundertakentoinvestigate
the role of beta 2-adrenoceptors (AR) and cAMP in regulating
the ubiquitin-proteasome system (UPS) in skeletal muscle. We
report that increased levels of cAMP in isolated muscles,
promoted by the cAMP phosphodiesterase inhibitor, isobutyl-
methylxanthine (IBMX), were accompanied by decreased
activity of the UPS, levels of ubiquitin-protein conjugates,
92 J Cachexia Sarcopenia Muscle (2010) 1:43–128and expression of atrogin-1, a key ubiquitin-protein ligase
involved in muscle atrophy. In cultured myotubes, atrogin-1
induction following dexamethasone treatment was completely
prevented by IBMX. Furthermore, administration of clenbu-
terol, a selective beta 2-agonist, to mice increased muscle
cAMP levels and suppressed the fasting induced expression of
atrogin-1 and MuRF-1, atrogin-1 mRNA being much more
responsive to clenbuterol. Moreover, clenbuterol increased the
phosphorylation of muscle Akt and Foxo3a in fasted rats.
Similar responses were observed in muscles exposed to
dibutyryl-cAMP. The stimulatory effect of clenbuterol on
cAMP and Akt was abolished in muscles from beta 2-AR
knockout (KO) mice. The suppressive effect of beta 2-agonist
on atrogin-1 was not mediated by PGC-1-alpha (peroxisome
proliferator-activated receptor gamma coactivator 1-alpha
known to be induced by beta 2-agonists and previously shown
to inhibit atrogin-1 expression), since food-deprived PGC-1-
alpha KO mice were still sensitive to clenbuterol. These
findings suggest that the cAMP increase induced by stimula-
tion of beta 2-AR in skeletal muscles from fasted mice is
possibly the mechanism by which catecholamines suppress
atrogin-1 and the UPS, this effect being mediated via
phosphorylation of Akt and thus inactivation of Foxo3.
Financial support by FAPESP (08/06694-6) and CNPq
(305847/06-6 and 300440/05-7).
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Background and aims: Decreased protein synthesis and
increased protein degradation cause muscle wasting. The
ubiquitin proteasome pathway is central in regulating these
processes. Zn has been shown to accumulate in cachexic
muscle. Zn chelating compounds have been demonstrated
to both increase protein synthesis and decrease protein
degradation. To explain these results on a molecular level,
we have formulated a novel hypothesis regarding zinc’s
role in the ubiquitin proteasome pathway.
Methods: The hypothesis is based on measurements of Ca
release from thapsigargin-sensitive intracellular pools, in
vitro mechanistic studies in murine myotubes, effect of the
zinc chelating compound D-myo-inositol 1,2,6-triphosphate
(alpha trinositol, AT) in the cachexia inducing MAC-16
model, data on the fluctuation and regulation of Zn
metabolism, and data on the activation of the ubiquitin
proteasome pathway.
Results: Extracellular Zn is a powerful signaling ion, and
in normal physiological conditions, virtually all Zn is
intracellular. Micromolar concentrations of extracellular
Zn can activate and mobilize intracellular Ca stores. This
intracellular Ca activation can be attenuated by extracellular
Zn chelation. The Ca release is zinc specific and cannot be
triggered by other heavy metals. PKR is activated by Ca
mobilizing agents. PKR activation attenuates protein
synthesis through the phosphorylation of eIF2α and
increases protein degradation through the activation of
NF-kB by phosphorylating IkB.
Conclusion: Extracellular Zn activates PKR by releasing
intracellular Ca stores from the ER. The PKR-mediated
pathways lead to both the depression of protein synthesis
and increase of protein degradation which together result in
muscle wasting (see Figure).
ZINC/UBIQUITIN PROTEOSOME PATHWAY HYPOTHESIS LINKS 
EXTRACELLULAR ZN LEVELS, PKR ACTIVATION AND CACHEXIA
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FOXO3a mediates signaling crosstalk to coordinate
expression of ubiquitin with Atrogin-1/muscle atrophy
F-box (MAFbx) and Muscle-specific RING finger
protein 1 (MuRF1) during muscle atrophy
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Muscle atrophy is a consequence of disuse and chronic diseases
like cancer and diabetes. It has been proposed that atrophy is a
result of coordinated increases in expression of genes encoding
various components of the ubiquitin-proteasome system includ-
ing ubiquitin and the muscle-specific E3 ligases Atrogin-1(AT-
1)/MAFbx and MuRF1; however, different signaling pathways
(e.g., PI3K/Akt/FOXO, IKK/NF-kB, and MEK/ERK/Sp1)
regulate these components. For example, insulin deficiency (i.
e., diabetes) accelerates proteolysis and increases AT-1/MuRF1
expression via downregulation of PI3K/Akt and subsequent
FOXO activation. In contrast, ubiquitin (UbC) transcription is
increased by the MEK/ERK/Sp1 pathway, which is activated
acutely by insulin. These seemingly paradoxical observations
raise questionsabouthowthetranscriptionofthese variousgenes
is coordinated. In this study, we tested whether chronic inhibition
of the PI3K/Akt pathway by glucocorticoids in muscle cells
indirectly activates the MEK/ERK pathway. L6 myotubes were
treatedwithdexamethasone(Dex)for upto48h.After24h,Dex
inhibited PI3K/Akt signaling and increased AT-1 mRNA. MEK/
ERK/Sp1 signaling and UbC transcription were simultaneously
activated. Interestingly, Dex decreased IRS-1 protein while
increasing IRS-2 protein. This suggested that downregulation
of IRS-1/PI3K/Akt and FOXO activation leads to a reciprocal
increase in IRS-2 expression and activation of MEK/ERK/Sp1
signaling. To test this possibility, we knocked down IRS-1
protein using siRNA or expressed constitutively activated
FOXO3a in myotubes. IRS-2 protein, MEK/ERK signaling,
and UbC expression were increased. We conclude that FOXO3a
mediates a reciprocal crosstalk between the PI3K/Akt and MEK/
ERK pathways that coordinately increases both AT-1/MuRF1
and ubiquitin expression, thereby supporting an increased rate of
proteolysis.
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Elucidating the role of the ubiquitin E3 ligases
and autophagy pathway in human cancer cachexia
Nathan A. Stephens
1, Iain J. Gallagher
1, Richard J. E.
Skipworth
1, James A. Ross
1, Denis C. Guttridge
2,
Kenneth C. H. Fearon
1
1Department of Clinical and Surgical Sciences (Surgery),
University of Edinburgh, Edinburgh, UK;
2Division of Human
Cancer Genetics, Ohio State University Medical Center,
Columbus, OH, USA
Background and aims: Skeletal muscle loss is a key
feature of cancer cachexia, but understanding of the process
in humans is limited. We aimed to determine the role of the
ubiquitin proteasome E3 ligases and autophagy pathways in
skeletal muscle of cancer cachexia patients.
Methods: Fifty-nine patients were recruited (seven weight-
stable controls and 52 patients with upper gastrointestinal
cancer). Rectus abdominis muscle biopsy was taken during
open surgery. FOXO1 and FOXO3a protein levels were
measured by Western blot, and expression of ubiquitin E3
ligases and autophagy-related BNIP3 and GABARAPL1
determined using qRT-PCR weight loss of ≥5% was used to
define weight-losing (WL) compared to weight-stable (WS)
patients,andsystemicinflammation(SI)wasdefinedasplasma
CRP ≥5 mg/l. Results were analyzed using SPSS ver. 15.
Results: FOXO protein levels and expression of the E3
ligases MuRF1/MAFBx did not significantly differ between
the groups. BNIP3 mRNA expression was increased in WL
patients compared to WS or control patients (fold change1.5
vs 1.2 vs 1.1, respectively; p=0.047). Gabarapl1 showed a
trend towards elevation (p=0.063) with WS patients
showing the greatest fold change (1.7) compared with
controls (1.1) or WL (1.5) patients. Both BNIP3 (p=0.003)
and Gabarapl1 (p=0.018) expression increased in patients
with SI compared to those without SI and control patients.
Conclusions: The individual prominence of proteolytic
pathways appear to differ between preclinical models and
human muscle wasting. Whilst this study did not demon-
strate increased expression of ubiquitin E3 ligases, there
was evidence for activation of the autophagy pathway in
patients at an early stage in their cancer/cachexia journey.
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Background and aims: Muscle breakdown is a key compo-
nent of cancer cachexia. The ubiquitin ligases MuRF1 and
MAFBxhavebeenshowntobeinvolvedinanumberofmodels
of cachexia including cancer. We aim to elucidate the upstream
signalling pathways involved in muscle loss in the quadriceps
muscle in cachectic and non-cachectic tumour-bearing mice.
Methods: Three groups of DBA/Balb-c mice were injected
s.c. with C-26 carcinoma cells (cachectic), C-26 carcinoma
94 J Cachexia Sarcopenia Muscle (2010) 1:43–128cells (non-cachectic) and vehicle, respectively. Mice were
sacrificed at day 14 at two different time points (2 a.m. and
2 p.m.), and quadriceps muscle and tumour were harvested
and stored at −80°C. Plasma was collected for ELISAs (2 p.
m. time point). RNA and protein were extracted for qRT-
PCR and Western blot analysis, respectively.
Results: Gene expression of IL-6 was increased 30-fold in
cachectic vs non-cachectic tumours. Plasma IL-6 levels
were increased 465-fold in cachectic vs control mice and
20-fold in non-cachectic vs control mice. MAFBx and
MuRF1 expression was increased 23- and 26-fold in
cachectic muscle vs control, respectively, with no signifi-
cant difference between control and non-cachectic. Fox01
and NFkB gene expression was increased seven- and
twofold, respectively, relative to control. The ratio of
phosphorylated to total STAT3 protein was elevated 18-
fold in cachectic mice vs control and ninefold in non-
cachectic mice vs control.
Conclusions: There is evidence of signalling through the
Forkhead, NFkB, and IL-6 signalling pathways in this
model that are more pronounced in cachectic mice.
Selective blocking of components of these pathways will
assist in identifying the predominant mechanism of muscle
proteolysis.
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Activation of the central melanocortin system induces
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Background: Activation of the central melanocortin
system by cytokines recapitulates many key features of
cachexia. Melanocortin blockade has been shown to
prevent the loss of lean mass in experimental cachexia
and increase lean mass in healthy animals. We hypothesize
that melanocortin activation potentiates the loss of muscle
mass in cachexia.
Methods: The melanocortin agonist MTII and antago-
nist AgRP were administered via acute injection or
chronic infusion through a lateral ventricle cannula.
Gene expression was measured using real-time PCR.
Analysis of fiber area and fiber composition was
performed by immunohistochemical analysis using
specific antibodies. Experimental cachexia was induced
in rats by either implantation of a syngenic sarcoma or
five-sixths nephrectomy.
Results: Acute and chronic administration of MTII results
in the upregulation of the E3 ubiquitin ligases MAFbx and
MuRF-1 in skeletal muscle. Furthermore, some of this
effect is independent of the decrease in food intake
associated with melanocortin activation. Melanocortin
blockade is associated with the retention of skeletal muscle
weight in experimental cachexia.
Conclusions: Melanocortin activation has been implicated
in the pathogenesis of alterations in food intake in cachexia.
Melanocortin signaling also has effects that are independent
of food intake, including increasing the mRNA levels of the
catabolic mediators MAFbx and MuRF-1 in skeletal
muscle. Furthermore, melanocortin blockade can reverse
myofibrillar atrophy in experimental cachexia. These
findings suggest an important role for the central melano-
cortin system in the pathogenesis of muscle catabolism in
cachexia, and further support the use of melanocortin
antagonists in its treatment.
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Background and aims: Intensive care patients suffering
from sepsis are characterised by muscle wasting due to
increased net protein breakdown. Myofibrillar proteins are
mainly degraded via the ubiquitin proteasome pathway.
Lysosomes are implicated in the degradation of extracellu-
lar and cytoplasmic constituents and of organelles like
mitochondria. Research on muscle-wasting conditions
previously focused on the importance of the proteasome
pathway. Recent reports have indicated that also the
lysosomal pathway is activated in atrophying muscle cells.
Thus, we have measured the proteolytic activity of both
proteasomes and lysosomes in leg muscle biopsies from
sepsis patients with multiple organ failure.
Methods: Patients (n=8) admitted with septic shock to the
intensive care unit and metabolically healthy controls (n=7)
undergoing elective surgery were studied. Muscle biopsies
were obtained from the vastus lateralis muscle. The
biopsies were homogenised; fractions for analyses of
proteasome and lysosome proteolytic activities were
obtained by differential centrifugation. Proteasome and
lysosomal cathepsin B and L activities were determined
using fluorogenic peptide substrates.
Results: In the patients, proteasome activity was 44%
higher (p<0.05) as compared to controls. Also, lysosomal
J Cachexia Sarcopenia Muscle (2010) 1:43–128 95proteolytic activities were higher, cathepsin B by 200% (p<
0.001) and cathepsin L by 150% (p<0.001), compared to
controls. The activities of both cathepsin B and L correlated
significantly (p<0.01) with the proteasome activity in the
patients, but not in the controls.
Conclusions: These results give evidence that during
catabolic conditions, not only the proteasomal pathway is
activated in skeletal muscle but also the lysosomal pathway,
possibly even to a greater extent.
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Background: The size of skeletal muscle is determined by
a balance between protein synthesis and protein degrada-
tion. In mammalian cells, half-life of proteins is controlled
by two proteolytic systems: the ubiquitin-proteasome and
the autophagy-lysosome. Autophagy is an evolutionarily
conserved mechanism that allows cell survival during
starvation through the bulk degradation of proteins and
organelles by lysosomal enzymes. In skeletal muscle, both
systems are under FoxO regulation, and their excessive
activation induces severe muscle loss. Conversely, altered
autophagy has been observed in various myopathies.
However, the role of autophagy in skeletal muscle has not
been determined by loss-of-function approaches.
Methods: Atg7 floxed mice were crossed with transgenic
mice expressing cre-recombinase under a muscle specific
promoter. Autophagy knockout muscles were characterized
by morphological, physiological, biochemical, and molecu-
lar approaches and compared to control wild-type muscles.
Results: Here, we report that muscle-specific deletion of
Atg7 gene resulted in profound muscle atrophy and age-
dependent decrease in force. Atg7 null muscles showed
accumulation of abnormal mitochondria, sarcoplasmic
reticulum distension, disorganization of sarcomere, and
formation of aberrant concentric membranous structures.
Atg7 null muscle showed an increase of oxidative stress
and an activation of unfolded protein response, which
contribute to muscle weakness. Importantly, autophagy
inhibition exacerbated muscle loss during denervation and
fasting.
Conclusions: In conclusion, autophagy flux is important to
preserve muscle mass and to maintain myofiber integrity.
Our results suggest that inhibition/alteration of autophagy
can contribute to myofiber degeneration and weakness in
muscle disorders characterized by accumulation of abnor-
mal mitochondria and inclusions.
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Background and aims: Cancer cachexia impacts on
treatment options, quality of life and survival. New treat-
ments are emerging but need to be assessed using outcomes
which patients find meaningful. One approach is the
measurement of physical activity levels (PAL) by small
lightweight monitors, but experience is limited in cancer
patients. The primary aim of this study was to formally
assess the acceptability of the ActivPAL™ monitor. We
also explored the optimal period of monitoring and the
added value of the monitor’s estimate of energy expenditure
over a step count.
Methods: Acceptability was assessed by compliance using
analysis of movement data. Mean values of daily step count
and energy expenditure (EE) for 2 or 4 and 6 days of
monitoring were compared. Relationships between step
count, stepping EE and non-stepping EE were explored.
Results: Sixty patients (mean age, 68 years; ECOG
performance status 0–2) with lung or upper-gastrointestinal
cancer took part. All but one found the monitor acceptable,
and mean (95% CI) compliance was 98% (94–100%).
Median daily step counts and EE scores over 2 or 4 days
were significantly higher than those from 6 days (p≤0.01).
Step count was strongly related to stepping and non-
stepping EE (r=−0.911, p<0.01).
Conclusions: The ActivPAL™ activity monitor is accept-
able to patients with outcomes obtained over 6 days
recommended for use in future studies.
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Age-dependent anti-catabolic effects of exercise training
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Purpose: Muscle wasting in chronic heart failure (CHF) is
an independent predictor of mortality. However, the
molecular mechanisms that mediate muscle catabolism are
largely unknown, and no specific pharmacological agents
are available to antagonize the loss of muscle mass. We
therefore analysed two different protein degradation path-
ways in skeletal muscle biopsies of CHF patients and tested
the age-dependent effects of exercise training to prevent
muscle wasting.
Methods: Sixty CHF patients and 60 healthy subjects
(HS) were randomized to 4 weeks of bicycle ergometer
training at 70% of the heart rate reserve 4×20 min/day
or to a control group (C). Before and after the
intervention, a spiroergometry, echocardiography and a
muscle biopsy of the vastus lateralis muscle were
performed. Expression of the E3 ligase Murf-1 as part
of the ubiquitin proteasome system was quantified by
real-time PCR standardized for 18S-rRNA and Western
blot. As a marker of lysosomal proteolysis, cathepsin-
L was measured by real-time PCR.
Results: (1) Clinical training effects: In younger CHF
patients (n=15; age, 45±3 years; BMI, 26.8±2.7; LV-EF,
26.8±2.6%), training improved VO2 m a xb y3 6 %f r o m
13.3±1.6 to 18.1±1.5 mL/minkg (p=0.008 vs. control).
In elderly CHF patients (n=15; age, 68±4 years; BMI,
25.3±2.9; LV-EF, 27.4±3.0%), training increased VO2
m a xb y3 3 %f r o m1 2 . 9 ± 1 . 4t o1 7 . 1 ± 1 . 1m L / m i n k g( p=
0.01 versus control). (2) Molecular training effects: At
baseline, Murf-1 mRNA expression CHF patients were
significantly elevated versus HS at 593±68 versus
410±27 rel. units (p=0.013) and protein expression at
0.90±0.08 versus 0.62±0.05 rel. units (p=0.018).
Cathepsin-L was not different between both groups.
Training induced a reduction of Murf-1 expression by
34.3% (p=0.02) in younger CHF patients and a reduction
of 24.3% (p<0.05) in elderly. Cathepsin-L expression
remained unchanged.
Conclusions: Muscle wasting in CHF is mediated via the
ubiquitin proteasome system and not the lysosomal system
in the skeletal muscle. Exercise training significantly
improves VO2 max in both younger and older patients
with CHF. Both younger and older patients with heart
failure derive a similar anticatabolic benefit from training
interventions. These data underline the clinical role of
exercise-based rehabilitation programs to prevent CHF-
related muscle wasting in the elderly.
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Phase II non-randomized study of the efficacy
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celecoxib on patients with cancer cachexia
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Background: Chronic inflammation is one of the main
features of cancer cachexia. Experimental and clinical
studies showed that cyclooxygenase-2 inhibitors, such as
celecoxib, may be beneficial in counteracting major
symptoms of this devastating syndrome.
Patients and methods: We carried out a prospective, phase
II clinical trial to test the safety and effectiveness of an
intervention with the COX-2 inhibitor celecoxib (300 mg/
day for 4 months) on key variables of cachexia (lean body
mass, resting energy expenditure, serum levels of proin-
flammatory cytokines, and fatigue) in patients with ad-
vanced cancer at different sites.
Results: A sample of 24 patients was enrolled from January
to December 2008 and was deemed assessable. A signifi-
cant increase of lean body mass and a significant decrease
of TNF-alpha were observed. Moreover, an improvement of
grip strength, quality of life, performance status, and
Glasgow prognostic score was shown. There were no grade
3/4 toxicities. Patient compliance was very good: no patient
had to reduce the celecoxib dosage nor interrupt treatment.
Conclusion: Our results showed that the COX-2 selective
inhibitor celecoxib is an effective single agent for the
treatment of cancer cachexia. Although the treatment of
cancer cachexia, a multifactorial syndrome, is more likely
to yield success with a multitargeted approach, in the
present study, we were able to show that a treatment, such
as celecoxib, addressing a single target, albeit very
important as chronic inflammation, could have positive
effects. Therefore, phase III clinical trials are warranted to
test the efficacy and safety of celecoxib.
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A phase I, pharmacokinetic (PK), and preliminary
efficacy assessment of ALD518, a humanized anti-
interleukin (IL) 6 antibody, in patients with advanced
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Background: ALD518 is a humanized anti-IL-6 antibody
being developed for the treatment of cancer cachexia and
fatigue. The primary objective of the study was to
determine the safety of ALD518.
Methods: Nine patients (pts) with advanced cancer,
ECOG 0-2, and C-reactive protein (CRP) >10 mg/L
were enrolled. Pts were assigned to one of three dose-
escalating cohorts (n=3/cohort). ALD518 was given as a
single i.v. infusion of 80, 160, or 320 mg. Pts were
followed up for 12 weeks. Data included lab safety tests
(LSTs), vital signs, ECGs, adverse events, handgrip
strength (HGS), FACIT-F, PK, and C-reactive protein
(CRP).
Results: Nine pts were evaluable for dose limiting
toxicity (DLT) assessment at week 4, and five of nine
pts completed all visits. Of the four pts who failed to
complete every visit, three were withdrawn due to
progressive disease and one to be treated with chemo-
therapy. There were no DLTs or infusion reactions. There
were four SAEs: three disease progressions and one
sepsis secondary to a blocked biliary stent. There were
no grade 3/4 toxicities. Changes in LSTs, CRP, HGS,
and FACIT-F fatigue subscale (pooled ITT analysis) are
shown below:
ALD518 PK elimination t1/2 was 31 days (range, 19–39 days)
*p<0.05 (Wilcoxon test)
Conclusion: ALD518 given to pts with advanced cancer
was safe and well tolerated. ALD518 reversed fatigue,
increased hemoglobin, and albumin, and there was a trend
to increased HGS. There was a mild decrease in platelet
count that remained stable throughout the study. There was
a mild transient fall in neutrophil count during the study.
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Background: AVR118 represents a new class of immuno-
modulatory and cytoprotective drugs in managing anorexia
cachexia. Previously in patients with advanced HIV-AIDS,
increases in appetite, strength, and alertness were noted.
Aim: The aim of this study is to determine the effect of
AVR118 on appetite, early satiety, and nutritional intake in
patients with advanced cancer. Secondary endpoints include
changes in performance status, lean muscle mass, and
quality of life (QOL).
Methods: Eligible patients received 4.0 ml of AVR118
subcutaneous daily injections. Patients underwent bi-
monthly evaluations during the 28-day initial treatment
(phase A). Evaluations included Karnofsky performance
status, Edmonton symptoms assessment scale (ESAS),
patient-generated subjective global assessment (PG-SGA),
Simmonds functional assessment (SFA), dyspepsia symp-
tom severity index (DSSI), weight, lean body mass, skin
fold thickness, and grip strength. Patients who benefited
Parameter (median, IQ range) Pre-dose (n=8) Post-dose (n=8)
Week 2 Week 4 Week 12
Hemoglobin (g/l) 12.3 (11.2–14.0) 13.2 (12.3–14.1)* 13.7 (12.4–15.1)* 14.0 (12.4–15.8)*
Albumin (g/l) 36.5 (33.5–39.5) 42.0 (38.0–42.5)* 41.5 (41.0–45.5)* 42.5 (38.5–46.0)*
Platelets (×10
9/l) 298 (268–362) 180 (117–234)* 142 (126–204)* 150 (109–203)*
Neutrophils (×10
9/l) 5.9 (5.8–7.5) 4.8 (3.7–5.9)* 4.3 (3.4–5.0)* 5.5 (4.5–5.6)*
CRP (mg/L) 44.0 (17.6–131.6) 0.9 (0.5–3.9) 0.8 (0.2–3.7) 1.0 (0.2–4.5)
HGS (kg) 26.0 (9.7–35.4) 26.8 (10.7–36.7)* 30.5 (17.3–36.3) 31.7 (19.5–35.9)
FACIT-F 21.5 (14.0–28.0) 30.5(20.5–32.5)* 30.5 (24.5–33.5)* 29.5 (20.0–33.5)*
98 J Cachexia Sarcopenia Muscle (2010) 1:43–128from phase A could elect to continue with therapy (phase
B).
Results: Of21enrolledpatients,11completedphaseA.Eight
patientschoosetocontinuewithAVR118treatment(phaseB).
Weight stabilization or gain was observed in seven of 11
patients. Total PG-SGA scores improved significantly (p≤
0.01). Appetite (p≤0.01) and depression (p=0.05) scores
improved on ESAS. Frequent burping/belching (p=0.02),
feeling full (p=0.04), and stomach distention (p=0.03)
improved on the DSSI. The SFA tests showed improvement
on time to sit and stand (p=0.01). AVR118 was well
tolerated with no serious side effects reported.
Conclusions: AVR118 again mediated statistically signifi-
cant improvements in anorexia, dyspepsia, strength, and
depression in this trial, consonant with the previous AIDS
trial results.
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Development of early biomarkers for muscle anabolism
with randomized, single-blind, placebo-controlled
studies involving 7 days of testosterone exposure
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Background and aims: Identifying early biomarkers for
muscle anabolism may facilitate development of therapies to
treat sarcopenia and cachexia. We investigated N-terminal
propeptide of type III collagen (P3NP), RNA and proteomic
profiling,urinary3-methyl-histidine/creatinine(3MH/Cr)ratio,
and muscle protein fractional synthetic rate (FSR) as potential
biomarkers for testosterone-induced muscle anabolism.
Design: Healthy men aged 60–75 years (n=22; study 1)
and 18–40 years (n=27; study 2) were given one
intramuscular injection after randomization to low-dose
(study 1, 100 mg; study 2, 200 mg) or high-dose (study 1,
300 mg or study 2, 600 mg) testosterone or placebo. Blood
and vastus lateralis muscle samples were analyzed at
baseline and 7 days after injection.
Results: Testosterone decreased urinary 3MH/Cr only in
elderly subjects. Blood and muscle proteomic profiles did
not reveal robust treatment-related changes. In study 1, FSR
tended to increase (+0.006%/h) in the 100-mg testosterone
group and (+0.011%/h) in the 300-mg testosterone group,
but was not statistically different from placebo (+0.005%/h).
Plasma P3NP increased in a testosterone dose-dependent
manner. A significant correlation between change from
baseline P3NP and serum total testosterone was noted (r=
0.43, p=0.047 in study 1; r=0.69, p<0.001 in study 2). We
identified alterations in muscle gene expression that
correlated with change in serum testosterone.
Conclusions: One testosterone injection increased plasma
P3NP levels in a dose-dependent manner. Skeletal muscle
RNA profiling analysis identified genes associated with
testosterone treatment. P3NP and RNA profiling are poten-
tially useful early biomarkers for muscle anabolic therapy.
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Oral amino acids and testosterone therapy to improve
muscle mass and quality of life during chemotherapy
in recurrent cervical cancer: a case study
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Background and aims: Muscle wasting is by far the most
important phenotypic feature of cancer cachexia, though
little success has been achieved toward reversing or
preventing this catabolic process. Anabolic interventions
including testosterone and amino acid supplements may be
beneficial in reducing and/or reversing muscle wasting in
these patient populations.
Methods: A 48-year-old woman diagnosed with recurrent
cervical cancer was scheduled to receive three 21-day cycles
of cisplatin and topotecan chemotherapy. She consented to a
10-week blinded interventional pilot study where she
received daily amino acid supplements (whey protein with
meals three times per day) and weekly injections of
testosterone enanthate (100 mg i.m.) before and during the
weeks of chemotherapy treatment. Blood, dual energy x-ray
absorptiometry (DEXA) scans, and functional assessment of
cancer therapy-general (FACT-G) questionnaire data were
collected before and after the 10-week period.
Results: Total serum testosterone concentrations were
raised from 15.6 to 1,210 ng/dL. Body weight increased
from 40.2 to 42.7 kg after 10 weeks. Total lean body mass
(LMB) increased from 25.5 to 28.5 kg. Trunk LBM
increased from 12.6 to 14 kg. Total fat mass decreased
from 13.6 to 13.1 kg, and trunk fat mass decreased from 5.5
to 5.2 kg. FACT-G scores improved from 55.4 to 78.1.
Conclusions: Concomitant treatment of oral amino acids
and testosterone may be a viable therapeutic option for
fighting cachexia and improving quality of life during
chemotherapeutic treatment of recurrent cervical cancer. A
J Cachexia Sarcopenia Muscle (2010) 1:43–128 99double-blinded, placebo-controlled interventional study is
in progress (NCT00878995).
This project is funded through NIH/NCI RO1 CA127971
(Sheffield-Moore). Dr. Dillon is funded through NIH T32
CA117834 to UTMB.
128
Performance improvement in chronic obstructive
pulmonary disease (COPD) cachexia with SUN11031
(a synthetic human ghrelin) in a placebo-controlled trial
Joseph M. Gertner, Charles Oo
Asubio Pharmaceuticals Inc, Rochelle Park, NJ, USA
Background: Cachexia occurs in 25% of COPD patients
and is associated with increased mortality. SUN11031 is
thought to improve appetite, energy balance, and functional
outcomes and is under investigation for the treatment of
COPD cachexia. Study objectives were to assess appetite,
body weight/composition, physical performance, and safety
in COPD patients with cachexia.
Methods: Twenty-fivepatientswererandomizedtoSUN11031
(10 μg/kg (N=9), 20 μg/kg (N=8), and placebo (N=8)) by
subcutaneous (SC) twice daily (bid) injections for 21 days.
Mean age was 65.3 years, and mean BMI was 19.48 kg/m
2.
Results: GH secretion increased similarly in both SUN11031
groups. Compared to placebo, 20 μg/kg significantly in-
creased mean (±SD) fasting morning body weight by 2.24±
1.16 kg (P<0.05; Fig. 1), while lean mass trended toward
significance (2.19±1.87 kg; P=0.128). Twenty micrograms
per kilogram also improved appetite compared to baseline
(P<0.001). The pharmacokinetics of SUN11031in COPD
patients was comparable to those in healthy subjects.
SUN11031 showed a dose proportional trend toward
improvement in chair stand score (P=0.07, P=0.08 vs
placebo; Fig. 2). SUN11031 was well tolerated, and most
adverse events were mild.
Conclusion: SC bid SUN11031 was safe, and in-
creased appetite, GH secretion, and body weight with
a dose proportional trend towards increase in physical
performance.
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Increases in lean body mass observed with a single
dose of ACE-031, a form of the soluble activin
receptor type IIB
Jas Seehra, Niels G. Borgstein, Yijun Yang, Carolyn H.
Condon, Jennifer L. Lachey, Matthew L. Sherman
Acceleron Pharma, Cambridge, MA, USA
Background and aims: ACE-031 is a soluble fusion
protein derived from a form of the extracellular domain of
the human activin receptor type IIB (ActRIIB) linked to the
Fc portion of human IgG1. Treatment with ACE-031
increases lean body mass (LBM) in numerous normal and
disease preclinical models, including cachexia. We con-
ducted a first-in-human, randomized, double-blind phase 1
study to evaluate the safety and tolerability and pharma-
cokinetic and pharmacodynamic properties of single,
escalating doses of ACE-031 in healthy postmenopausal
women. -0.5
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100 J Cachexia Sarcopenia Muscle (2010) 1:43–128Methods: Forty-eight subjects received single subcutane-
ous injections of placebo or ACE-031 at dose levels
ranging from 0.02 to 3 mg/kg. Safety, PK, and biomarkers
were assessed throughout the study. Effects on LBM and
thigh muscle volume were measured by dual energy X-ray
absorptiometry (DXA) and MRI, respectively.
Results: ACE-031 was well tolerated at all dose levels and
demonstratedalinearpharmacokineticprofilewithanaverage
half-life of 10–15 days. ACE-031 at 1 and 3 mg/kg produced
dose-dependent increases (2.4% and 2.6%) in LBM measured
by DXA as early as day 15 that were sustained through
day57.Subjectsgiven placebohada 0.2%decreaseinmuscle
volume assessedbyMRI atday29comparedtoa 5%increase
in subjects receiving 3 mg/kg ACE-031. ACE-031 favorably
affected biomarkers of fat mass and bone formation and
resorption at doses of 1 and 3 mg/kg.
Conclusions: These data provide clinical proof of concept
that blocking ActRIIB signaling has rapid, potent, and durable
effects on LBM and supportfurther developmentof ACE-031.
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Improved insulin sensitivity after therapy with the
selective peroxisome proliferator-activated receptor-γ
(PPAR-γ) modulating angiotensin receptor blocker irbe-
sartan in patients with chronic heart failure—IRIS-HF: a
placebo-controlled, double blinded, randomized study
Tibor Szabó, Cornelia Kennecke, Johanna Todorovic,
Mathias Rauchhaus, Anja Sandek, Stefan D. Anker,
Wolfram Doehner
Center for Stroke Research Berlin and Applied Cachexia
Research, Department of Cardiology, Campus Virchow
Hospital, Charité, Berlin, Germany
Background: Impaired insulin sensitivity (Si) is common
in chronic heart failure (CHF), contributes to symptomatic
status, and independently predicts prognosis. It has been
suggested that the angiotensin II-receptor antagonist irbe-
sartan can improve insulin sensitivity via selective activa-
tion of the peroxisome proliferator-activated receptor
gamma (PPAR-gamma). We aimed to assess the effect of
irbesartan on impaired insulin sensitivity in patients with
CHF.
Methods: In a prospective, placebo-controlled, double-
blinded, randomized single center study, we included 36
non-diabetic patients with stable ischemic CHF (age, 63±
9 years; BMI, 28.2±3.9 kg/m
2;p e a kV O 2, 16.6±4.8 mL/kg/
min, all mean±SD). Irbesartan (target dose 300 mg/day) or
placebo was given on top of standard optimum CHF therapy
including ACE inhibitor and beta-blockers for 16 weeks.
Change of insulin sensitivity from baseline to week 16
(primary endpoint) was assessed using the minimal modeling
technique from glucose and insulin profiles of a frequently
sampled intravenous glucose tolerance test.
Results: At baseline, both groups were similar for age,
NYHA class, peak VO2, BMI, body composition (DEXA
scan), Si (p=0.2), and main clinical characteristics. Si was
2.51±1.58 min
−1μUmL
−110
4 in the study population,
which is 30% lower than in healthy controls of similar
age (p<0.05). In the irbesartan-treated group, SI increased
by 26% (p<0.001 within group), but it decreased by 15% in
the placebo group (p=0.17 within group). Change in SI
from baseline was significantly different between groups
(mean difference, 1.044 min
−1μUmL
−110
4; 95% CI, 0.45
to 1.64; p=0.001). Treatment with irbesartan was well
tolerated. NYHA class, peak VO2, and body composition
did not change, but blood pressure significantly decreased
on irbesartan (−5±2 mmHg, p<0.002).
Conclusion: Our study shows that 16 weeks of added
therapy with irbesartan compared to placebo significantly
improves impaired insulin sensitivity in non-diabetic
patients with chronic heart failure. Whether this metabolic
effect of irbesartan translates into additional clinical benefits
for heart failure patients should be tested in larger studies.
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Use of PORT-A-CATH® for total parenteral nutrition
in end-of-life patients
Elwira J. Góraj, Ewa Tomaszewicz
Palliative Care Department, Cancer Centre-Institute Warsaw,
Warsaw, Poland
Background and aim: Vascular access port implantation
represents a valid method for long-term chemotherapy. The
aim of the present study was to confirm usefulness of ports
for TPN.
Method: In the period 1 January 2008 to 30 September
2009 in PMD, in our department, 175 ports were implanted.
Twenty of them were used for TPN. We compared the rate
of complications in group I patients receiving chemother-
apy and group II receiving TPN through port. The catheter
and vascular access patency was controlled by fluoroscopy
before TPN was started and maintained by flushing with
normal saline after each infusion. Chemotherapy group
lines were flushed once a month with heparin and saline.
Results: Several complications were encountered in group
I: catheter total occlusion 1.14%, partial occlusion 5%, skin
infection 1.71%, leakage 2.28%, skin atrophy 1.14%, and
no blood back flow after implantation 0.57%. There was no
line complication in TPN group.
Conclusion: Lack of complications in group II can be
accidental, but the aim of the study was to prove that TPN
does not increase the rate of port-a-caths complications,
J Cachexia Sarcopenia Muscle (2010) 1:43–128 101particularly occlusion of the catheter. Vascular access port
is suitable for TPN and can improve the well-being of end-
of-live patient. The experience of the medical staff is
probably the most important factor in decreasing the total
rate of complications.
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Evaluation of visceral lean and fat body mass
with CT-scan image analysis in oncological patients
with anorexia and cachexia symptoms before
and after an anti-cachexia pharmaconutritional
treatment
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Background and aims: Body composition evaluation is
one of the most important malnutrition indicators, either in
physiological or pathological states. Oncological patient
with anorexia/cachexia syndrome shows typical symptoms
characterized by loss of lean body mass with or without
loss of fat mass. Precise assessment of this tissue waste is
important to evaluate patient’s cachexia characteristics and
for the appropriated therapy. CT-scan image analysis
technology is an innovative, sensible, and precise new tool
in evaluation of body composition, positively described by
many authors in different pathologies. The aim of this study
is to determine the variations of lean and fat body mass in
cachectics oncologic patients treated with anticachexia
pharmaconutritional therapy.
Methods: Twenty-five patients with cancer-related anorex-
ia and cachexia were enrolled. Region L2–L3 vertebra
abdominal CT was performed at enrollment date and before
the start of treatment. The same CT was performed at the
end of treatment, after 16 weeks. DICOM radiological
images were processed with specific images analysis
software Slice-O-Matic (Tomovision, Montreal, QC, Can-
ada) to obtain areas of abdominal tissues.
Results: The results shows a significant increase of muscle
mass at L3 vertebra level as well as no significant decrease
of mass in the same region in a subset of this patient,
confirming the improvement shown in clinical and func-
tional parameters after treatment. The methodology seems
to be very good and fit with other data.
Conclusion: This preliminary study confirms the quality of
CT image analyses data in oncological cachectic patients,
either for first assessment or for follow-up body composi-
tion evaluation.
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Randomised controlled pilot study of neuromuscular
electrical stimulation of the quadriceps in patients
with non-small cell lung cancer
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Background and aims: Patients with lung cancer experi-
ence muscle wasting and weakness. Therapeutic exercise
may be beneficial but is not always practical. An alternative
approach may be neuromuscular electrical stimulation
(NMES) of the quadriceps muscles, but this has not been
formally examined in patients with cancer. Thus, we have
undertaken this pilot study to assess feasibility and inform
the design of future studies.
Methods: Sixteen patients were randomised to receive
usual care (control group) or usual care plus NMES for
4 weeks. NMES consisted of daily stimulation to both
thighs for up to 30 min (frequency 50 Hz, \’on\’ cycle 11 to
25%). Adherence was assessed by a self-report diary and
semi-structured evaluation form. Quadriceps muscle
strength, exercise endurance and free-living physical
activity were assessed using a Cybex NORM dynamometer,
an endurance shuttle walk test, and an ActivPAL acceler-
ometer (mean daily step count), respectively. Changes in
outcome from baseline were compared between groups by
mean differences and their 95% confidence intervals using
independent t test (P=0.05).
Results: Median (range) adherence to the programme was
80% (69ƒ{100). All patients found the NMES device easy
to use. Changes in outcome favoured the NMES group with
mean differences of 9.4 Nm (21%) in quadriceps muscle
strength, 768 steps (15%) in free-living activity and 138 m
(8%) in exercise endurance, but none of the differences was
statistically significant.
Conclusion: NMES appear to be acceptable and warrants
further study in patients with lung cancer.
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Twenty weeks resistance training in older people
is associated with rejuvenation of leg blood flow
responses to exercise and feeding
which are not attributable to changes
in endothelial markers
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Background and aims: Sarcopenia is associated with
blunted anabolic responses to feeding and exercise,
perhaps partly as a consequence of reduced leg blood
flow (LBF) responses. We tested the hypothesis that
resistance-training (RT) would improve age-associated
blunting in LBF in the resting state and responses to
prior exercise and feeding.
Methods: We studied participants of three ages (young, 25
±3 years, n=12; middle-aged, 50±3 years, n=12; and old,
70±4 years, n=8) before and after 20 weeks of whole-body
RT. LBF was measured, and muscle biopsies were taken at
rest, postabsorptively, and 120 (LBF) or 150 (biopsies)min
after oral feeding began, with one leg rested and the other
recovering from 6×8 repetitions of leg extensions (75%,
one RM).
Results: Postabsorptive basal LBF was identical in middle-
aged and old subjects (0.32±0.03 vs. 0.33±0.03 lmin
−1),
but tended to be higher in the young (0.51±0.1 lmin
−1) and
was unaffected by RT. Before RT, only the young and
middle-aged subjects showed increased LBF after exercise-
plus-feeding, whereas after RT, the middle-aged subjects’
responses to exercise-plus-feeding were significantly en-
hanced (+101±16% vs. +147±32%, P<0.01) and the old,
rejuvenated (+59±15% vs. +115±47%, P<0.001). There
were no differences in endothelial marker proteins (e.g.,
CD31) or adrenergic receptor proteins (i.e., α-1 or β-2)
after RT, nor in eNOS or PKCα phosphorylation after acute
exercise-plus-feeding before or after RT.
Conclusions: LBF responses to exercise-plus-food are
diminished in older subjects but are restored to the pattern
of young subjects by RT without changes in markers
previously identified as likely to be involved in microvas-
cular adaptation/vasodilatation.
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Importance of cancer-related inflammatory state (CIS)
measured by a prognostic index (PI) for clinical trial
completion?
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Background: High dropout rates limit interpretation of
cancer chemotherapy trials. Biologic characteristics of
dropouts are uncommonly reported. We hypothesized that
CIS as measured by PI associates with high dropout rate,
and that dropout is not a random event.
Methodology: This is a retrospective analysis of stage 3B/4
NSCLC participants of first line platinum-based chemotherapy
trials. Patients with available pre-treatment CRP and WBC
were included. They were categorized as screen failures,
dropouts, or completers and assigned a PI score as an indicator
of CIS: 0 if CRP and WBC were normal, 1 if one of them
elevated; or 2 if both were elevated (ASCO 2005, 17035).
Results: One hundred nineteen pts (65 male, 54 female)
aged 63 (38–80)years were studied. There were 13/119 pts
screen failures, 18/119 dropouts, and 88/119 completers.
There was no difference in CRP and WBC level between
screen failures and those who started the treatment. However,
baseline mean CRP level was more than threefold higher in
dropouts compared to those who completed the study (105.4
vs. 31.4 mg/L; p<0.001). Baseline WBC was also higher in
dropouts when compared to completers (11.4 vs 8.8; p=
0.01). Weight loss was significantly higher in dropouts when
compared to completers (6.4% vs 3.6%, p=0.05).
Significantly higher proportion of PI 0 and 1 were among
completers and PI 2 among dropouts.
PI score Trial completion Total p value
Completers Dropouts
0 36 (41%) 2 (11%) 38 <0.0001
1 37 (42%) 10 (56%) 47 <0.0001
2 15 (17%) 6 (33%) 21 0.006
Total 88 (100%) 18 (100%) 106
Conclusion: Patients with high PI are more likely to drop
out of a trial. Thus, PI marks a patient subset to whom
phase III trial outcomes may not apply. PI should be
considered as a separate prospectively defined stratum.
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Complex treatment of anorexia–cachexia syndrome
Anton V. Snegovoy, Liudmila V. Manzyuk, Alexander I.
Saltanov, Vladimir U. Selchuk
N.N. Blokhin Russian Cancer Research Center, RAMS,
Moscow, Russia
Background and aims: Decrease in total body mass is one
of the major symptoms of presence or development of
tumor. In cancer pts, it is mandatory to note that tumor
cachexia combines with anorexia and, as a result, develops
anorexia–cachexia syndrome.
Materials and methods: History of 23 pts with locally
advanced and metastatic tumor process, undergoing
ambulatory chemotherapy (CT) for various tumor local-
izations, was analyzed: a median decrease of 13–15 kg,
anorexia stage 1–2, asthenia, low-grade fever, depres-
sion, alimentary failure, nausea, foul taste, anemia,
hypoprotenemia, pain syndrome (two to three points).
Additionally, PG-SGA, QLQ C-30, VAS, and “ABC” (in-
house design) scale were used. The treatment scheme
included (1) pain control, (2) nutrition support, (3)
prokinetics, (4) pro- and prebiotics, (5) correction of
anemia, and (6) COX-2 and MOA inhibitors. The pts
were divided into two groups according to the duration of
complex treatment use: in the first group (n=12), the
treatment was conducted for a period of 14 days before
every cycle of CT, whereas in the second group (n=11),
the treatment was additionally resumed on the seventh to
eighth day after administration of CT for a period of
20 days. Evaluation was performed after two cycles of
CT.
Results: As a result of complex treatment use, stabilized
body mass, increased physical activity, and increased
appetite were observed in 72% of pts from the second
group. Similar results were observed only in 18% of pts
from the first group (Student’s criteria 4, 3; p≤0.001).
Conclusion: The obtained results allow us to suggest that
treatment of anorexia–cachexia syndrome should be com-
plex and prolonged.
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To which extent is cancer cachexia reversible
under successful anticancer treatment? An analysis
of data in advanced non-small cell lung cancer
Rolf Oberholzer, David Blum, Susanne Linder, Florian
Strasser
Oncological Palliative Medicine, Section Oncology,
Department of Internal Medicine and Palliative Care
Centre, Cantonal Hospital, St. Gallen, Switzerland
Introduction: Cancer cachexia (CC) causes high burden of
morbidity and mortality in advanced solid tumour patients; it
is an independent prognostic factor. CC can improve under
successful anticancer treatment, as a key pathophysiologic
mechanism of CC is catabolic drive caused by the cancer
itself. We systematically investigate the evidence for the
reversibility of CCS under successful anticancer treatment in
advanced (stage III/IV) non-small cell lung cancer.
Methods: Systematic literature review of phase-III trials
investigating chemo- or chemo-radiotherapies in advanced
NSCLC, published 2000–2009 in major (oncology) jour-
nals (JCO, EJC, Ann Oncol, JAMA, Lancet and NEJM).
Data extraction includes presence of weight assessment at
baseline and overtime, weight as trial endpoint, extent of
weight response associated with anticancer treatment and
mentioning of CC assessment.
Results: Of 101 trials, 89 met inclusion criteria; mentioning
weight assessment, 50 trials; weight in patient characteristics/
stratification parameters, 30; weight as prognostic factor, 15;
weight loss mentioned in eligibility criteria, 12; weight (loss)
in adverse events tables, 5; composite endpoint clinical
benefit including weight, 2; direct monitoring of weight
change, 3; improvement of weight under study treatment,
none; and mentioning the word cachexia in publication, none.
Discussion: This is the first systematic review exploring
development of weight associated with anticancer treatment
in advanced NSCLC patients. Not one single trial reported
weight gain under successful anticancer treatment. Cachexia
is commonly an exclusion criteria for study participation and
is rather noticed as an adverse factor for successful treatment,
but data about weight development were not reported.
Prospective trials with weight as endpoint are required.
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Background and aims: Patients, their caregivers and
healthcare professionals describe a sense of hopelessness and
helplessness when confronted with the consequences of
104 J Cachexia Sarcopenia Muscle (2010) 1:43–128cancer-induced anorexia–cachexia syndrome (ACS) [1]. Yet,
it is a significant cause of both physical and psychosocial
morbidity. A 3-year project, funded by Macmillan Cancer
Support, was undertaken in order to define strategies to
improve the experience of ACS for patients with cancer. This
led to the development of a professional resource pack.
Methods: Baseline projects addressed the following key
aspects of care: (a) professionals’ awareness and
approaches to cachexia, (b) symptom burden for patients
with ACS and (c) impact of standardised assessment and
management tools on patient symptom scores.
Results: Key findings are as follows: (a) awareness and
approach to ACS is highly variable, leading to inconsistent
care [2]; (b) symptom burden associated with ACS is
significant [3]; and (c) simple interventions can make a
significant difference to the experience of ACS [4]. These
results led to the development of a set of guidelines on the
assessment and management of ACS, the Macmillan Durham
cachexia pack (MDCP). This is intended for use by any
healthcare professional. The pack includes a short assessment
tool, algorithms for management of dietary and exercise
needs according to patient’s fitness, symptom management
advice and a number of patient/carer information sheets
addressing the practical and psychological issues they face.
Conclusions: There is room for significant improvement in
theexperienceofACS,butsimplemeasuresmakeadifference.
The MDCP provides a framework for improved assessment
and management of common problems seen in ACS.
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The need for qualitative methodologies in cancer
cachexia research
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Background: Cancer cachexia is not well understood or
managed in clinical practice (Delmore 2000; Poole and
Froggatt 2002). Whilst a dedicated effort has been made
towards understanding the biological processes of the
syndrome, little attention has been paid to its multidimen-
sional impact. This is despite previous qualitative research,
enriching our understanding of the holistic impact of the
syndrome which traditional quantitative methods could not
have uncovered (Reid 2007).
Aim: The aim of this study is to determine the adequacy of
the existing clinical knowledge base of cancer cachexia
management.
Methods: A systematic critical review of the literature on
cancer cachexia was undertaken.
Results: There is a need to develop protocols for care
delivery, which move beyond a purely biological
approach to care towards a more holistic approach. This
can only be achieved by gaining the perspectives of those
who are involved in care delivery to advanced cancer
patients with cachexia and their families using qualitative
methodologies.
Conclusions: Cancer cachexia is a complex, challenging
syndrome, which must be understood from a holistic bio-
psychosocial model of care in order to meet the multidi-
mensional needs of this client population. The perspectives
of those involved in care delivery is required in order to
contribute to a knowledge base which will inform the
development of interventions directed at empowering
patients and their families to understand cancer cachexia
and recognise it as part of the disease process.
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Background and aims: Malnutrition in hepatopancreato-
biliary cancer (HPBC) patients has been associated with
higher postoperative morbidity and mortality. Our aim was
to estimate rates of consent and compliance to specialized
presurgical assessments (SPA) in patients with HPBC and
to identify potential variation in nutritional and perfor-
mance characteristics related to the time of assessment.
J Cachexia Sarcopenia Muscle (2010) 1:43–128 105Methods: Consenting subjects with resectable HPBC were
required to undergo testing for CBC and differentials, CRP,
albumin, DXA, 3-day food recall, upper and lower limb
muscle strength, and 6-min walk distance during two separate
visits (≥4 weeks (visit 1) and ≤1 week (visit 2) pre-surgery).
Results: Of the 160 newly diagnosed HPBC, 55 (34%)
were eligible and 31 (56%) consented. Of the consented
patients, 23 (74.2%) completed visit 1 and 16 (51.6%)
completed visit 2. Difficulties with transportation, hospital-
ization, or participation in other studies were the main
reasons for not completing visit 2. No differences were
found between patients completed only visit 1 or those
completed the study. However, patients completed visit 2
had a lower WBC count (5.7 vs. 7.3, p=0.045) and covered
longer distances (499 vs. 478 m, p=0.045), as compared
with visit 1. Nutritional and strength parameters did not
change significantly between the two visits.
Conclusions: This study reveals that the recruitment of
HPBC patients into SPA is feasible and well received. Pts
who completed both visits had objective improvement in
inflammatory and functional measures. Current results will
guide future clinical trials evaluating the effectiveness of
preoperative rehabilitation programs in decreasing postop-
erative complications.
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Background: The ongoing efforts to agree upon an
international definition of cachexia recognize the multidi-
mensional nature of its underlying mechanisms and clinical
presentations. As one of the commonly encountered
features of cancer cachexia is reduced physical functioning,
there is a need to identify and define the spectrum of
impairments, activity limitations, and participation restric-
tions experienced by individuals with cancer cachexia.
Such an exercise would be an important step in cataloguing
the range of functional impairments and would help direct
use of appropriate measurement tools and thus help assess
the functional impact of anticachexia treatment programs.
The International Classification of Functioning, Disability,
and Health (ICF) was developed by the World Health
Organization (WHO) to provide a common language to
describe health-related states. The ICF adopts a bi-
directional bio-psychosocial framework representing an
integrated model of human functioning.
Objectives: The objective of this study is to establish
standardized functional status indicators (FSIs) that repre-
sent all components of human functioning and environ-
mental factors in individuals with cancer cachexia.
Methods: A literature review followed by a Delphi process
involving known experts in the field will establish an
international consensus on indicators of all functional
limitations in patients with cancer cachexia. These FSIs
will be validated using data obtained from patient focus
groups. FSIs will be coded and linked to items on
appropriate outcome measures using a standardized ICF
mapping protocol.
Contribution: Standardized cancer cachexia FSIs will
promote communication among researchers and healthcare
providers, and will help guide choices of appropriate
outcome measures and preventative and intervention
strategies for patients.
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Association between quality of life and directly
monitored activity in patients with upper
gastrointestinal (GI) cancer
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Background and aims: Cachexia/anorexia is associated with
both reduced quality of life and spontaneous physical activity.
We monitored directly spontaneous physical activity (PA) in
n=53 patients with upper GI cancer to verify associations
between quality of life scores in (1) the symptom-focused
anorexia/cachexia subscale (ACS) of the Functional Assess-
ment of Anorexia/Cachexia Treatment Questionnaire
(FAACT) and (2) the broader quality of life score represented
by the Trial Outcome Index (TOI, association of the ACS plus
physical wellbeing (PWB) and functional wellbeing (FWB)
scores) of the same questionnaire.
Methods: Physical activity, including daily time sitting/
lying, standing, walking, number of steps taken, and step
cadence, was monitored using an accelerometry-based
system (ActivPAL™, UK). Anorexia/cachexia severity
was assessed by the application of the FAACT question-
naire. The spearman coefficient was employed to verify
associations between the variables.
106 J Cachexia Sarcopenia Muscle (2010) 1:43–128Results: TOI was strongly associated with time sitting/lying
(rs=−0.435, p=0.002) and time standing (rs=0.423, p=
0.002), and was also associated with time stepping (rs=
0.385, p=0.005) and number of steps taken (rs=0.427, p=
0.002). Anorexia/cachexia score was associated (albeit to a
lesser degree than TOI) with the time sitting/lying (rs=
−0.281, p=0.05) and the time standing (rs=0.289, p=0.040).
Conclusions: Spontaneous physical activity is strongly
associated with the broader physical and functional aspects
of quality of life. Specific symptoms of anorexia/cachexia
are associated to a lesser degree. PA monitoring provides
data that are meaningful in terms of patient-reported quality
of life and can be used to document objectively the variable
impact of cancer and its treatment throughout the cancer
journey.
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Background: The McGill Cancer Nutrition-Rehabilitation
Program (CNRP) is a multi-disciplinary team that addresses
weight loss, nutritional symptoms, and impaired functional
status in patients with advanced cancer. There is evidence
of associations between reported weight loss, performance
status, and symptoms at a single time point, but our
experience suggests that the inter-relationships between
these variables are complex and may alter over short time
scales. In this study, we investigated the relationships
between changes in weight, patient-reported performance
status, quality of life and strength between consecutive
clinic visits.
Methods: A retrospective study was conducted using the
CNRP database. Weight, self-assessed performance status
(PS-pt) taken from box 4 of the patient-generated subjective
global assessment, and patient-rated strength and QoL from
the Edmonton symptom assessment scale were recorded at
first and second visits.
Results: Three hundred twenty-three patients (male/female,
169/154; mean age, 64.5±12.0) were included. Between
assessments (mean, 6.2 weeks, SD 4.1), 142 patients lost
weight (WL, mean −3.71%), 132 gained weight (WG,
mean 3.33%), and 49 remained stable. Between the clinic
visits, changes in weight, PS-pt, QoL, and strength were
significantly correlated. Interestingly, correlations were
strongest in the WL group: weight change vs change in
PS-pt (R
2=0.23, p=0.01), change in PS-pt vs change in
QoL (R
2=0.20, p=0.02), and change in QoL vs change
strength (R
2=0.30, p=0.01).
Conclusions: The associations between weight change,
PS-pt, strength, and QoL hold true over short timeframes.
This highlights the potential for influencing PS and QoL
using targeted rehabilitation interventions in advanced
cancer.
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Cancer-related fatigue: the impact of skeletal muscle
mass and strength in newly diagnosed patients
with advanced cancer
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Background and aims: Little is known about skeletal
muscle mass and strength development and their associa-
tion with cancer-related fatigue (CRF). The purpose of this
study was to determine if CRF is associated with measures
of muscle mass and strength in advanced cancer patients
(ACP).
Methods: Eighty-four patients (48 men, 36 women, aged
61.6±13.2 years) newly diagnosed (≤6 months) with
inoperable (stages III–IV) gastrointestinal or non-small cell
lung cancer participated in this study. All patients complet-
ed the brief fatigue inventory (BFI). Handgrip (HGS) and
quadriceps (QS) strength was assessed using isometric and
isokinetic dynamometry, respectively. Skeletal muscle mass
index (SMMI) was calculated from the appendicular lean
mass measured via dual-energy X-ray absorptiometry
divided by body height squared.
Results: When compared to women, men had significantly
greater amounts of total lean body mass, as well as arm and leg
mass. Furthermore, men displayed greater handgrip and
quadriceps strength. BFI scores (−1, 33), 95% CI (−2.05:
−0.61), and QS (−019; β) were negatively associated with
HGS (−0.34:−0.04) and SMMI (−9.25; −14.15:−4.34) when
J Cachexia Sarcopenia Muscle (2010) 1:43–128 107adjustingforage,diagnosis,andsurvival.Multivariateanalyses
revealed that, in general, women had lower BFI scores than
men. There was a significant sex×SMMI interaction (13.49;
2.52:24.46), where BFI decreased with increasing SMMI in
men, but did not change with SMMI in women.
Conclusion: These results suggest that in ACP, CRF is
related to muscle mass and strength, which may provide a
target for future intervention.
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Background: Leptin, a well-known adipokine, plays an
important role in the regulation of energy balance; however,
its role in human cancer cachexia is still unknown. We
investigated serum leptin levels and leptin gene expression
in subcutaneous adipose tissue (SAT) of cancer patients and
explored its crosstalk with adipokine zinc-α2-glycoprotein
(ZAG), a potential cachexia mediator.
Methods: Thirty-nine patients with oesophageal (n=8),
gastric (n=16), or pancreatic (n=15) cancer, with (n=24) or
without (n=15) cachexia (weight loss ≥5%), were recruited.
Circulating serum leptin levels were quantified by ELISA.
Leptin and ZAG mRNA levels in SAT were determined
using quantitative real-time PCR. Human SGBS adipocytes
were treated with recombinant leptin.
Results: Both serum leptin levels (8.3±1.62 vs 15.1±2.7 ng/
mL, P=0.03) and SAT leptin mRNA expression (ΔCt=−4.3
vs −3.01, P=0.03) were lower in cachectic compared with
weight-stable cancer patients. Significant correlations were
demonstrated between serum leptin and BMI (r=0.68, P=
0.0001) and weight loss (r=−0.36, P=0.02), and also between
leptin mRNA levels in SATand BMI (r=0.71,P=0.0001) and
weight loss (r=−0.48, P=0.008). Serum leptin positively
correlated with leptin mRNA in SAT (r=0.45, P=0.02) and,
furthermore, negatively correlated with ZAG mRNA in SAT
(r=−0.57, P=0.004). In vitro, leptin treatment led to a
decrease in ZAG mRNA in human adipocytes.
Conclusions: In cancer patients, both circulating leptin
levels and SAT leptin gene expression decrease with
weight loss. Lowered circulating leptin levels may
result from the reduction in leptin synthesis by
adipocytes. Finally, reduced production of leptin may
permit a rise in ZAG expression in SAT in cancer
cachexia.
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Systemic zinc redistribution in cancer cachexia
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Background and aims: Cachexia is characterized by loss
of muscle with or without loss of fat mass. Its
manifestations commonly include anorexia, growth fail-
ure in children, inflammation, insulin resistance, and
hypogonadism. We have formulated a novel hypothesis
addressing the links between these seemingly unrelated
syndromes.
Methods: We identified a possible common unifying
factor behind some of cachexia’s clinical manifestations
based on mechanistic studies in murine myotubes, effects
of the Zn chelating compound D-myo-inositol 1,2,6-
triphosphate (alpha trinositol) in the cachexia inducing
MAC-16 model, and pre-clinical and clinical data on
cachexia and Zn deficiency.
Results: Zn is a critical trace element in physiology. It has
been recognized that many tumors draw Zn, and systemic
Zn levels often decline in cancer. However, it has not been
recognized that in cachexia, skeletal muscle tissue, that
constitutes a large portion of total BM (~40% in humans),
also significantly and progressively accumulates Zn.
Extracellular Zn activates PKR-mediated pathways lead-
ing to muscle wasting by mobilizing intracellular Ca. The
continuous redistribution of Zn restricts its availability for
critical physiological functions. A large body of research
demonstrates that Zn depletion and/or deficiency frequent-
ly and predictably results in anorexia, growth failure in
children, increased inflammation, insulin resistance, and
hypogonadism.
Conclusion: In cancer cachexia, Zn is continuously
diverted from its normal physiological functions. The
clinical manifestations of Zn deficiency are strikingly
similar to the symptoms characterizing cancer cachexia.
Several conditions are known to cause systemic Zn
depletion and deficiency. We suggest that cancer cachexia
is one of them (see Figure).
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Zinc-alpha2-glycoprotein mRNA expression is increased
in omental and subcutaneous adipose tissue
of pancreatic cancer patients
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Background and aims: Cachexia involves loss of adipose
tissue and is a major cause of death in patients with advanced
pancreatic cancer. Elevated plasma levels of zinc-alpha2-
glycoprotein (ZAG) are associated with several types of
cancer and may affect lipolysis. ZAG is expressed and
secreted by adipocytes, and its expression in adipose tissue is
elevated in mice with cancer cachexia. However, the clinical
relevance of these findings for loss of adipose tissue mass in
patients with pancreatic cancer prior to clinical manifesta-
tions of advanced cachexia remains to be established.
Methods: Biopsies of omental and subcutaneous adipose
tissue were sampled from non-cachectic pancreatic cancer
patients undergoing tumor resection (n=22) and control
patients without cancer (n=11). mRNA expression levels of
ZAG and other genes were analyzed by qRT-PCR relative
to GAPDH. Alterations in subcutaneous and omental
adipose tissue mass were monitored by volumetric CT
analysis (9 cm from L4/L5 in cranial direction) at inclusion
and during follow-up.
Results: Pancreatic cancer patients displayed 3.1- and
1.7-fold higher median levels of ZAG mRNA in omental
and subcutaneous adipose tissue, respectively, as com-
pared to controls (P<0.01). Investigations at the mRNA
level of 27 other genes involved in fatty acid and
triacylglyceride metabolism revealed that 17 were en-
hanced in omental adipose tissue, whereas three were
upregulated in subcutaneous adipose tissue. Preliminary
volumetric results comparing adipose tissue mass before
surgery and at follow-up suggest that omental adipose
tissue is selectively lost as compared to subcutaneous
adipose tissue.
Conclusions: These data suggest that ZAG mRNA expres-
sion is increased in both omental and subcutaneous adipose
tissue in pancreatic cancer patients without clinical symp-
toms of advanced cachexia. Altered expression levels of
genes involved in lipid metabolism might be predictive of
selective loss of omental adipose tissue mass in the early
stages of cachectic development.
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(HRV) in cancer patients: a pilot study
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J Cachexia Sarcopenia Muscle (2010) 1:43–128 109Background and aims: The hypothalamus is involved in
the control of food intake and energy expenditure via the
autonomous nervous system. In cancer patients, anorexia
and cachexia frequently occur, which can be related to
deranged sympatovagal balance. HRV is a reliable index of
the autonomous nervous system activity. Thus, in cancer
patients, a relationship may exist between anorexia, HRV,
and energy expenditure.
Methods: Anorexia and body cell mass (BCM) were
measured in four lung cancer patients, using a visual
analogue scale (VAS; +100, hunger; −100, satiety) and
bioimpedance analysis, respectively. Resting energy expen-
diture (REE) was calculated based on BCM. HRV was
measured using Holter EKG recordings via a computerized
software, and the time domain of pNN50 was obtained.
Pearson’s correlation test was used.
Results: VAS significantly correlates with pNN50 (r=
0.994; p<0.01); negative correlations exist between pNN50
and BCM and REE (r=−0.967, p<0.05; r=−0.966, p<
0.05; respectively).
Conclusions: Data obtained support the hypothalamic
involvement in anorexia and cachexia. If confirmed by
larger studies, HRV may also represent a useful, non-
invasive tool to detect and predict the development of
nutritional complications in cancer patients.
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Background: In pancreatic cancer (PCA), cachexia,
fatigue, and dyspnea are frequently seen. We hypothesize
that the development of cancer fatigue syndrome is at least
in part due to cardiovascular pertubation with the
consequence of decreased exercise capacity and reduced
quality of life.
Methods: To investigate the cardiovascular parameters, we
prospectively studied 96 patients with PCA (age, 58.9±
0.9 years; mean±SE, 60 male; body mass index (BMI),
23.2±0.4 kg/m
2; hemoglobin (Hb), 11.3±0.2 g/dl) and 74
healthy controls (CON, 59.7±1.3 years, 40 male; BMI,
26.2±0.5 kg/m
2; Hb, 13.9±0.2 g/dl) in exercise capacity
using symptom-limited exercise test, cardiac function using
echocardiography, body composition using dual energy X-
ray absorptiometry, heart rate variability using 24-h ECG,
and peripheral blood flow using venous occlusion plethy-
mography in patients and controls. In a subgroup of 42
PCA patients and 22 CON, TNF-α, interleukin-6, and
TNF-receptor 1/2 (TNF-R1/2) were analyzed. Cachectic
and non-cachectic patients were compared.
Results: No significant difference was detected between
patients and CON in terms of sex, age, and systolic
function. Patients with PCA compared to CON displayed
impaired exercise capacity (peak VO2, 21.1±0.6 vs. 27.2±
1.0 mL/min/kg), less total lean mass (68.6±1.3 vs. 78.4±
1.6 kg), increased resting blood flow in the leg (4.3±0.4 vs.
2.8.3±0.2 mL/100 mL/min), impaired autonomic function
(SDNN24h, 100.3±30.8 vs. 134±37.5 ms), and elevated
pro-inflammatory markers (IL-6, 5.2±0.8 vs. 1.8±0.2 pg/
mL; TNF-R1, 1828±132 vs. 1245±69 pg/mL; TNF-R2,
2811±143 vs. 2018±120 pg/mL; all p<0.05). Autonomic
dysfunction in cachectic patients was even worse than in
non-cachectic patients (SDNN24h, 94.6±4.9 vs. 109.9±
4.5 ms, p=0.03).
Conclusions: Reduced exercise capacity, less lean mass,
autonomic dysfunction, increased resting blood flow, and
elevated proinflammatory markers are present in patients
with PCA. Further studies are required.
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110 J Cachexia Sarcopenia Muscle (2010) 1:43–128Background: The assembly and maintenance of the cardiac
sarcomere, which contains the basic contractile components
of actin and myosin, are essential for cardiac function.
While often described as a static structure, the sarcomere is
actually dynamic and undergoes constant turnover, allow-
ing it to adapt to physiological changes while still
maintaining function.
Objective: We evaluated the role of miR199a-5p (miR199)
for the sarcomere disorganization in tumor rats with cardiac
atrophy.
Methods and results: Quantitative real-time PCR analysis
revealed robust expression of miR199 in normal adult rat
hearts, while its expression was markedly lower (−40%, P
<0.05) in tumor-bearing rats with cardiac atrophy. Immu-
noblotting revealed a marked reduction in cardiac myosin
heavy chain protein (α-a n dβ-MHC) in hearts from
tumor-bearing rats compared to normal rats, while cardiac
troponin T and tropomyosin were not affected. Cultured
neonatal rat cardiomyocyte (NRCM) express high levels
of miR-199. Lipofectamin-based transfection of anti-
miR199 in NRCM reduced miR199 levels by 50- to 100-
fold, which was associated with growth retention of cells.
Liquid chromatography tandem mass spectrometry
revealed enhanced ubiquitination and degradation of α-
and β-MHC and Titin, but not of Troponin T and
Tropomyosin in anti-miR199-treated NRCM. Further-
more, electron microscopy revealed disappearance of the
Z-disc in anti-miR199-treated NRCM. Three ubiquitin-
conjugating enzymes, Ube2i, Ube2g1, and Ube2o,
emerged as direct targets of miR-199a in NRCM, which
was confirmed by immunoblotting and with a reporter
plasmids (psiCheck) containing the potential miRNA
binding sites of Ube2i, Ube2g1, and Ube2o at the 3′-
position of the luciferase reporter gene. In turn, over-
expression of miR199 by pre-miR199 transfection pre-
vented MHC degradation and significantly reduced
protein levels of Ube2i (−74%, P<0.01 vs control pre-
miR), Ube2g1 (−69%, P<0.01 vs control pre-miR), and
Ube2o (−55%, P<0.01 vs control pre-miR). Similarly,
transfection of cardiomyocytes with siRNA directed against
Ube2i, Ube2g1, or Ube2o prevented MHC degradation, an
effect that was not observed with control siRNA or siRNA
directed against Ube2j, a ubiquitin conjugating enzyme that
is not a target of miR-199. Furthermore, HIF1-alpha, a pro-
angiogenic protein mainly regulated by the UPS, was not
affected by modulations of miR199 and or Ube2i, Ube2g1,
and Ube2o expression.
Conclusion: Our observations suggest a key role of
miR199 for the homeostasis of sarcomeric protein turnover
in postnatal cardiomyocytes and adult hearts. Reduction of
miR199 as we report here in tumor-bearing rats promotes
cardiac cachexia by increasing UPS-mediated degradation
of sarcomeric proteins, i.e., MHC and Titin. miR199 targets
hereby a specific subset of ubiquitin conjugating enzymes,
i.e., Ube2i, Ube2g1, and Ube2o that seem to be responsible
for degrading specific sarcomeric proteins, i.e., MHC and
Titin.
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Background: Cachexia is a common co-morbidity in
patients with cancer, which drastically reduces quality of
life and survival. Cancer patients also develop shortness of
breath of unknown reason, particularly when cachectic.
Whether cancer cachexia causes heart failure is not
known.
Methods: Juvenile Wistar rats (weight approximately
200 g) were inoculated intra-peritoneally with AH-130
hepatoma cells or saline (sham). Heart function was
measured before inoculation and on the day of sacrifice,
when invasive hemodynamic assessment and ECG were
also performed. Weight and body composition (NMR
scan) were analyzed on day 0 and after sacrifice (without
tumor).
Results: Animals of all groups showed similar baseline
values for weight, body composition, and heart function.
Rats with cancer reached a cachectic state on day 7.
Animals lost only fat mass at this stage. With progressing
disease and cachexia deterioration, cardiac function be-
came severely impaired (see Table). At the end of the
study, animals displayed severe cachexia (136±3 g
(day 13) vs sham, 239±4 g, p<0.0001). Cancer rats lost
fat (−11.7±0.6 g (day 13) vs sham, 6.3±0.9 g, p<0.0001)
and lean tissue (−35.6±1.5 g (day 13) vs sham, 32.3±2.1 g,
p<0.0001).
J Cachexia Sarcopenia Muscle (2010) 1:43–128 111BW body weight, LV left ventricular, EF ejection fraction, FS fractional shortening, EDD enddiastolic diameter, EDV
enddiastolic volume, SV stroke volume, EDP enddiastolic pressure, ESP endsystolic pressure
*p>0.05; **p<0.01; ***p<0.001 tumor vs sham
Conclusion: In this model system, severe cancer cachexia
causes severe impairment of cardiac function. The nature of
these impairments is only partially comparable to processes
in chronic heart failure. However, heart failure therapies
may be beneficial in this clinical setting.
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A soluble activin receptor type IIB increases muscle
mass in a mouse model of cancer cachexia
Abigail E. Pullen, Jennifer L. Lachey, Ravi Kumar,
Kathryn Underwood, R. Scott Pearsall, Jas Seehra
Acceleron Pharma, Cambridge, MA, USA
Background: Cachexia is characterized by undesired
weight loss resulting from loss of both muscle and adipose
tissue. Myostatin, a known negative regulator of muscle
mass, is upregulated in the colon-26 rodent model of
cachexia. Myostatin and other negative muscle mass
regulators signal via the activin receptor type IIB
(ActRIIB), and treatment of normal mice with a non-
signaling, decoy ActRIIB results in a robust increase in lean
tissue. This study evaluates the potential beneficial effects
of ACE-435, a fusion protein comprised of an optimized
extracellular domain of ActRIIB linked to a human Fc, in
cachectic mice.
Materials and methods: Eight-week-old BALB/c mice
were injected subcutaneously with 1×106 colon-26 adeno-
carcinoma cells. Two weeks post-implantation, mice were
randomly assigned to receive vehicle or 10 mg/kg ACE-
435 two times a week. Body weight and in vivo body
composition were tracked throughout the study.
Results: ACE-435 treatment resulted in a significant body
weight increase that was maintained across the study (p<0.05).
Seven weeks post-tumor implantation vehicle-treated mice had
a 7% loss of baseline lean mass, whereas the ACE-435 group
had a 27% increase in baseline lean mass (p<0.001).
Importantly, fat mass was not different between groups,
illustrating that the ACE-435 anabolic effect did not exacerbate
fat loss. Also, although not reaching significance (p<0.076), the
ACE-435 group had an 8-day mean increase in survival.
Conclusions: These data demonstrate that ACE-435 has
beneficial effects in alleviating cachexia in tumor-
bearing mice. Thus, a soluble ActIIB-Fc fusion protein
could be an effective therapy for treating cancer-induced
cachexia.
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STAT3 in skeletal muscle links the acute phase response
and muscle wasting in colon-26 cancer cachexia
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Tumor Sham
Day 5 Day 7 Day 9 Day 11 Day 13 Combined
N 61 0 9 7 1 2 1 5
Delta BW (g) 8.0±1.1*** −9.0±2.7*** −10.3±3.2*** −40.3±10.0*** −42.4±1.7*** 45.2±3.9
LVEF (%) 85.8±0.6 74.1±1.9 80.1±1.5 53.4±1.6*** 50.5±1.4*** 79.7±1.4
LVFS (%) 52.7±1.5 43.0±1.5** 47.9±2.3 26.5±0.7*** 30.3±0.9*** 50.5±1.4
LVEDD (mm) 7.02±0.17 6.52±0.19 6.04±0.35 4.94±0.48* 4.05±0.32*** 6.50±0.13
LVEDV (μl) 257.5±9.0 197.4±10.9** 186.2±10.7** 102.2±13.5*** 68.55±3.96*** 251.9±12.6
LVSV (μl) 221.1±8.4 146.2±9.0** 150.5±9.3* 55.0±8.3*** 34.4±1.8*** 202.1±12.5
LV-mass (mg) 473±25*** 495±18*** 447±48** 481±76* 220±29*** 642±23
LVEDP (mm/Hg) 8.1±3.0 14.2±2.7 −2.9±0.4*** 1.5±1.6 * −2.3±0.4*** 19.2±9.0
LVESP (mm/Hg) 108.4±3.9 117.1±4.5 103.9±4.5 82.9±6.2* 66.9±3.7*** 110.6±5.4
QRS (ms) 16.1±1.3 17.9±1.2 19.93±2.0 28.1±2.9** 31.6±1,4*** 17.2±1.1
BNP (pg/mL) 303±48 1728±737* 774±265 191±58 142±25 435.4±69
112 J Cachexia Sarcopenia Muscle (2010) 1:43–128Background and aims: Cancer cachexia is associated with
increased serum cytokines, particularly interleukin-6 (IL-6),
and the acute phase response (APR). We hypothesized
these observations are mechanistically linked through IL-6/
STAT3 actions in skeletal muscle.
Methods: Quadriceps gene expression from mice with
colon-26 cachexia, known to be mediated largely by IL-6,
was profiled using Illumina BeadChips. GeneSpring was
used for data normalization, statistical analysis, and
hierarchical clustering. Metacore and NextBio were used
for gene and pathway analyses. Selected profiles were
validated by qPCR and Western blotting.
Results: Gene expression profiles in early and late cachexia
were significantly correlated. The top canonical pathways
upregulated in both were inflammation/IL-6/STAT3 signal-
ing, proteolysis, and MAPK signaling. The top down-
regulated pathways were the PGC1A pathway, calcium
regulation/signaling, ECM, focal adhesion, skeletal myo-
genesis, and insulin signaling. Increased pSTAT3 was
observed in cachexia both in liver and skeletal muscle.
STAT3 target genes, including SOCS3, fibrinogen, serum
amyloid A, lipid binding protein, and haptoglobin were
coordinately induced in both tissues. By Western blotting,
fibrinogen was induced 80-fold over normal in quadriceps
and tenfold in liver. Quantitation of muscle versus liver
fibrinogen demonstrated that up to 40% of serum fibrino-
gen could be muscle derived.
Conclusions: The IL-6/STAT3 signaling pathway is highly
induced in liver and skeletal muscle in colon-26 cachexia.
APR genes were highly expressed not only in liver but also
in skeletal muscle. These results indicate that skeletal
muscle contributes to the APR in cancer and that STAT3
activation in muscle provides a mechanistic link between
muscle wasting and the APR.
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Male hypogonadism in advanced cancer patients:
nutritional, functional, and quality of life correlates
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Background: Male hypogonadism often occurs in ad-
vanced cancer patients (ACP), but its clinical impact
remains unclear. Our aim was to explore the relationships
between low free testosterone (LFT) and nutritional,
functional, and quality of life (QOL) characteristics in ACP.
Methods: Free testosterone levels were measured in 100
males (median age, 64 years) newly diagnosed with
advanced non-small cell lung (38.8%) and gastrointestinal
(61.2%) cancers. The Edmonton symptom assessment scale
(ESAS), brief fatigue inventory (BFI), patient-generated
subjective global assessment (PG-SGA), McGill quality of
life questionnaire (MQOL), handgrip strength test (Jamar®),
DXA for body composition, albumin, CRP, and WBC were
evaluated. Multiple regression analyses (controlling for age,
diagnosis (lung/GI), treatment (radio/chemo), survival, and
concurrent medications) were performed.
Results: Seventy-six patients (76%) presented with LFT
(<31.1 pmol/L). As compared to eugonadic patients,
patients with LFT had similar QOL, weakness, dyspnea,
and appetite according to the ESAS and similar CRP and
WBC levels, worse performance status by PG-SGA
Box 4 (beta, 0.59; 95% CI, 0.07, 1.11), worse BFI total
score (16.68; 2.03, 31.32), worse MQOL physical score
(−2.20; −4.01,−0.39) andtotal score (−1.42; −2.54,−0.30),
lower handgrip strength (−11.67 lbs; −20.39, −2.95) and
percentile (−11.23; −20.56, −1.89), lower lean mass for the
upper limbs (−0.76 kg; −1.44, −0.09), and lower albumin
(−3.77; −7.21, −0.77).
Conclusion: Our data show relationships between male
hypogonadism and worse nutritional, functional, and QOL
characteristics in ACP. Clinical trials for the treatment of
hypogonadism in this patient population are warranted to
confirm a cause–effect nature of these associations.
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Functional, nutritional, and quality of life correlates
of hypogonadism in advanced cancer: a qualitative
systematic review of the literature
Melissa Piccioni, Barbara Trutschnigg, Robert D.
Kilgour, Prosanto Chaudhury, Laura Hornby, Antonio
A. L. Vigano
McGill Nutrition and Performance Laboratory, McGill
University Health Centre, Montreal, QC, Canada
Background and aims: Hypogonadism has been associated
with a host of secondary symptoms including diminished
energy, poor concentration, depression, and decreased phys-
ical performance. These symptoms are often present in
advanced cancer patients (ACP), and hypogonadism is a key
pathophysiologic mechanism for both sarcopenia and cancer
cachexia (CC). To our knowledge, no study has yet
systematically reviewed available literature on clinical corre-
lates of hypogonadism in ACP. Therefore, we conducted a
qualitative systematic review of the literature regarding the
J Cachexia Sarcopenia Muscle (2010) 1:43–128 113impact of hypogonadism on functional and nutritional status,
body composition, symptoms, and quality of life in ACP.
Methods: Through a systematic search of both Pubmed and
EMBASE databases, six original articles were selected, and
their results were tabulated for comparative qualitative analysis.
Results: No definitive associations between nutritional,
functional, or QOL characteristics and hypogonadism were
found in the reviewed studies. Possible associations
between hypogonadism and weight loss, low albumin,
body cell mass, peripheral fat, and muscle mass, inflam-
mation, pain, and opioid consumption, as well as worse
emotional and functional well-being, must be confirmed by
better-designed studies.
Conclusions: Clear epidemiological data is not yet avail-
able to indicate whether hypogonadism is independently
correlated with clinical and biological sequaela of CC.
Future studies examining hypogonadism in ACP should (a)
use standardized kits with sufficient sensitivity and precision
in the lower ranges for either free or bio-available testoster-
one, (b)usemultivariate modelson adequatelysized samples
to identify independent clinical correlates of hypogonadism;
and (c) include measurements of luteinizing hormone to
differentiate primary from secondary hypogonadism.
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Metabolic, nutritional, and inflammatory characteristics
in elderly women with newly diagnosed advanced
cancer
Barbara Trutschnigg, Robert D. Kilgour, Jose A.
Morais, Enriqueta Lucar Figueroa, Laura Hornby,
Antonio A. L. Vigano
McGill Nutrition and Performance Laboratory, McGill
University Health Centre (MUHC), Montreal, QC, Canada;
Division of Geriatrics, MUHC, Montreal, QC, Canada
Background and aims: Few studies have focused on the
metabolic, nutritional, and inflammatory profiling of elderly
patients with advanced cancer. The aim of the study was to
determine energy expenditure at rest and during activity,
body composition, nutrition, and inflammatory character-
istics of elderly females with and without advanced
gastrointestinal cancer.
Methods: Twenty elderly (74.8±6.7 years) females (nine
newly diagnosed advanced gastrointestinal cancer and 11
healthy) were evaluated using indirect calorimetry at rest and
throughout a 6-min walk test. Body composition, nutritional
intake, and blood markers of nutrition and inflammation
(CBC, albumin, and CRP) were also measured in all study
subjects.
Results: Compared to healthy controls (H), cancer patients
(C) had similar energy expenditures, but significantly lower
respiratory quotients at rest (C, 0.74±0.02; H, 0.81±0.07;
p<0.05). During the 6MWT, the cancer group walked
shorter distances (337.2±92.0 m; 480.4±49.0; p<0.001) at
slower speeds (0.94±0.26 m/s; 1.33±0.14; p<0.001) with
lower oxygen uptakes (11.7±3.6 mlO2/kg/min; 15.0±2.4; p
<0.05). The cancer patients ingested fewer calories (22.4±
5.6 kcal/kg; 33.1±2.3; p<0.01) and presented with higher
levels of CRP (27.1±40.5 mg/L; 2.1±1.4; p<0.05). No
differences in body composition were observed.
Conclusions: Our preliminary data suggest that elderly
women with newly diagnosed advanced cancer have a
greater reliance on fat metabolism at rest and walk shorter
distances at lower heart rates and levels of oxygen
consumption. These metabolic differences, coupled with
the elevation in inflammatory markers and reduction in
caloric intake, may signal an early anorectic-cachectic
condition, which may have important diagnostic, treatment,
and prognostic implications.
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Association between hypogonadism, C-reactive protein,
symptom burden, and survival in male cancer patients
with cachexia: a preliminary report
Egidio Del Fabbro, David Hui, Rony Dev, Shalini Dalal,
Gina Freer, Eduardo Bruera
MD Anderson Cancer Center, Houston, TX, USA
Background and aims: In patients without cancer,
hypogonadism is associated with lower lean body mass,
increased symptom burden, and decreased survival. Hypo-
gonadism in cancer cachexia could exacerbate symptoms,
facilitate a pro-inflammatory state, and decrease survival.
Methods: A retrospective chart review of 98 consecutive
male patients referred to a cachexia clinic at a cancer center,
57 (58%) had serum C-reactive protein (CRP) and 68 (69%)
had total testosterone evaluated. Symptoms were evaluated
by the Edmonton symptom assessment scale (ESAS) and
bioimpedance by Tanita body composition scale.
Results: Allmalepatientsreportedweightlossof>5%within
the preceding 6 months; median age, 60; CRP, 20 mg/L; and
median testosterone, 185 ng/dL (6.42 nmol/L). The degree of
weight loss over the preceding 3 months correlated with CRP
levels (r=0.42, p<0.05), but not with testosterone. Fat free
mass and body mass index (BMI) showed no correlation
with CRP levels or testosterone. Testosterone correlated
inversely with CRP levels (p<0.01). Survival with testos-
terone ≤185 ng/dL (6.42 nmol/L) decreased compared to
those >185 ng/dL (13 vs. 62 weeks, p=0.004). Patients with
CRP>10mg/Lhaddecreasedsurvivalcomparedto≤10mg/L
(15 vs. 46 weeks, p=0.01). Among patients with both
testosterone and CRP, the combination of low testosterone
114 J Cachexia Sarcopenia Muscle (2010) 1:43–128and high CRP levels significantly decreased survival
compared to other groups (p=0.039).
Conclusions: Elevated CRP levels were associated with
increased symptom burden and decreased survival. Low
testosterone was associated with decreased survival and
correlated inversely with CRP levels. Our results suggest
testosterone and CRP may be additive or synergistic as
markers for survival in male patients with cachexia.
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Does interleukin (IL) 6 best reflect cachexia in advanced
cancer patients?
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Background and aims: Recent diagnostic criteria of
cachexia (Evans et al. 2008) have included higher levels
of circulating IL-6. The aim of this study was to compare
the clinical relevance of four commonly studied pro-
inflammatory cytokines, IL-6, IL-1-beta, IL-8, and TNF-
alpha, in advanced cancer patients (ACP).
Methods: Plasmacollectedfrom83patients(61.8±12.9years)
with newly diagnosed advanced lung and gastrointestinal (GI)
cancer was analyzed for the above cytokines. Adjusting for
gender, age, diagnosis (lung/GI), treatment (radio/chemo),
comorbidity, and medications, we explored differences in
albumin and CRP levels, presence of >5% weight loss/
6 months, sarcopenia, and survival between patients with
“low levels” (lowest tertile) versus those with “high levels”
(highest tertiles) for the considered cytokines.
Results: Patients with high IL-6 had the lowest levels of
albumin (IL-6-beta, −5.02; 95% CI, −7.69 to −2.35; IL-1-
beta, −3.90, −6.53 to −1.26; IL-8, −2.91, −5.64 to −0.17;
and TNF-alpha, −3.15, −5.89 to −0.40) and highest levels
of CRP (IL-6, 44.21, 28.78 to 59.65; IL-1-beta, 27.34, 9.45
to 45.24; IL-8, 26.14, 9.06 to 43.22). Sarcopenia was
primarily associated with high TNF-alpha (5.56, 1.47 to
20.97) and IL-1-beta (5.35, 1.37 to 20.97), whereas only
IL-1-beta reflected weight loss (7.14, 1.87 to 27.26).
Decreased survival was associated with high IL-8 (HR,
7.58, 2.84 to 20.22), IL-6 (3.76, 1.44 to 9.87), IL-1-beta
(3.50, 1.42 to 8.63), and TNF-alpha (3.17, 1.26 to 7.89).
Conclusions: While IL-6 remains the best marker of
inflammation, other cytokines (in particular IL-1-beta)
may better reflect clinical correlates of cachexia in ACP.
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Increased activity of liver 11-beta-hydroxysteroid
dehydrogenase type 1 (11-beta-HSD1) in male colon
cancer patients: role of the deregulation of growth
hormone (GH)—insulin-like growth factor I (IGF-I)
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Background and aims: Liver 11-beta HSD1 converts
cortisone to the biologically active hormone cortisol: its
increased activity plays a central role in the visceral fat
accumulation of the metabolic syndrome and Cushing’s
syndrome. The activity of the enzyme is under the control
of GH-IGF-I axis, with GH playing an inhibitory role.
Cancer-cachexia patients often display GH resistance and/
or GH deficiency and enhanced cortisol levels.
Methods: We evaluated the cortisone to cortisol conversion
in 20 male colon cancer-cachexia patients (and 20 age-
matched controls) by measuring serum cortisol after oral
cortisone (Cortone®) administration. We also evaluated by
L4 CAT the abdominal visceral and subcutaneous fat.
Results: We found enhanced cortisol peak levels (P<0.01)
and larger area-under-the-curve (P<0.01) after oral cortisone
administration in cancer patients. There was a correlation (r=
51, P<0.01) between the visceral fat area and cortisol peak.
No significant changes were observed in basal ACTH and GH
levels. IGF-1 levels were lower in cancer patients (P<0.01).
Conclusions: An enhanced cortisol production by liver
may contribute to visceral fat accumulation in colon cancer-
cachexia patients so contributing to their cardiovascular
derangement and is related to the downregulation of GH-
IGF-1 axis.
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and peripheral blood flow in cachectic and non-cachectic
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Background: In non-small cell lung cancer (NSCLC),
cachexia, fatigue, and dyspnea are frequently seen. We
J Cachexia Sarcopenia Muscle (2010) 1:43–128 115hypothesize that the development of cancer fatigue syn-
drome is at least in part due to cardiovascular pertubation
with the consequence of decreased exercise capacity and
reduced quality of life.
Methods: To investigate the cardiovascular parameters, we
prospectively studied 42 patients with NSCLC (age, 60±
9 years; mean±SE, 26 male; body mass index (BMI), 24.8±
4.7 kg/m
2; hemoglobin (Hb), 12.2±1.9 g/dl) and 41
healthy controls (CON, 61±11 years, 26 male; BMI,
25.4±3.5 kg/m
2; Hb, 14.4±1.0 g/dl) in exercise capacity
using symptom-limited exercise test, cardiac function
using echocardiography, body composition using dual
energy X-ray absorptiometry, peripheral blood flow using
venous occlusion plethysmography, and heart rate vari-
ability using 24-h ECG in patients and controls. A
subgroup analysis of non-cachectic (N-CACH; n=28)
and cachectic (CACH) patients (n=13) was performed
due to the consensus definition of cachexia.
Results: No significant difference was detected between
patients and CON in terms of sex, age, and systolic
function. Patients with NSCLC displayed impaired exercise
capacity (peak VO2 in NSCLC, 17.6±0.9 mL/min/kg vs.
CON, 28.3±1.1 mL/min/kg), less total lean mass (NSCLC,
47.8±1.8 vs. 53.3±1.8 kg), lower peak blood flow in
forearm (NSCLC, 17.4±1.0 mL/100 mL/min vs. CON,
22.3±1.4 mL/100 mL/min) and leg (NSCLC, 11.0±
1.1 mL/100 mL/min vs. CON, 15.4±1.4 mL/100 mL/
min), and impaired autonomic function (SDNN in NSCLC,
97.5±36.5 ms vs. CON, 142±36.9 ms; all p<0.05). CACH
patients showed significantly impaired exercise capacity
compared to N-CACH patients (CACH, 18.84±0.97 mL/
min/kg vs. N-CACH, 13.96±1.4 mL/min/kg, p=0.03).
Conclusions: Reduced exercise capacity, less lean mass,
worse blood flow, and autonomic dysfunction are present in
patients with NSCLC. Symptoms may due to systemic
changes like neuroendocrine activation and inflammation.
Further studies are required.
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Background and aims: Accelerometer-based activity mon-
itoring offers potential for simple, inexpensive, and objective
assessment of physical activity and energy expenditure of
cachectic patients in practice and clinical trials. This study
aimed to assess criterion-based validity of an activity monitor
(ActivPAL™) using a stable isotope dilution technique.
Methods: Accelerometer-based measurements were vali-
dated against total energy expenditure (TEE) and energy
expenditure of activity (EEA) assessment by a 2-week
doubly labelled water (DLW) and indirect calorimetry
protocol in advanced cancer patients (n=7 outpatients)
and healthy controls (n=10 assessments in nine subjects).
Agreement was assessed by Bland–Altman plots and
within-subject standard deviations (Sw).
Results: Cancer patients were older (mean, 62 versus
29 years; p<0.001) and had lower KPS (mean, 87 versus
100; p<0.001), TEEDLW (mean, 2,321 versus 3,202 kcal/
day; p<0.01), and EEADLW (mean, 742 versus 1,609 kcal/
day; p<0.01) compared with controls, but did not differ
significantly in lean body mass or fat mass. TEEActivPAL
(mean, 2,859 kcal/day; SD, 787; range, 2,129–5,045) and
TEEDLW (mean, 2,849 kcal/day; SD, 849; range, 2,017–
5,309) demonstrateda meandifference of9kcal/day(Sw,198;
95% LOA, −191, 587) or absolute percentage error of 0.4%.
EEAActivPAL (mean, 1,244 kcal/day; SD, 825; range, 486–
3,334) and EEADLW (mean, 1,262 kcal/day; SD, 807; range,
374–3,424) demonstrated a mean difference of −18 kcal/day
(Sw, 168; 95% LOA, −161, 497) or absolute percentage error
of 1.4%. In a multivariate model, EEAActivPAL explained
85.1% of the variation in TEEDLW (p<0.001).
Conclusions: Activity monitoring provides valid estimates
of EEA and TEE in cancer patients and controls, and
should be considered as an endpoint in trials of anti-
cachexia therapies.
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Background and aim: Predictive equations to estimate
body composition in advanced cancer patients (ACP) from
computed tomography (CT) images have been recently
proposed (Mourtzakis et al. 2008). We evaluated the
accuracy of these equations to estimate whole body fat
116 J Cachexia Sarcopenia Muscle (2010) 1:43–128mass (FM), whole body fat-free mass (FFM), and appen-
dicular skeletal muscle (ASM) in a new inception cohort of
ACP who also underwent dual-energy X-ray absorptiom-
etry (DXA) measurements.
Methods: FM, FFM, and ASM estimates from CTand DXA
measurements obtained within 2 weeks (n=18) or 1 month
(n=25) from one another were compared using Spearman’s
correlation coefficient and Bland–Altman analysis.
Results: For the 2-week interval, CT and DXA measure-
ments correlated as follows: FM (ρ=0.94; p<0.01), FFM
(ρ=0.74; p<0.01), and ASM (ρ=0.68; p<0.01). The limits
of agreement between both methods were FM (−2.88±3.86
(−10.45, 4.68)kg), FFM (−0.93±7.51 (−15.64, 13.79)kg),
and ASM (0.71±1.02 (−1.29, 2.71)kg).
For the 1-month interval, the following correlations were
obtained: FM (ρ=0.88; p<0.01), FFM (ρ=0.80; p<0.01),
and ASM (ρ=0.74; p<0.01). The limits of agreement were
FM (−3.82±4.07 (−11.79, 4.15)kg), FFM (−2.97±7.47
(−17.61, 11.68)kg), and ASM (0.13±0.97 (−1.78, 2.04)kg).
Conclusions: Despite high to moderate correlation between
both methods for the measurements of FM, FFM, and
ASM, the CT model does not appear to be a surrogate for
DXA. Further studies are needed to clarify both the
precision and the clinical value of CT for measuring body
composition in ACP.
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A frequent manifestation of advanced cancer is protein-
energy malnutrition (PEM), timely identification and
treatment of which can lead to improved patient outcomes.
Bioelectrical impedance analysis (BIA) is an easy-to-use,
non-invasive and reproducible technique to evaluate
changes in body composition and nutritional status. Phase
angle, derived from by BIA, has been described as a
prognostic tool in several chronic diseases and in cancer
patients. Thirteen patients (58.4±7.5 years, 58.0±10.6 kg
and BMI 20.2±3.5 kg/m
2) with advanced cancer have been
consecutively referred to the Clinical Nutrition Unit of
Federico II University, in Naples. Primary cancer localiza-
tion was gastric in five, colorectal in three, esophageal in
two, pancreatic in two, and pulmonary in one. Anthropo-
metric (weight, height, body mass index and skinfolds) and
haematobiochemical (albumin, cholesterol, lymphocytes,
haemoglobin and cholinesterase) parameters have been
measured. BIA (STA/BIA, Akern) was performed in all
patients, and phase angle (expressed in degrees) calculated.
The Kaplan–Meier method was used to calculate survival
and Cox model to evaluate the prognostic effect of phase
angle independent of other clinical and nutritional varia-
bles. Phase angle resulted strictly related (R
2=0.384, p=
0.024) with survival time, slightly (p=0.055) related with
lymphocyte count, but not related with the other anthro-
pometric and biochemical parameters evaluated. This
preliminary study confirms phase angle as a prognostic
indicator in patients with advanced cancer. Similar studies
on larger sample sizes are needed to further validate the
prognostic significance of phase angle in advanced cancer
patients.
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Changes in body composition during and after head
and neck cancer treatment: preliminary results
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Background and aims: Head and neck cancer patients
(HNCP) are at risk for weight loss during treatment, due to
oral sequalae of cancer treatment, e.g., mucositis and
swallowing problems, dental problems, and trismus. Loss
of fat free mass (FFM) reduces immune function and
quality of life. To determine whether weight loss during
treatment consists of loss of fat mass and/or FFM, we
measured body composition prospectively.
Methods: Adult patients with squamous cell carcinoma in
the oral cavity, pharynx, or larynx and undergoing surgery
plus radiotherapy, radiotherapy, or chemoradiation with
curative intent were included. All patients received dietary
intervention during treatment. Only patients treated with
chemoradiation (n=4) received prophylactic gastrostomy
placement. Fat mass and FFM were measured by dual
energy X-ray absorptiometry, before treatment (T0) and
after treatment (T1). Paired samples t test was used to
analyze changes in FFM and fat mass between T0 and T1.
J Cachexia Sarcopenia Muscle (2010) 1:43–128 117In total, 30 patients will be included. Data of the current 11
patients will be presented here.
Results: Interval between T0 and T1 was 82±21 days.
Mean body weight and body mass index at T0 were 75.5±
18.7 kg and 23.3±5.5, respectively. Ten patients lost body
weight during treatment. Body weight declined with 2.8±
4.2 kg (p=0.051). FFM significantly declined with 1.8±
2.7 kg (p=0.049). Fat mass declined with 1.0±2.4 kg
(p=0.224).
Conclusions: The preliminary results indicate that HNCP
lose weight, of which 64% is FFM. Intervention should be
adapted to maintain or increase FFM.
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Plasma myoglobin concentration is unrelated to muscle
mass in elderly patients with early colorectal cancer
Sitaramachandra M. Nyasavajjala, Anna Selby, Wulf
Hildebrandt, John P. Williams, Rajeev Singh, Kenneth
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Background and aims: Progressive muscle wasting is a
characteristic feature of cancer cachexia and increases
the risk of a poor prognosis and diminished quality of
life. It has been suggested that in patients with
pancreatic and gastric cancers (Weber et al., J Mol
Med 85:887–896, 2007), plasma myoglobin concentra-
tion is a good index of muscle mass, enabling wasting to
be assessed conveniently. Therefore, we wished to test
its reliability for this purpose in patients with early
colorectal cancer.
Methods: We studied 11 patients with colorectal cancer
(five men, six women; 74±11 years) and eight age and sex-
matched healthy controls (four men, four women, 64±
3 years), and 56 previously examined control patients with
a normal diagnostic CT. We measured plasma myoglobin
concentration, both leg muscle mass (LMM), by dual-
energy X-ray absorptiometry (DXA) and psoas muscle
cross-sectional area (CSA) by computerized tomography
(CT) at the third lumbar vertebra.
Results: Plasma myoglobin was 31.2±9.6 vs. 42.9±
8.71 ng/ml (P>0.05) in patients with cancers and controls,
respectively. LMM was 6.49±1.94 vs. 6.42±1.62 kg in
patients and controls, respectively; psoas CSA in the
patients with colorectal cancer was 3,363±1,631 mm
2,i .
e., not significantly different from that in the controls
(2,873±1,103 mm
2). There was no significant correlation
between myoglobin and psoas CSA (r
2=0.0074; P=0.87)
or LMM (r
2=0.4684; P=0.80) in patients who lost LMM of
8( 2 –15)g/day.
Conclusion: In early colorectal cancer, the extent of muscle
wasting cannot be assessed by measurement of plasma
myoglobin concentration.
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A central role for neuronal mTOR in cancer-induced
anorexia
Rodrigo Miguel Marin, Eduardo R. Ropelle, Guilherme
Zweig Rocha, Patricia O. Prada, Marilia Meira Dias,
Jose Barreto Campello Carvalheira
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Background and aims: Accumulating evidence indicates
that the pathogenesis of cancer anorexia is mediated by
persistent anorexigenic signals into the hypothalamus.
Several factors are considered to be putative mediators
of cancer anorexia, including interleukin 1 and 6 (IL-1,
IL-6) and tumor necrosis factor (TNF). Recently,
hypothalamic mammalian target of rapamycin (mTOR)
signaling has been considered a cellular fuel sensor for
regulation of food intake. The aim of this study was to
examine the role of hypothalamic mTOR in the control of
food intake model of cancer-induced anorexia in rodents.
Methods: Walker-256 tumor and Lewis lung carcinoma
(LLC) cells were implanted in rat and mouse, respectively.
Intrahypothalamic infusion of rapamycin was performed in
tumor-bearing (TB) rats during 4 days before analysis,
whereas recombinant IL-1-beta and TNF-alpha were acute-
ly infused into the third ventricle of control rats. Food
intake analysis, dissection of hypothalamic regions, and
Western blotting were combined to evaluate the hypotha-
lamic mTOR activity.
Results: Here, we show that neuronal mTOR pathway is
activated in anorexic TB rat and mouse model. As
expected, we found high levels of TNF and IL1 in the
hypothalamus of TB rat group. Interestingly, intrahypotha-
lamic infusion of recombinant IL-1 or TNF increases
mTOR activity and evokes anorexia in control rats.
Moreover, central infusion of specific inhibitor of mTOR
rapamycin partially blunts the anorectic effect in TB rats.
We also observed that the mTOR expression was most
intense in the arcuate nucleus, DMH/VMH and PVN when
compared to LH in control rats.
118 J Cachexia Sarcopenia Muscle (2010) 1:43–128Conclusion: Taken together, our data demonstrated that
hypothalamic mTOR activity is critical to decreases food
intake in tumor-bearing (TB) rodent models.
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The role of the 5-Ht2c receptor in tumor-induced
anorexia and gastrointestinal motility in rats
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Background and aims: Cancer cachexia is a debilitating
and life-threatening syndrome characterized by anorexia
and loss of fat and skeletal muscle. It is a major source of
increasing the morbidity and mortality of cancer patients.
We examined the role of the serotonergic system in the
food intake, gastrointestinal (GI) motility, and appetite-
regulating neuropeptide gene expression in tumor-bearing
rats.
Methods: Tumor-bearing rats received an intraperitoneal
inoculum of 108 AH-130 Yoshida ascites hepatoma cells.
GI motility was measured in conscious, freely moving rats
by a strain gauge force transducer method. Plasma acyl
ghrelin levels were determined by EIA. Appetite-regulating
neuropeptide gene expressions in the hypothalamus were
quantified by real-time RT-PCR. Effects of acyl ghelin and
5-HT2c receptor antagonist (SB242084) on food intake and
GI motility in tumor-bearing rats were examined.
Results: Anorexia was induced after day 5 following tumor
implantation. At day 7, food intake, body weight, fat, and
skeletal muscle were significantly reduced in tumor-bearing
rats, while plasma cytokine (IL-1-beta, IL-10, and IFN-
gamma) levels were elevated. Plasma acyl ghrelin concentra-
tion was significantly higher in tumor-bearing rats than
normal rats in freely fed state; however, acyl ghrelin was
lower in24-hfood-deprivedstate.NeuropeptideY(NPY)and
agouti-related peptide (AgRP) mRNA expression in the
hypothalamus were upregulated in freely fed tumor-bearing
rats. The fasted motor patterns in both the antrum and
duodenum were disrupted and replaced by the fed-like pattern
in tumor-bearing rats. Acyl ghelin (3 nmol) significantly
increased the motor activity in the antrum of tumor-bearing
rats, however failed to improve the phase III-like contractions
offasted motility and food intake. 5-HT2c receptor antagonist
induced the fasted motor patterns and markedly reversed the
decreased food intake in tumor-bearing rats. In addition,
hypothalamic NPY mRNA expression was significantly
increased by 5-HT2c receptor antagonist.
Conclusions: The present study demonstrated that 5-HT2c
receptor plays an important role in tumor-induced anorexia
and relieving gastrointestinal motility, and it may be a
potential target for the treatment of cancer cachexia.
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Methotrexate-induced anorexia is not associated
with the systemic inflammatory response
but with a decrease in serum levels
of alpha-MSH autoantibodies
Maria Hamze Sinno, Quentin Coquerel, Mutsumi
Terashi, Moïse Coëffier, Pierre Déchelotte, Serguei O.
Fetissov
ADEN Laboratory, Institute of Medical Research and
Innovation, Rouen University, Rouen, France
Background and aim: Methotrexate (MTX) chemotherapy
is accompanied by intestinal inflammation and anorexia of an
unknown mechanism. In this work, we studied if MTX-
induced anorexia can be related to a systemic increase in
interleukin 1β (IL-1β) or to altered production of autoanti-
bodies (autoAbs) against α-melanocyte-stimulating hormone
(α-MSH).
Methods: Sprague–Dawley rats received MTX (2.5 mg/kg
s.c. for 3 days, D1–D3), while pair-fed (PF) and ad libitum-
fed control rats received saline. PF rats were allowed ad
libitum food intake from D9. Blood samples were taken at
D1, D5, D19, and D33. Food intake and body weigh were
monitored daily.
Results: In MTX rats, D5 was characterized by maximal
suppression of food intake and body weight as well as by
intestinal inflammation. PF rats showed identical with
MTX group body weight loss till D9. Serum levels of IL-
1β were not different among the groups at D1, but at D5,
both MTX and PF groups showed a decrease in IL-1β vs.
controls, which can be attributed to food restriction. At
D19, levels of IL-1β recovered in both MTX and PF rats.
At D5, levels of both total and free α-MSH IgG and IgM
autoAbs were decreased in MTX but increased in PF rats.
In contrast, at D19 levels of α-MSH, autoAbs were higher
in MTX than in PF or control rats.
Conclusions: These data do not support involvement of
systemic proinflammatory factors but suggest that a
decrease of autoAbs against α-MSH, an anorexigenic
hormone, can play a role in MTX-induced anorexia.
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Changes of affinity of autoantibodies against
alpha-melanocyte-stimulating hormone are involved
in the mechanisms of anorexia nervosa and bulimia
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Background and aim: Autoantibodies (autoAbs) against
α-MSH have been identified in humans, and their serum
levels were oppositely correlated with psychological traits
in anorexia nervosa and bulimia. In this work, we studied if
patients with anorexia and bulimia may display autoAbs
with different affinity for α-MSH resulting in their opposite
role to modulate α-MSH signaling.
Methods: Total IgG and IgM were isolated from sera of
patients with anorexia nervosa restrictive type, bulimia, or
healthy controls. Affinity of IgG and IgM autoAbs for α-
MSH was measured using BIAcore, and the epitope
responsible for IgG binding to α-MSH was determined.
Effect of IgG autoAbs on binding of α-MSH-I125 to
melanocortin MC4 receptors was studied in transfected cos-
7 cells. The effect of α-MSH autoAbs on feeding and
anxiety was studied in a rat model of passive transfer of
affinity purified IgG α-MSH autoAbs from patients with
anorexia or bulimia into the hypothalamus of rats.
Results: An increased affinity of IgG autoAbs for α-MSH
was found in subjects with bulimia, while affinity of IgM
autoAbs was lower in both anorexia nervosa and bulimia.
AutoAbs of higher but not of lower affinity was able to
block α-MSH-I125 binding on MC4 receptors. Central
injections of high or low affinity α-MSH autoAbs in rats
resulted in increased and decreased food intake and body
weight, respectively, and increased anxiety in both groups.
Conclusions: These results provide the strong evidence that
pathological changes in affinity of α-MSH autoAbs are
involved in biological mechanisms of anorexia nervosa and
bulimia.
170
Leukemia inhibitory factor (LIF) inhibits food intake by
directly activating proopiomelanocortin (POMC) neurons
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Background: Cachexia is linked to an increase in
circulating inflammatory cytokines, including leukemia
inhibitory factor (LIF). Central LIF administration recapit-
ulates the cardinal features of cachexia, which closely
resemble central melanocortin activation. We hypothesized
that LIF inhibits feeding by directly activating proopiome-
lanocortin (POMC) neurons.
Methods: LIFwas administeredbybolus injectionorchronic
infusion through a lateral ventricle cannula to evaluate effects
on food intake. Expression of LIF-R and activation of POMC
neurons were evaluated using in situ hybridization and IHC.
We measured LIF-induced alpha-MSH release from hypo-
thalami byradioimmunoassay. Micenullforgp130,the signal
transducing subunit of the LIF-R complex, in POMC neurons
(PomcCre-gp130flox) were generated to confirm that LIF
directly activates POMC neurons, and that this activation
mediates LIF-induced anorexia.
Results: LIF-R is expressed by 20% of ARC POMC
neurons, and LIF significantly increased cFos in POMC
neurons compared to vehicle. LIF administration maintained a
significant decrease in food intake over 3.5 days. Though
control animals reduced food intake post-injection, PomcCre-
gp130flox mice were resistant to LIF-induced anorexia. LIF
increased MSH release ex vivo compared to a CSF in control
hypothalami, but not PomcCre-gp130flox hypothalami.
Conclusions: LIF acts centrally to inhibit food intake by
directly activating POMC neurons, thereby increasing
melanocortin tone. This effect requires expression of
functional LIF-R/gp130 complex in POMC neurons.
Further, LIF induces anorexia without evidence of
tachyphylaxis, closely resembling the clinical syndrome
of cachexia. This research implicates the role of LIF in
cachexia and supports the utility of melanocortin
antagonism in its treatment.
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Key phosphatase in cancer-induced anorexia
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Background: Cancer anorexia–cachexia syndrome is ob-
served in 80% of patients in the advanced stages of cancer
and is a strong independent risk factor for mortality.
Accumulating evidence indicates that the pathogenesis of
cancer anorexia is mediated by persistent anorexigenic
signals into the hypothalamus.
120 J Cachexia Sarcopenia Muscle (2010) 1:43–128Objective: Here, we investigated the role of neuronal protein
tyrosinephosphatase1B(PTP1B)inthecontroloffoodintake
a n db o d yw e i g h td u r i n gc a n c e r - i n d u c e da n o r e x i a .
Methods: Western blot, ELISA, and protein tyrosine
phosphatase activity assays were combined to evaluate the
role of hypothalamic PTP1B during cancer-induced an-
orexia in rodents.
Results: A selective transient reduction of PTP1B expression
in areas surrounding the third ventricle of hypothalamus drive
by antisense oligonucleotide (ASO PTP1B 4.0 nmol) evoked
anorexia, severe weight loss, and death in control rats (n=10).
Interestingly, hypothalamic PTP1B expression was markedly
reduced (~70%) in three different models of cancer-induced
anorexia in rodents, contributing to anorexigenic signals
mediated by STAT-3 (n=5). Furthermore, we found that
classical pro-inflammatory mediators are able to suppress the
neuronal PTP1B expression. Acute i.c.v. infusion of recom-
binant IL-1-beta (5 ng) or TNF-alpha (10
−6 M) reduced
hypothalamic PTP1B expression 45% and 40%, respectively,
in control rats (n=5). Similar results were found 6 h after
intraperitoneal LPS infusion (n=6). Conversely, i.c.v. infu-
sion of anti-IL-1-beta antibody (50 ng) or specific TNF-alpha
inhibitor, Inflixmab (0.6 μg) during 4 days, restored PTP1B
activity, increased food intake 42% and 35%, respectively,
body weight 32% and 30%, respectively, and survival in
tumor-bearing animals (n=10). Whilst forced reduction in
the PTP1B expression using i.c.v. infusion of ASOPTP1B
blunted the effects of i.c.v. infusion of anti-IL-1-beta
antibody or Inflixmab to increased food intake and survival
in tumor-bearing rats (n=6).
Conclusion: Collectively, these data showed that hypotha-
lamic PTP1B activity represents a core modulator of food
intake and body weight, linkingthe central inflammation and
the anorexigenic signals during cancer-induced anorexia.
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Resting and total energy expenditure in simple
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Protein-energy malnutrition (PEM) derives from the imbal-
ance between the supply of nutrients and the body’s
demand to ensure vital functions. While in anorexia
nervosa (AN) works, a physiological adaptive response
defined “simple starvation” in cancer patients acts an
inflammatory cascade inducing a metabolic stress (“stress
starvation”): amino acids from the protein stores and fatty
acids from the adipose tissue are converted into energy to
satisfy the metabolic needs. Energy requirements not only
depend on the aggressiveness of the disease and level of
inactivity it causes but also on the treatment and the
presence of prior malnutrition. Resting metabolic rate
(RMR) has been measured in 16 young women with
restrictive AN, 12 patients with cancer cachexia (CC), and
15 healthy subjects. RMR resulted not significantly
different between healthy controls and CC (2,415±1,227
vs 2,475±1,987 kcal/die) patients, but significantly lower in
restrictive AN (1,345±726 kcal/die; p=0.001). Physical
activity level (PAL), evaluated with a questionnaire,
resulted very poor in CC (corresponding to 601±512 kcal/
die), due to fatigue and asthenia, but very dynamic in AN
patients (1,340±712 kcal/die). Dietary induced thermo-
genesis (DIT) was comparable in all the three groups.
Finally, TEE (total energy expenditure) results slightly low
in CC patients than healthy controls. This observation
should invite in CC patients to carefully consider the
quality than the quantity of the given nutritional support.
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Differences between severe undernutrition in case
of cachexia and anorexia nervosa
Igor E. Khoroshilov
St. Petersburg I. I. Mechnikov State Medical Academy, St.
Petersburg, Russia
Aims: We aim to study the distinctive features between
severe malnutrition in case of cachexia and anorexia
nervosa.
Methods: Twenty-two patients were divided into two groups.
G r o u p1( t h r e em e n ,n i n ew o m e n ,a g e df r o m2 7u pt o6 9y e a r s )
included patients with severe organical pathology, which led to
development, undernutrition, and cachexia (cancer, stroke,
malabsorption, and short bowel syndrome). The second group
amounted to ten women aged from 14 up to 45 years, suffering
by the anorexia nervosa, cited to development of severe
undernutrition, and studied the clinical signs and body
composition (bioelectrical impedance and DEXA).
Results: In patients from group 1, body mass index is 15.9–
18.0, content of body fat is 4–15%, midarm circumference is
16–24 cm, and total protein of blood is 51–73 g/l. In the
process of treatment, the mass of the body has increased only
at 25% of ill, up to 1–2 kg. Lethality in this group is 33%. At
patients with anorexia nervosa (group 2), body mass index is
9.1–16.5, content of body fat is 2–17%, midarm circumfer-
ence is 12–22 cm, and total protein of blood is 48–66 g/l.
During treatment, the mass of the body increased in all
patients, on 4–11 kg. Lethality in this group is 0%.
Conclusions: Despite the fact that the anorexia nervosa
results in development considerably more distinct undernu-
J Cachexia Sarcopenia Muscle (2010) 1:43–128 121trition, it is distinguished by more favorable flow and
practically full convertibility than in contrast to cachexia,
developing on the background of organical pathology.
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The obesity paradox in cats with spontaneously
occurring heart failure
Emily Finn, Lisa M. Freeman, John Rush
Tufts Cumming School of Veterinary Medicine, North
Grafton, MA, USA
Background: Although cachexia is associated with impaired
survival in heart failure, overweight or obese human and canine
heart failure patients appear to have a survival advantage. It is
not known if this relationship also exists in other species. The
purpose of this study was to determine the effects of body
condition and body weight changes in cats with spontaneously
occurring heart failure due to cardiomyopathy.
Methods: All cats with congestive heart failure secondary to
cardiomyopathies (e.g., hypertrophic (HCM), dilated
(DCM), restrictive, and arrhythmogenic right ventricular
(ARVC)) were eligible for the study. Medical records were
reviewed, and data regarding initial body weight and body
condition, subsequent changes in body weight, and treatment
were collected. Survival times were determined for cats that
were discharged from the hospital and that lived >1 day.
Results: One hundred one cats were enrolled in the study:
HCM (n=74), DCM (n=5), ARVC (n=1), and other
cardiomyopathies (n=21). Survival was significantly dif-
ferent between cats that gained, lost, or maintained body
weight over the course of their disease, with cats that
gained weight surviving the longest (P=0.003). There was
a trend for initial body condition score to be associated with
survival (P=0.051), but medications were not significantly
associated with survival time.
Conclusions: These results suggest that changes in body
weight are an important consideration in the survival of cats
with heart failure, as in people and dogs. Further studies on
mechanisms of body composition changes in cats with
spontaneously occurring heart failure and potential treat-
ments are warranted.
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Hormonal profile, appetite, and energy/protein
homeostasis in response to fasting and re-feeding
in hemodialysis patients and control subjects
Manish Suneja, Victoria S. Lim
Division of Nephrology, Department of Medicine, University
of Iowa, Hospital and Clinic, Iowa City, IA, USA
Background and aims: Malnutrition is thought to be
prevalent in uremia due to either anorexia or heightened
catabolism. We aimed to study the pathogenesis of anorexia
and catabolism.
Methods: We examined the profile of peptides known to
regulate energy homeostasis including leptin, NPY,
alphaMSH, acylated ghrelin, PYY, and GLP-1 during
baseline, 40 h of fasting and 20 h of re-feeding.
Simultaneously, we assessed body composition with
DEXA scan, recorded the visual analogue scale (VSA)
for appetite assessment, and measured energy and protein
intake and output in ten hemodialysis (HD) patients and
eight controls (C).
Results: Endocrine assessment showed elevated plasma
leptin, PYY, NPY, and reduced acylated ghrelin in HD
patients. MSH and GLP-1 were not different from the
controls. Fasting suppressed leptin and PYY in both groups;
post-prandial rise of PYY and GLP-1 was prominent, and
pre-prandial rise of ghrelin was less in HD patients.
Kinetics showed that the elevation of leptin and PYY was
due to increased secretion and not impaired degradation.
Energy intake, expenditure, protein intake, output, and
balance were similar in the two groups. The VAS and body
fat and lean mass distribution were not different between
the C and the HD groups.
Conclusion: In contrast to prevailing view, we found that
well-dialyzed HD patients, in the absence of any
concomitant illness, were neither anorexic nor catabolic.
The endocrine finding of elevated PYY, leptin, and
suppressed ghrelin is, however, consistent with an
anorexigenic profile. Pathogenesis of these hormonal
changes is unknown.
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Neural activation in anorexia lung cancer patients
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Background and aims: Anorexia is a major symptom in
cancer patients, is the most common cause of malnutrition,
and is associated with a poor response to treatment and may
contribute to early death. The etiology of cancer anorexia is
122 J Cachexia Sarcopenia Muscle (2010) 1:43–128not completely understood, is multifactorial, and involves
most of the neural signaling pathways modulating energy
intake. We examined cerebral responses to visual stimuli in
anorexia lung cancer patients (LCP) to describe neural
activations to food stimuli.
Methods: Functional neuroimaging data were collected
from anorexia LCP, after four postprandial hours, using
magnetic 3.0-T resonance imaging (fMRI) with pleasant
and unpleasant visual food images. Thirty slices were
positioned in axial orientation with field of view 240×
240 mm
2, matrix 64×64, slice thickness 5.0 mm, GAP
0 mm, echo time 40 ms, repetition time 3,000 ms, and flip
angle of 90°. Data were analyzed with Brain Wave software
AW1.5 on a voxelwise basis using multiple regression
generating a t test map.
Results: Preliminary results of six anorectic LCP showed
significant activation in bilateral visual occipital cortex,
regardless of the pleasant or unpleasant stimuli. Anorexia
LCP displayed no activation of neural regions in hungry
process associated with an increased desire to eat, including
prefrontal cortex and amygdala, consistent with previous
study with a sample of satiety or even obese subjects, the
weak activation with food stimuli point to decreased food-
related somatosensory processing stimuli in anorexia LCP.
Conclusions: Preliminary findings support a development
model of cancer anorexia-related changes in cerebral
functioning develop from lower order sensory processing
in anorexia CLP.
177
Tastedisordersinoncologypatientsunderchemotherapy
Karla Sánchez-Lara
1, Ricardo Sosa
1,D a nG r e e n
1,
Alessandro Laviano
2, Daniel Motola, Oscar Arrieta
3
1Oncology Center, Medicasur Clinic Foundation, Mexico
City, Mexico;
2Department of Clinical Medicine, Sapienza
University of Rome, Rome, Italy;
3Lung Cancer Department,
National Cancer Institute, Mexico City, Mexico
Background and aims: Smell or taste dysfunction can
have a significant role in the anorexia development of
oncologist patients and can adversely affect food choice
and weight loss. We evaluated self-perceived taste function
to ascertain whether differences in threshold taste percep-
tion exist in patients and control subjects and were
associated with global subjective evaluation for malnutri-
tion and nutrients ingestion.
Methods: We enrolled 60 subjects, 30 patients with cancer
after the second chemotherapy cycle and 30 control
subjects without cancer. Dietary nutrients consumption
was obtained with a validate food frequency questionnaire.
Three concentrations of three basic flavors: sucrose (sweet),
urea (bitter), and umami (glutamate) were dissolved in
distilled water to ascertain perception threshold (PT) and
recognition threshold (RT).
Results: Cancer patients presented higher PT to sweet
flavor (6.4 vs 4.4 mmol/ml, p=0.03) and higher RT (100 vs
95 mmol/ml, p=0.04) to bitter flavor than the controls.
Cancer patients with sweet PT higher than the median
showed significant lower ingestion of calories per day
(2,043 vs 1,586 kcal, p=0.02), proteins (81.4 vs 54 g/day,
p=0.01), carbohydrates (246 vs 192 g/day, p=0.05), and
zinc (19 vs 11 mg/day, p=0.01). There was no association
with PT or RT in any of the three basic flavors and nutrient
ingestion in the control group.
Conclusions: Changes of sweet PT and bitter RT were
found in patients under chemotherapy which were associ-
ated with lower ingestion of nutrients and total energy
consumption. Taste alterations could be an important factor
in malnutrition in cancer patients under chemotherapy.
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Early weight loss is not caused by dysphagia in patients
with non-small lung cancer treated with concurrent
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Background: Concurrent chemoradiotherapy (chemo-RT)
in locally advanced non-small cell lung cancer (NSCLC) is
associated with increased acute oesophageal toxicity and
dysphagia.
Aim: The aim of this study is to investigate body weight
changes during concurrent chemo-RT in relation to the
onset of dysphagia.
Methods: Fifty-one patients with NSCLC treated with
chemo-RT were included. Body weight was measured at
diagnosis, at start, and at week 1, 2, and 3 of chemo-RT.
Toxicity was scored according to the CTCAE system.
Associations between body weight loss and grade of
dysphagia were analyzed in a linear mixed regression
model. Results are expressed as mean±standard deviation.
Results: Between diagnosis and start of chemo-RT, patients
lost 0.34±3.4% of body weight (p=0.57). During concur-
rent chemo-RT, patients lost 1.4±2.2% (p 1 at start of
chemo-RT, and only 7%, 19%, and 31% of patients had
grade >1 dysphagia at week 1, 2, and 3, respectively.
J Cachexia Sarcopenia Muscle (2010) 1:43–128 123Regression analysis showed no association between body
weight loss and grade of dysphagia.
Conclusions: In this study, we show that body weight loss
already occurs during the first 3 weeks of concurrent
chemo-RT and is not associated with dysphagia. Further
research is ongoing to elucidate the mechanisms underlying
this observation. Understanding the mechanisms of weight
loss would allow for intervention strategies.
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Aim: Cancer cachexia and weight loss are major contrib-
utors to morbidity in advanced pancreatic cancer (PC).
Weight loss can be considered as a disturbance of energy
balance, but little is known about the importance of
symptoms for changes in energy intake (EI). Study
objectives were to prospectively assess EI, weight, and
symptoms during the disease course and investigate
associations between symptoms and EI.
Methods: From 2006 to 2008, 39 patients (females, 18/
males, 21) with advanced PC were included and monitored
every fourth week until death. EI was measured by the 24-
h recall method. The Edmonton symptom assessment scale
(ESAS) was used to assess symptoms.
Results: The patients had a median age of 62 years (48,
88), median ECOG status 1, and median survival of
5 months. Seventeen patients (44%) had locally unresect-
able cancer, 16 (41%) metastatic, and six (15%) recurrent
disease. Upon inclusion, 28 (72%) patients reported weight
loss ≥10%, and the median daily EI was 7.1 MJ (1.3, 14.8).
Negative correlations (Spearman’s rho, p<0.05) were found
between EI and pain (−0.44), fatigue (−0.47), dry mouth
(−0.37), depression (−0.35), and wellbeing (−0.41), but not
between EI and appetite loss (−0.28, p>0.05). After
1 month (n=28), median daily EI was 7.6 MJ (0.3, 16.2),
and general wellbeing was the only symptom significantly
associated with EI (−0.44, p<0.05).
Conclusion: Several symptoms seem to contribute to
reduce EI at inclusion. Careful monitoring and follow-up
of symptoms might therefore be an important intervention
to reduce weight loss in advanced PC.
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Influence of poor nutritional status on clinical outcome
of elderly women with primary or recurrent ovarian
cancer: results of a prospective study
Marco Kuhberg, Frank K. Chen, Paulina Skowronek,
Guelten Oskay-Oezcelik, Jalid Sehouli
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Background: Global malnutrition is widespread among
patients with ovarian cancer. The purpose of this study was
to investigate the influence of the nutritional status on the
clinical outcome of patients with primary or recurrent
ovarian cancer with respect to their age, as age and tumour-
free surgery are independent prognostic parameters for
overall survival.
Methods: In a 2-year-period (January 2007 to December
2008), 152 consecutive patients were analysed. Seventy-
nine (52%) of them had primary and 73 (48%) recurrent
disease. At the time of admission for surgical therapy, the
body composition was analysed with bioelectrical imped-
ance analysis (BIA) using phase angle alpha and ratio of
extra-cellular mass and body cell mass (ECM/BCM).
Serum protein parameters were registered. The risk of
malnutrition was estimated by nutritional risk score (NRS)
and nutritional risk index (NRI). Nutritional risk was
defined as NRS ≥3 or NRI ≤100. During operation, a
standardised and validated tumour documentation tool
(IMO) was performed. Clinical outcome parameters such
as length of hospital stay or postoperative complications
were documented with regard to the age (</>65 years).
Results: The median age of patients was 56 years (range,
48–6 6 ) ,w i t hm e d i a nB M I ,2 4 . 4k g / m
2 (range, 21.8–
27.3). Almost one third were older than 65 years (n=43/
29%). The ≥65-year group had a significant higher rate of
nutritional risk classified by NRS (14/43 vs. 16/109, p<
0.05) and NRI (99.6 vs. 105.7, p<0.001), whereas the
BMI (25.4 vs. 24.1, p<0.05) was significantly increased.
These patients (≥65 years) had significantly higher BIA-
ECM/BCM ratio (1.3 vs. 1.1, p<0.001), they needed
significantly more often blood transfusions during or after
s u r g e r y( 3v s .0 . 5 ,p<0.001), the length of stay was
significantly higher (18 vs. 14 days, p<0.005) and the
phase angle α was significantly lower (4.5° vs. 5.2°, p<
0.001) as well as serum albumin (4.0 vs. 4.3, p<0.005).
There were no differences in weight loss, food intake,
post-operative complications and complete resection rate
between the ≥65 and <65 group.
124 J Cachexia Sarcopenia Muscle (2010) 1:43–128Conclusions: Elderly patients with ovarian cancer have an
increased risk of malnutrition before oncologic surgery,
evaluated by NRS, NRI and BIA, phase angle α and ECM/
BCM ratio, although operative and postoperative compli-
cations are not increased. Elderly patients with nutritional
risk factors should be identified for an individualised
nutritive care before surgery and may thereby have an
improved outcome.
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Under-nutrition and cachexia occur frequently in cancer
patients and are, per se, responsible for excess morbid-
ity and mortality. Since January 2008 to August 2009,
all cancer outpatients consecutively referred to our
ward, no more eligible for oncologic therapy, have
been evaluated. Demographic, anthropometric and on-
cologic (site of primary tumour, weight loss in the last
6 months, presence of systemic symptoms and Karnof-
sky performance status (KPS)) data were collected.
Patients have been divided according to the previous
body weight loss and the class of KPS (56 have KPS
≤5 0a n d4 4K P S≥60). Patients were 100 (48 male, 42
female; median, 61 years (38–79)), BMI was 19.05 kg/
m
2 (13.6–27.5), weight loss was 18.6% (range, 6–47%;
26 have lost <10% and 74 ≥10%) and primary cancer
localization was 32 stomach, 24 colon, 12 ovary, 11
esophagus, 11 pancreas, 6 lung, 2 gallbladder and 2
uterus. All patients complained anorexia and fatigue, in
18 cases associated with dysphagia, in 37 nausea/
vomiting, in 12 pain and in 5 mild ascites. Median
survival was 4 months (2–10): 68 patients survived
<4 months and 32 ≥4 months. When patients were divided
according to the primary cancer localization and the previous
weight loss, prognosis resulted not different in the different
groups; when divided according to KPS, survival resulted
significantly different (3.7±1.7 months when KPS ≤50 and
5.4±1.4 months in KPS ≥60; p=0.0001). Weight loss and
anorexia are frequent in an unselected series of cancer
terminal outpatients. Karnofsky results related with survival
being a prognostic indicator for terminal cancer patients on
HPN. This study is part of an ongoing international
prospective investigation on the predictability of survival in
incurable cancer patients on HPN. The study is sponsored by
the European Society of Clinical Nutrition and Metabolism
(ESPEN) and is still open to the clinical investigators who
are involved in this field.
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Translation initiation of protein synthesis and myosin
transcription in human skeletal muscle tissue
in response to overnight total parenteral nutrition
(TPN) before operation
Britt-Marie Iresjö, Ulla Körner, Anders Hyltander,
Ulrika Smedh, Kent Lundholm
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Aim: In recent years, it has been a great increase in
knowledge of translational control of protein synthesis after
feeding or provision of amino acids, but such information
in patients is based on labelled tracer kinetics mainly, which
is based upon pool uncertainties. Our aim of the present
study was therefore to determine if overnight provision of a
“standard” total parenteral nutrition (TPN) regimen was
enough to activate translation initiation factors for protein
synthesis and transcription of myofibrillar proteins in
patients scheduled for surgery.
Methods: Patients who underwent surgery in the upper
gastrointestinal tract were included in the study and received
overnight (12 h) infusions of either saline or TPN as all in
one (30 cal/kg/day, 0.16 gN/kg/day) prior to surgery.
Infusions lasted until muscle biopsies were taken from the
rectus abdominus muscle directly after anaesthesia induction.
Initiation factor complexes in the muscle tissue were
analysed with immunoprecipitation of proteins followed by
Western blot. mRNA expressions of myosin heavy chain 2A
(MHC 2A) and actin were measured by real-time PCR.
Results: Standard overnight TPN infusion increased
formation of eIF4G·eIF4E complexes and reduced the
amount of 4EBP1 found in complex with eIF4E,
indicating increased protein synthesis compared to
patients who received saline infusions (p<0.05). TPN
infusion also increased phosphorylation of 4E-binding
protein 1 and p70s6 kinase (p<0.05). MHC 2A mRNA
expression was significantly altered by TPN treatment
(p<0.05), while similar alterations in actin expression
did not reach significant levels in the same tissue
specimens.
Conclusions: Provision of standard total parenteral nutri-
tion for 12 h activates initiation factors for translation of
skeletal muscle proteins, which was translated into altered
tissue content of myosin transcripts, indicating stimulation
of synthesis of myofibrillar proteins.
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Reduction of low grade inflammation restores blunting
of postprandial muscle anabolism and limits sarcopenia
in old rats
Isabelle Rieu, Hugues Magne, Isabelle Savary-
Auzeloux, Marie-Agnes Peyron, Lydie Combaret,
Dominique Dardevet
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Background and aim: Sarcopenia may result from a defect
in muscle protein synthesis stimulation and proteolysis
inhibition after food intake. With aging, muscle is less
sensitive to the stimulatory effects of amino acids. Aging is
also characterized by the development of a low-grade
inflammation (LGI) with increased plasma levels of
cytokines and acute phase proteins (fibrinogen and
alpha2-macroglobulin (alpha2M)). Whether or not blunting
LGI may restore the stimulation of post-prandial (PP)
muscle protein synthesis during aging has been assessed.
Methods: Eighteen- to 20-month-old rats were divided into
a control group (C) and a group treated with a non-steroidal
anti-inflammatory drug (ibuprofen (IBU), 30 mg/kg/day).
After 5 months of treatment, rats were studied at the post-
absorptive (PA) or PP state; muscle proteolysis and protein
synthesis were assessed. Signaling pathways (mTOR/S6K1/
S6/4EBP1) and FoxO3a were measured.
Results: Body weight, fibrinogen, and alpha2M levels were
similar in both groups at the beginning of the experiment.
Five months of treatment decreased significantly fibrino-
gen, alpha2M, and IL6 levels in IBU vs. C. Muscles were
significantly heavier in IBU vs. C rats (+6%). As expected,
food intake had no effect on muscle protein synthesis and
proteolysis in C rats, whereas ibuprofen restored the
stimulation of muscle protein synthesis (+25%) and the
inhibition of proteolysis (−16%). IBU treatment did not
affect the mTOR signaling pathway, whereas it restored
muscle FoxO3a phosphorylation.
Conclusion: Prevention of LGI development during aging
maintained muscle protein anabolism by food intake and
slowed down muscle atrophy in elderly.
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Impaired muscle recovery after immobilization-induced
atrophy in old rats is not due to a lack of normalization
of the ubiquitin-proteasome-dependant proteolysis
or the mitochondria-associated apoptotic pathway
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INRA, UMR 1019 Human Nutrition Unit, Saint Genès
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Background and aim: Sarcopenia might be partially
explained by an impaired recovery of skeletal muscle mass
after a catabolic state. Associated with this, periods of
immobilization increase with age (bed-rest and convales-
cence) and may contribute by themselves to muscle atrophy
during aging. An imbalance of muscle protein metabolism,
apoptosis, and cellular regeneration/differentiation is cer-
tainly involved. This study aimed to explore the mecha-
nisms involved in muscle atrophy during immobilization
and subsequent recovery in old rats.
Methods: Forty-eight-old rats were subjected to unilateral
hind limb casting immobilization for 8 days (I8) and
allowed to recover for 10 to 40 days (R10–R40; n=8 per
time). Muscle atrophy, apoptotic (caspase-3 and -9, apop-
tosome) and proteasome-dependent proteolytic activities,
and regeneration/differentiation processes (myogenic factor,
Myf5) were assessed in the same rat on both non-
immobilized (C) and immobilized (I) gastrocnemius
muscles.
Results: At I8, a significant muscle atrophy (−21%, P<
0.05) occurred in the gastrocnemius muscle, and recovery
was absent even at R40. In parallel, we observed at I8 (1)
an increase of caspases-3 and -9, apoptosome, proteasome
chymotrypsin-like activities (+20% to +80%, P<0.05), and
amount of apoptotic nuclei; (2) a decrease amount in Myf5
(−50%, P<0.05) in I compared to C. These proteolytic and
apoptotic activities were rapidly normalized (R10).
Conclusion: Our results showed that a short immobiliza-
tion period during aging initiated muscle atrophy that was
not recovered after 40 days and may then contribute to
initiate sarcopenia. The lack of recovery is not due to a
defect in proteolysis or apoptosis downregulation during
the recovery period and remains to be explored.
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Exercise induced time-dependent transcription
in human skeletal muscle
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An extensive long-term, longitudinal assessment of muscle
functional and genome-wide transcriptional changes during
heavy resistance training in human volunteers has not yet
been described. We investigated muscle mass (DEXA) and
isometric strength increases and transcriptional changes
(Affymetrix Array) in muscle at several time points over the
course of a 70-day resistance training program (supervised
exercise, three times/week, at 80% of one repetition
126 J Cachexia Sarcopenia Muscle (2010) 1:43–128maximum). The data show a linear relationship between
changes in muscle mass and strength gains with training
(r>|0.6|, p<0.01). There was a rapid and profound change
in the muscle transcriptome within 2 days of the first bout
of exercise, but many of these changes waned after 35 days
of training. The changes clustered into several patterns that
range from those genes that changed early, but then
returned rapidly to baseline expression levels, to those that
changed only after several bouts of exercise and continued
to show a change whilst the training program progressed.
We have seen that each individual pattern appears to
activate different metabolic programs. Thus, the data
suggest that muscle undergoes discreet sequential transcrip-
tional changes in response to exercise to affect a series of
sequential metabolic changes that ultimately result in the
training adaptations observed.
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Muscle quality is associated with longer and less
fragmented sedentary time in healthy older men
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Background and aims: Physical activity interventions for
sarcopenia promote a decrease in sedentary time and an
increase in energy expenditure. However, recent work has
shown that programmed physical activity is accompanied
by a spontaneous increase in sedentary time both before
and after physical activity; muscle quality is improved
while maintaining a constant energy cost of daily living.
We hypothesized that muscle quality in healthy older
people would be associated with increased sedentary
behaviour.
Methods: We studied 26 healthy volunteers (14 men,
mean age, 79.3 (3.4)years). Spontaneous physical activity
was directly monitored (7 days) using the ActivPAL™
accelerometry-based system, which continuously registers
time sitting/lying, time standing, time walking, number of
steps taken and step cadence. Sedentary behaviour, i.e.
total and pattern of sedentary time, was measured with
pattern (fragmentation) defined as the number of sedentary
bouts/total sedentary time. Body composition was mea-
sured using DEXA (Hologic Discovery) and lower limb
extensor power (LEP) using the Nottingham Power Rig.
Muscle quality (MQ) was defined as LEP/lower limb lean
mass (Wkg
−1).
Results: MQ was 13.11 (4.90)Wkg
−1. Sedentary time was
17.26 (1.79)hday
−1. In men (but not women), muscle
quality was significantly associated with not a longer (r=
0.608, p=0.021) and less fragmented (r=−0.620, p=0.018)
pattern of sedentary time, in between longer bouts of
activity (r=0.555, p=0.039).
Conclusions: In men, an increase in sedentary time and a
less fragmented activity pattern may be a consequence of
maintaining optimum muscle quality in older age. Sex
differences in sedentary activity behaviour need to be
resolved further.
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Background: Lower lean mass is thought to increase risk
of poor outcomes in old age. Cachexia is associated with
loss of both lean and adipose. Using computerized
tomography (CT) data of the thigh from a large
population-based study, we explored whether adipose
depots imaged in the thigh might be protective for death
risk in persons with lower lean.
Methods: We used mid-thigh CT scan data from 687 men
(215 deaths) and 932 women (170 deaths) aged 79±5.5 in
the AGES-Reykjavik follow-up (2002–2004) of the ran-
domly chosen Reykjavik Study. Only persons in the lowest
tertile of thigh lean cross-sectional area (men <118 cm
2,
women <85 cm
2) wereincluded.Logisticmodelswere used to
assess risk for thigh subcutaneous fat, intermuscular fat,
or fatty infiltration into muscle from Hounsfield Unit
(HU). Final models were adjusted for age, BMI, height,
smoking, functional status, C-reactive protein, lean CSA,
and leg strength.
Results: None of the adipose depots was protective of
risk of death. In the men, greater fatty infiltration into
muscle increased risk of death (P=0.04 men, P=0.69
women). In women, smaller lean CSA increased risk of
death (P=0.02 women), but lean CSA was not associated
with risk in men, adjusting for other confounders (P=0.44
men).
Conclusions: Within this large population of men and
women with lower lean mass, no adipose depot as assessed
J Cachexia Sarcopenia Muscle (2010) 1:43–128 127from CT improved risk of short-term survival. Increased
fatty infiltration into muscle as assessed by HU increased
risk of death in men only.
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Sarcopenia is predictive of convalescent care in elderly
cancer patients following resection of colorectal cancer
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Background and aims: Skeletal muscle wasting is
defining characteristic of cancer cachexia and has
been associated with poor physical function. We tested
if muscle depletion (sarcopenia) predicts convalescent
care requirement after primary colorectal cancer (CRC)
resection.
Methods: Stage 2–4 CRC patients (n=237) were studied;
surgery dates were identified using the Alberta Cancer
Registry. A computed tomography (CT) image taken before
surgery was used to compute total muscle surface area
(square centimeter) at the third lumbar vertebra (L3).
Sarcopenia was defined using reported L3 muscle index
(L3 muscle (square centimeter)/height (square centimeter))
cut points (female, 38.5 cm
2/m
2; male, 52.4cm
2/m
2; Prado
et al., Lancet Oncology 2008). Inpatient hospitalization data
from the provincial ministry of health was searched for
ICD-10 diagnostic codes suggesting inpatient convalescent
care following surgery.
Results: Overall, 39.2% of patients were sarcopenic, and
9.3% of the patients in the entire population received
c o n v a l e s c e n tc a r e .T h em e a nl e n g t ho fs t a yi nc o n v a l e s c e n t
care was 14.4±10.5 (SD)days. Of patients, 47.7% were
≥65 years, and 93% of all patients needing convalescent care
were in this age group. In patients ≥65 years, 49.5% of
patients were sarcopenic, and the risk of convalescent care
after surgery was significantly higher in individuals with
sarcopenia compared to those without (25.0% vs. 10.5%,
p=0.0438, χ
2 test).
Conclusions: Sarcopenia is common before CRC primary
tumor resection surgery. Convalescent care largely occurred
in patients ≥65 years, and sarcopenia is a risk factor for this
outcome, suggesting functional impairments. This is poten-
tially associated with higher costs and burden on the
healthcare system.
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